WO2010065681A1 - Inhibitors of hcv ns5a - Google Patents

Inhibitors of hcv ns5a Download PDF

Info

Publication number
WO2010065681A1
WO2010065681A1 PCT/US2009/066467 US2009066467W WO2010065681A1 WO 2010065681 A1 WO2010065681 A1 WO 2010065681A1 US 2009066467 W US2009066467 W US 2009066467W WO 2010065681 A1 WO2010065681 A1 WO 2010065681A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
heteroaryl
compound
heterocycle
independently
Prior art date
Application number
PCT/US2009/066467
Other languages
French (fr)
Inventor
Leping Li
Min Zhong
Original Assignee
Presidio Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010065681(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US13/132,606 priority Critical patent/US9120779B2/en
Priority to EP09831084A priority patent/EP2373168A4/en
Priority to CN200980155944.3A priority patent/CN102300462B/en
Priority to NZ593808A priority patent/NZ593808A/en
Priority to JP2011539670A priority patent/JP2012510525A/en
Application filed by Presidio Pharmaceuticals, Inc. filed Critical Presidio Pharmaceuticals, Inc.
Priority to CA2750577A priority patent/CA2750577A1/en
Priority to SG2011039781A priority patent/SG171890A1/en
Priority to AU2009322400A priority patent/AU2009322400A1/en
Priority to ARP090104678A priority patent/AR074474A1/en
Publication of WO2010065681A1 publication Critical patent/WO2010065681A1/en
Priority to IL213279A priority patent/IL213279A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention relates to compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non-structural 5 A (“NS5A”) protein of HCV.
  • HCV hepatitis C virus
  • HCV is a single-stranded RNA virus that is a member of the Flaviviridae family.
  • the virus shows extensive genetic heterogeneity as there are currently seven identified genotypes and more than 50 identified subtypes.
  • viral RNA is translated into a polyprotein that is cleaved into ten individual proteins.
  • the core (C) protein and the envelope glycoproteins El and E2.
  • p7 an integral membrane protein, follows El and E2.
  • there are six nonstructural proteins, NS2, NS3, NS4A, NS4B, NS5A and NS5B which play a functional role in the HCV lifecycle. (see, for example, Lindenbach, B.D. and CM. Rice, Nature. 436:933- 938, 2005).
  • HCV infection is a serious health issue. It is estimated that 170 million people worldwide are chronically infected with HCV. HCV infection can lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. Chronic HCV infection is thus a major worldwide cause of liver-related premature mortality.
  • a and A' are independently selected from the group consisting of a single bond, -(CR 2 ) n -C(O)-(CR 2 ) p - -(CR 2 ) n -O-(CR 2 ) p - -(CR 2 ) n -N(R N )-(CR 2 ) p - -(CR 2 ) n -S(O) k -N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-N(R N )-(CR 2 )p-, -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-O-(CR 2 ) p -, -(CR 2 ) n -N(R N )-C(O)-O-(CR
  • heteroaryl group selected from the group consisting of
  • X 1 is CH 2 , NH, O or S,
  • Y 1 , Y 2 and Z 1 are each independently CH or N,
  • X 2 is NH, O or S
  • a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0, optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
  • the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
  • a and b are independently 1, 2, or 3.
  • c and d are independently 1 or 2
  • n and p are independently 0, 1, 2 or 3
  • k 0, 1, or 2
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • each R N is independently selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • the A-B-A' can be any of:
  • B is Q or Q Q , wherein each Q is independently selected from the group consisting of a cycloalkyl group, cycloalkenyl group, heterocycle, aryl group or heteroaryl group, with the proviso that only one Q is a six member aromatic ring when B is Q Q and with the proviso that if B is Q Q , any Q is that is poly cyclic is connected to the remainder of the molecule through only one cycle of the poly cycle;
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of R c , R d , R e and R f may optionally be substituted by Ci to C 8 alkyl, Ci to C 8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)- and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2, -S(O) 2 -R 81 and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 7 and R 8 together form a 4-7 membered ring
  • each t is independently 0, 1, 2, 3, or 4, and
  • u 0, 1, or 2.
  • each Q is independently optionally substituted with one or more substituents each independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and if Q is not aromatic, it is optionally substituted with oxo.
  • substituents each independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulf
  • each Q is independently optionally substituted with -CN, -OCF 3 , -OCHF 2 , -CF 3 or -F.
  • B is selected from the group consisting of:
  • each r and s is independently 0, 1, 2, 3, or 4;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • each R b is independently Ci-Ci 2 alkyl, hydroxyl, halogen, or oxo.
  • each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
  • each R a if present, -CN, -OCF 3 , -OCHF 2 , -CF 3 , or -F.
  • a and A' are independently selected from the group consisting of a single bond, -(CR2) n -C(O)-(CR2) p -, -(CR2) n -O-(CR2) p -, -(CR 2 )n-N(R N )-(CR2)p-, -(CR2)n-C(O)-N(R N )-(CR 2 )p-, -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) p - and -(CR 2 ) n -N(R N )-C(O)-O-(CR 2 ) p - and a
  • heteroaryl group selected from the group consisting of - ⁇ X 1 ,
  • a and A' are independently selected
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl and Ci to Cg heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
  • R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • R c and R d or R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • R c and R d are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to C 12 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • R e and R f are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to
  • C 12 alkyl Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • A' is selected from the group consisting of single bond, H H
  • R N is selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
  • ⁇ / optionally includes 1 or 2 nitrogens as heteroatoms
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • r is selected from the group consisting of 0, 1, 2, 3, or 4.
  • A' is V H
  • A' is selected from the group consisting of
  • a and A' are independently selected from the group consisting of single bond, H
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
  • r is O, 1, 2, 3 or 4;
  • each R b is independently C1-C5 alkyl, hydroxyl, halogen, or oxo;
  • s is O, 1, 2, 3, 4, 5, or 6;
  • each of X 1 and X 2 are independently C or N.
  • a and A' are each independently
  • a and A' are independently selected from the group consisting of single bond, C(O)-N(R N )-(CR 2 ) P -, wherein R N is selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • r is O, 1, 2, 3 or 4. 30]
  • a and A' are each independently
  • each - ⁇ ⁇ - --v- 1 iSs 1 iTndependently a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns; each r is independently 0, 1, 2, 3, or 4;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
  • a and A' are independently selected from the group consisting of a single bond, -(CR 2 ) n -C(O)-(CR 2 ) p - -(CR 2 ) n -O-(CR 2 ) p - -(CR 2 ) n -N(R N )-(CR 2 ) p - -(CR 2 ) n -S(O) k -N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-N(R N )-(CR 2 ) p -, -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-O-(CR 2 )p-, -(CR 2 ) n -N(R N )-C(O)-O-(CR
  • X 1 is CH 2 , NH, O or S,
  • Y 1 , Y 2 and Z 1 are each independently CH or N,
  • X 2 is NH, O or S
  • a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0, optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
  • the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
  • a and b are independently 1, 2, or 3.
  • c and d are independently 1 or 2
  • n and p are independently 0, 1, 2 or 3
  • k 0, 1, or 2
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • each R N is independently selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • a or A' being the A-B-A' can be any of:
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of R c , R d , R e and R f may optionally be substituted by Ci to Cg alkyl, Ci to Cg heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ) t ] u -U-(CR 4 2 ) t -NR 7 -(CR 4 2 ) t -R 8 , -U-(CR 4 2 ) t -R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)- and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2 , -S(O) 2 -R 81 and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, optionally, R 7 and R 8 together form a 4-7 membered ring, each t is independently 0, 1, 2, 3, or 4, and u is 0, 1, or 2.
  • each - ⁇ - IS 1 ndependently
  • each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
  • a and A' are independently selected from the group consisting of a single bond, -(CR2) n -C(O)-(CR2) p -, -(CR2) n -O-(CR2) p -, -(CR 2 )n-N(R N )-(CR2)p-, -(CR2)n-C(O)-N(R N )-(CR 2 )p-, -(CR 2 )n-N(R N )-C(O)-N(R N )-(CR 2 )p- and -(CR 2 )n-N(R N )-C(O)-O-(CR 2 )p- and a
  • a and A' are independently selected
  • a and A' are each independently
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cs alkyl and Ci to Cs heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
  • R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • one of R c and R d or R e and R f are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • both of R c and R d and R e and R f are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • R c and R d are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • R e and R f are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to
  • C 12 alkyl Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • each R a if present in a compound of any of the second through sixth aspects, is independently -CN, -OCF3, -OCHF 2 , -CF 3 , or -F.
  • one of Y and Y' is N.
  • both Y and Y' are N.
  • Z and Z' in any of the previous aspects are each 1-3 amino acids.
  • the amino acids are in the D configuration.
  • Z and Z' in any of the previous aspects are each independently selected from the group consisting of -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • Z and Z' are -U-(CR 4 2 ),-NR 5 -(CR 4 2 ),-U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -[C(O)-(CR 4 2 )t-NR 5 -(CR 4 2 )t] u -U-(CR 4 2 )t-NR 7 -(CR 4 2 )t-R 8 .
  • Z and Z' are -C(O)-(CR 4 2 ),-NR 5 -(CR 4 2 ),-U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -[C(O)-(CR 4 2 )t-NR 5 -(CR 4 2 )t] u -C(O)-(CR 4 2 )t-NR 7 -(CR 4 2 )t-R 8 .
  • Z and Z' are -C(O)-(CR 4 2 ),-NR 5 -(CR 4 2 ),-C(O)-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • Z and Z' are -C(O)-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -(CR 4 2 ) n -C(O)-R 81 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -C(O)-R 81 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -(CR 4 2 ) n -C(O)-O-R 81 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -C(O)-O-R 81 .
  • one or both of Z and Z' are -U- (CR 4 2 ) t -R 8 .
  • one or both of Z and Z' are - C(O)-(CR 4 2 ) t -R 8 .
  • one or both of Z and Z' are -[U-(CR 4 2 )t-NR 5 -(CR 4 2 )t] u -U-(CR 4 2 )t-O-(CR 4 2 )t-R 8 .
  • Z and Z' are -U-(CR 4 2 ),-NR 5 -(CR 4 2 ),-U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 )t-NR 5 -(CR 4 2 )t-C(O)-(CR 4 2 )t-O-(CR 4 2 ) t -R 8 .
  • Z and Z' are -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 )t-O-(CR 4 2 )t-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -R 8 wherein R 7 and R 8 together form a 4-7 membered ring.
  • r is from 0 to 4
  • each R a is independently selected from the group consisting of -OH,
  • Ci to Ci 2 alkyl Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
  • a and A' are independently selected from the group consisting of
  • a or A' is a heteroaryl group, it is optionally substituted with one or more of the substituents selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and
  • n and p are independently 0, 1, or 2
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • R N is selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • B' is optionally substituted with between 1 and 4 substituents, each independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino and oxo,
  • X b is either C or N;
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)- and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2 , -S(O) 2 -R 81 and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 7 and R 8 together form a 4-7 membered ring
  • each t is independently O, 1, 2, 3, or 4, and
  • B' is selected from the group consisting of
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • B' is selected from the group consisting of ⁇ ⁇ V_v- s ⁇ ⁇ N — /- ,- ⁇ — / and
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • B' is selected from the group consisting of - ⁇ - - ⁇ - -
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • the sixteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention.
  • the seventeenth aspect of the invention provides the use of the compounds of the invention in the manufacture of a medicament.
  • the medicament is for the treatment of hepatitis C.
  • the eighteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention.
  • alkanoyl as used herein contemplates a carbonyl group with a lower alkyl group as a substituent.
  • alkenyl as used herein contemplates substituted or unsubstituted, straight and branched chain alkene radicals, including both the E- and Z-forms, containing from two to eight carbon atoms.
  • the alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, -NO 2 , CO 2 R, C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(O)R, -N(R N )S(O) 2 R, -SR, -C(O)N(R N ) 2 , -OC(O)R, -0C(0)N(R N ) 2 , S(O)R, SO 2 R, -SO 3 R, -S(O) 2 N(R N ) 2 , phosphate, phosphonate, cycloalkyl, cycloalkenyl
  • alkoxy contemplates an oxygen with a lower alkyl group as a substituent and includes methoxy, ethoxy, butoxy, trifluromethoxy and the like. It also includes divalent substituents linked to two separated oxygen atoms such as, without limitation, -O-(CH 2 )i. 4 -O-, -0-CF 2 -O-, -0-(CH 2 )L 4 -O-(CH 2 CH 2 -O)L 4 - and
  • alkoxycarbonyl as used herein contemplates a carbonyl group with an alkoxy group as a substituent.
  • alkyl as used herein contemplates substituted or unsubstituted, straight and branched chain alkyl radicals containing from one to fifteen carbon atoms.
  • lower alkyl as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl and the like.
  • the alkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -NO 2 , -C(O) 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(O) 2 R, -SR, -C(0)N(R N ) 2 , -OC(O)R, -0C(0)N(R N ) 2 , -SOR, -SO 2 R, -SO3R, -S(O) 2 N(R N ) 2 , phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halogen, -CN, -NO 2 , -C(O) 2 R, -C(O)R, -O-R, -N(R N ) 2 ,
  • alkylene alkenylene and alkynylene as used herein refers to the groups “alkyl,” “alkenyl” and “alkynyl” respectively, when they are divalent, ie, attached to two atoms.
  • alkylsulfonyl as used herein contemplates a sulfonyl group which has a lower alkyl group as a substituent.
  • alkynyl as used herein contemplates substituted or unsubstituted, straight and branched carbon chain containing from two to eight carbon atoms and having at least one carbon-carbon triple bond.
  • alkynyl includes, for example ethynyl, 1- propynyl, 2- propynyl, 1-butynyl, 3 -methyl- 1-butynyl and the like.
  • the alkynyl group may be optionally substituted with one or more substituents selected from halo, -CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(O) 2 R, -SR, -C(0)N(R N ) 2 , -OC(O)R, -0C(0)N(R N ) 2 , -SOR, -SO 2 R, -SO3R, -S(O)2N(R N )2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, -CN, NO 2 , CO 2 R, C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N
  • amino as used herein contemplates a group of the structure -NR N 2 .
  • amino acid as used herein contemplates a group of the structure
  • the present invention also includes, without limitation, D-configuration amino acids, beta-amino acids, amino acids having side chains as well as all non-natural amino acids known to one skilled in the art.
  • aralkyl as used herein contemplates a lower alkyl group which has as a substituent an aromatic group, which aromatic group may be substituted or unsubstituted.
  • the aralkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -NO 2 , -CO 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(O)R, -N(R N )S(O) 2 R, -SR, -
  • aryl as used herein contemplates substituted or unsubstituted single-ring and multiple aromatic groups (for example, phenyl, pyridyl and pyrazole, etc.) and polycyclic ring systems (naphthyl and quinolinyl, etc.).
  • the polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • the aryl group may be optionally substituted with one or more substituents selected from halogen, alkyl, -CN, -NO 2 , -CO 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(O)R, - N(R N )S(O) 2 R, -SR, -C(O)N(R N ) 2 ,
  • arylsulfonyl contemplates a sulfonyl group which has as a substituent an aryl group. The term is meant to include, without limitation, monovalent as well as multiply valent aryls (eg, divalent aryls).
  • cycloalkyl as used herein contemplates substituted or unsubstituted cyclic alkyl radicals containing from three to twelve carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl and the like.
  • cycloalkyl also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused").
  • the cycloalkyl group may be optionally substituted with one or more substituents selected from halo, -CN, -NO 2 , -CO 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(O)R, -N(R N )S(O) 2 R, -SR, -C(O)N(R N ) 2 , -OC(O)R, -OC(O)N(R N ) 2 , -SOR, -SO 2 R, -S(O) 2 N(R N ) 2 , phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, -CN, -NO 2 , -CO 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N
  • cycloalkenyl as used herein contemplates substituted or unsubstituted cyclic alkenyl radicals containing from four to twelve carbon atoms in which there is at least one double bond between two of the ring carbons and includes cyclopentenyl, cyclohexenyl and the like.
  • cycloalkenyl also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused").
  • the cycloalkenyl group may be optionally substituted with one or more substituents selected from halo, -CN, -NO 2 , -CO 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(O)R, -N(R N )S(O) 2 R, -SR, -C(O)N(R N ) 2 , -OC(O)R, -OC(O)N(R N ) 2 , -SOR, -SO 2 R, -S(O) 2 N(R N ) 2 , phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
  • halo or "halogen” as used herein includes fluorine, chlorine, bromine and iodine.
  • heteroalkyl as used herein contemplates an alkyl with one or more heteroatoms.
  • heteroatom particularly within a ring system, refers to N, O and S.
  • heterocyclic group contemplates substituted or unsubstituted aromatic and non-aromatic cyclic radicals having at least one heteroatom as a ring member.
  • Preferred heterocyclic groups are those containing five or six ring atoms which includes at least one hetero atom and includes cyclic amines such as morpholino, piperidino, pyrrolidino and the like and cyclic ethers, such as tetrahydrofuran, tetrahydropyran and the like.
  • Aromatic heterocyclic groups also termed "heteroaryl” groups, contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, oxodiazole, thiadiazole, pyridine, pyrazine, pyridazine, pyrimidine and the like.
  • heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two or more atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • polycyclic heteroaromatic systems examples include quinoline, isoquinoline, cinnoline, tetrahydroisoquinoline, quinoxaline, quinazoline, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, indazole, purine, benzotriazole, pyrrolepyridine, pyrrazolopyridine and the like.
  • the heterocyclic group may be optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, -CN, -NO 2 , -CO 2 R, -C(O)R, -O-R, -N(R N ) 2 , -N(R N )C(O)R, -N(R N )S(O) 2 R, -SR, -C(O)N(R N ) 2 , -OC(O)R, -OC(O)N(R N ) 2 , -SOR, -SO 2 R, -SO 3 R, -S(O) 2 N(R N ) 2 , -SiR 3 , -P(O)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from the group consisting of halo, alkyl, -CN, -NO 2
  • oxo as used herein contemplates an oxygen atom attached with a double bond.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention which is made with counterions understood in the art to be generally acceptable for pharmaceutical uses and which possesses the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethane-disulfonic acid,
  • salts of amino acids such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like (see, e.g., Berge et al, 1977, J. Pharm. Sci. 66:1-19).
  • salts and “hydrates” refers to the hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion.
  • Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity, flowability and manufacturability of the resulting bulk drug.
  • sulfonamide as used herein contemplates a group having the structure
  • R s is selected from the group consisting of hydrogen, C 1 -C 10 alkyl,
  • alkylsulfonyl including, but not limited to alkylsulfonyl and arylsulfonyl.
  • thiocarbonyl means a carbonyl wherein an oxygen atom has been replaced with a sulfur.
  • Each R is independently selected from hydrogen, -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to C 12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino, and oxo.
  • Each R N is independently selected from the group consisting of hydrogen, -OH, Ci to C 12 alkyl, Ci to C 12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • Two R N may be taken together with C, O, N or S to which they are attached to form a five to seven membered ring which may optionally contain a further heteroatom.
  • the compounds of the present invention may be used to inhibit or reduce the activity of HCV, particularly HCVs NS5A protein.
  • inhibition and reduction of activity of the NS5A protein refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound.
  • the inhibition or reduction in the measured activity is at least a 10% reduction or inhibition.
  • reduction or inhibition of the measured activity of at least 20%, 50%, 75%, 90% or 100%, or any number in between, may be preferred for particular applications.
  • a and A' are independently selected from the group consisting of a single bond, -(CR 2 ) n -C(O)-(CR 2 ) p - -(CR 2 ) n -O-(CR 2 ) p - -(CR 2 ) n -N(R N )-(CR 2 ) p - -(CR 2 ) n -S(O) k -N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-N(R N )-(CR 2 ) p -, -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-O-(CR 2 )p-, -(CR 2 ) n -N(R N )-C(O)-O-(CR
  • X 1 is CH 2 , NH, O or S,
  • Y 1 , Y 2 and Z 1 are each independently CH or N,
  • X 2 is NH, O or S
  • the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
  • a and b are independently 1, 2, or 3.
  • c and d are independently 1 or 2
  • n and p are independently 0, 1, 2 or 3
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • each R N is independently selected from the group consisting of hydrogen, -OH, Ci to C 12 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • the A-B-A' can be any of:
  • B is Q or Q Q , wherein each Q is independently selected from the group consisting of a cycloalkyl group, cycloalkenyl group, heterocycle, aryl group or heteroaryl group, with the proviso that only one Q is a six member aromatic ring when B is Q Q and with the proviso that if B is Q Q , any Q is that is poly cyclic is connected to the remainder of the molecule through only one cycle of the poly cycle;
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to C 8 alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein,
  • each hetero atom if present, is independently N, O or S,
  • each of R c , R d , R e and R f may optionally be substituted by Ci to C 8 alkyl, Ci to C 8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)- and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2, -S(O) 2 -R 81 and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 7 and R 8 together form a 4-7 membered ring
  • each t is independently O, 1, 2, 3, or 4, and
  • u 0, 1, or 2.
  • the compounds of the present invention include pharmaceutically acceptable salts of I as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • each Q is independently optionally substituted with one or more substituents each independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and if Q is not aromatic, it is optionally substituted with oxo.
  • each Q is independently optionally substituted with -CN, -OCF 3 , -OCHF 2 , -CF 3 , or -F.
  • B is selected from the group consisting of
  • each r and s is independently 0, 1, 2, 3, or 4;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • each R b is independently C 1 -C 12 alkyl, hydroxyl, halogen or oxo.
  • each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
  • each R a is independently -CN, -OCF 3 , -OCHF 2 , -CF 3 , or -F.
  • a and A' are independently selected from the group consisting of a single bond, -(CR 2 ) n -C(O)-(CR 2 )p-, -(CR 2 ) n -O-(CR 2 )p-, -(CR 2 ) n -N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-N(R N )-(CR 2 )p-, -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) P - and -(CR 2 ) n -N(R N )-C(O)-O-(CR 2 ) p - and a
  • heteroaryl group selected from the group consisting of ⁇ X 1
  • a and A' are independently selected
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl and Ci to Cg heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
  • R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • R c and R d or R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • R c and R d are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • R e and R f are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R 1N is selected from the group consisting of hydrogen, -OH, Ci to
  • A' is selected from the group consisting of single bond, H , H
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • r is selected from the group consisting of 0, 1, 2, 3, or 4.
  • the compounds of the present invention include pharmaceutically acceptable salts of III as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • A' is H , H , -(CR 2 ) n -C(O)-(CR 2 ) p - -(CR 2 ) n -C(O)N(R N )-(CR 2 ) p - or -(CR 2 ) n -N(R N )C(O)-(CR 2 ) p -.
  • A' is V H
  • the compounds of the present invention include pharmaceutically acceptable salts of Ilia as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. [0133] In a fourth embodiment of the second aspect, compounds have formula III
  • A' is selected from the group consisting of
  • the compounds of the present invention include pharmaceutically acceptable salts of IHb as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. 6] In a third aspect of the invention, compounds have formula IV:
  • a and A' are independently selected from the group consisting of single bond, H
  • R N is selected from the group consisting of hydrogen, - OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
  • ⁇ / optionally includes 1 or 2 nitrogens as heteroatoms
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
  • r is O, 1, 2, 3 or 4;
  • each R b is independently C 1 -C 5 alkyl, hydroxyl, halogen, or oxo;
  • s is O, 1, 2, 3, 4, 5, or 6;
  • each of X 1 and X 2 are independently C or N.
  • the compounds of the present invention include pharmaceutically acceptable salts of IV as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • a and A' are each independently ⁇ y H ⁇ or -(CR 2 ) n -C(O)N(R N )-(CR 2 ) p -.
  • the compounds of the present invention include pharmaceutically acceptable salts of IVa as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • the compounds of the present invention include pharmaceutically acceptable salts of IVb as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • a and A' are independently selected from the group consisting of single bond,
  • R N is selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
  • ⁇ / optionally includes 1 or 2 nitrogens as heteroatoms
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • r is O, 1, 2, 3 or 4.
  • the compounds of the present invention include pharmaceutically acceptable salts of V as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • a and A' are each independently [0146]
  • compounds have formula Va:
  • the compounds of the present invention include pharmaceutically acceptable salts of Va as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • the compounds of the present invention include pharmaceutically acceptable salts of Vb as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • each -O- IS l independently a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns
  • each r is independently 0, 1, 2, 3, or 4;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
  • a and A' are independently selected from the group consisting of a single bond, -(CR 2 ) n -C(O)-(CR 2 ) p - -(CR 2 ) n -O-(CR 2 ) p - -(CR 2 ) n -N(R N )-(CR 2 ) p - -(CR 2 ) n -S(O) k -N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-N(R N )-(CR 2 )p-, -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) p -, -(CR 2 ) n -C(O)-O-(CR 2 )p-, -(CR 2 ) n -N(R N )-S(O) k -N(R
  • X 1 is CH 2 , NH, O or S,
  • Y 1 , Y 2 and Z 1 are each independently CH or N,
  • X 2 is NH, O or S
  • the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
  • a and b are independently 1, 2, or 3.
  • c and d are independently 1 or 2
  • n and p are independently 0, 1, 2 or 3
  • k 0, 1, or 2
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • each R N is independently selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • a and A' may be attached to either side of A and A' so that in the example of A or A' being the A-B-A' can be any of:
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein,
  • each hetero atom if present, is independently N, O or S,
  • each of R c , R d , R e and R f may optionally be substituted by Ci to Cs alkyl, Ci to Cs heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and
  • R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)- and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2, -S(O) 2 -R 81 and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 7 and R 8 together form a 4-7 membered ring
  • each t is independently 0, 1, 2, 3, or 4, and
  • u 0, 1, or 2.
  • the compounds of the present invention include pharmaceutically acceptable salts of VI as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • each - ⁇ - IS 1 ndependently
  • each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
  • a and A' are independently selected from the group consisting of a single bond, -(CR 2 )n-O-(CR 2 )p-, -(CR 2 )n-N(R N )-(CR 2 )p-, -(CR 2 ) n -C(O)-N(R N )-(CR 2 ) p - -(CR 2 ) n -N(R N )-C(O)-N(R N )-(CR 2 ) p - and -(CR 2 )n-N(R N )-C(O)-O-(CR 2 )p- and a heteroaryl group selected from the group consisting
  • a and A' are independently selected
  • a and A' are each independently ⁇ y H ⁇ or -(CR 2 ) n -C(O)N(R N )-(CR 2 ) p -.
  • R c , R d , R e and R f are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl and Ci to Cg heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S, R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
  • R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • one of R c and R d or R e and R f are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • both of R c and R d and R e and R f are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
  • R c and R d are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • R e and R f are joined and form a heterocyclic fused ring system selected from the group consisting of:
  • R N is selected from the group consisting of hydrogen, -OH, Ci to
  • C 12 alkyl Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • each R a if present in a compound of any of the second through sixth aspects, is independently -CN, -OCF 3 , -OCHF 2 , -CF 3 , or -F.
  • one of Y and Y' is N.
  • both Y and Y' are N.
  • Z and Z' in any of the previous aspects are each 1-3 amino acids.
  • the amino acids are in the D configuration.
  • Z and Z' in any of the previous aspects are each independently selected from the group consisting of -[U-(CR 4 2 ) t -NR 5 -(CR 4 2 ) t ] u -U-(CR 4 2 ) t -NR 7 -(CR 4 2 ) t -R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -U-(CR 4 2 ),-NR 5 -(CR 4 2 ) t -U-(CR 4 2 ) t -NR 7 -(CR 4 2 ) t -R 8 .
  • one or both of Z and Z' are -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -[C(O)-(CR 4 2 ) t -NR 5 -(CR 4 2 ) t ] u -U-(CR 4 2 ) t -NR 7 -(CR 4 2 ) t -R 8 .
  • Z and Z' are -C(O)-(CR 4 2 ),-NR 5 -(CR 4 2 ),-U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -[C(O)-(CR 4 2 ) t -NR 5 -(CR 4 2 ) t ] u -C(O)-(CR 4 2 ) t -NR 7 -(CR 4 2 ) t -R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ),-NR 5 -(CR 4 2 ),-C(O)-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • Z and Z' are -C(O)-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -(CR 4 2 ) n -C(O)-R 81 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -C(O)-R 81 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -(CR 4 2 ) n -C(O)-O-R 81 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -C(O)-O-R 81 .
  • one or both of Z and Z' are -U- (CR 4 2 ) t -R 8 .
  • one or both of Z and Z' are - C(O)-(CR 4 2 ) t -R 8 .
  • one or both of Z and Z' are -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • Z and Z' are -U-(CR 4 2 ),-NR 5 -(CR 4 2 ),-U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 )t-NR 5 -(CR 4 2 )t-C(O)-(CR 4 2 )t-O-(CR 4 2 ) t -R 8 .
  • Z and Z' are -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ),-O-(CR 4 2 ),-R 8 .
  • one or both of Z and Z' are -C(O)-(CR 4 2 ) n -NR 7 -R 8 wherein R 7 and R 8 together form a 4-7 membered ring.
  • r is from 0 to 4
  • each R a is independently selected from the group consisting of -OH,
  • Ci to Ci 2 alkyl Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
  • a and A' are independently selected from the group consisting of H
  • a or A' is a heteroaryl group, it is optionally substituted with one or more of the substituents selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and
  • n and p are independently O, 1, or 2
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • R N is selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • B' is optionally substituted with between 1 and 4 substituents, each independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to C 12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino and oxo,
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)- and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2, -S(O) 2 -R 81 and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 7 and R 8 together form a 4-7 membered ring
  • each t is independently O, 1, 2, 3, or 4, and
  • u is O, 1, or 2.
  • the compounds of the present invention include pharmaceutically acceptable salts of VII as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • the compounds of the present invention include pharmaceutically acceptable salts of IX as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • B' is selected from the group consisting of - ⁇ - - ⁇ - -
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • the compounds of the present invention include pharmaceutically acceptable salts of IX as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • compounds have formula X:
  • B' is selected from the group consisting of - ⁇ - - ⁇ - -
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • each R 81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R 4 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl.
  • each R 4 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl.
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
  • the compounds of the present invention include pharmaceutically acceptable salts of XI as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. 7] In an additional aspect of the invention, compounds of formula XII are provided:
  • a and A' are independently selected from the group consisting of a single bond
  • X 1 is CH 2 , NH, O or S,
  • Y 1 , Y 2 and Z 1 are each independently CH or N,
  • X 2 is NH, O or S
  • a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0, optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
  • the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to C12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C 12 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
  • a and b are independently 1, 2, or 3
  • c and d are independently 1 or 2
  • n and p are independently 0, 1, 2 or 3
  • k 0, 1, or 2
  • each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
  • each R N is independently selected from the group consisting of hydrogen, -OH, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
  • the A-B-A' can be any of: B is selected f rom the group consisting of v ' s ,
  • - ⁇ - i s a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns
  • X 1 is CH 2 , NH, O or S,
  • each Y 1 is independently CH or N
  • each r and s is independently 0, 1, 2, 3 or 4;
  • each R a is independently selected from the group consisting of -OH, -CN, -NO 2 , halogen, Ci to Ci 2 alkyl, Ci to Ci 2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
  • each R b is independently selected from the group consisting of Ci-Ci 2 alkyl, hydroxyl, halogen and oxo;
  • R c , R d , R e , and R f are each independently selected from the group consisting of: hydrogen, Ci to C 8 alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of R c , R d , R e , and R f may optionally be substituted by Ci to C 8 alkyl, Ci to C 8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
  • R c and R d are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and R e and R f are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
  • Y and Y' are each independently carbon or nitrogen;
  • Z and Z' are independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-NR 7 -(CR 4 2 ),-R 8 , -U-(CR 4 2 ),-R 8 , and -[U-(CR 4 2 ),-NR 5 -(CR 4 2 ),] U -U-(CR 4 2 ),-O-(CR 4 2 ),-R 8 , wherein,
  • U is selected from the group consisting of -C(O)-, -C(S)-, and -S(O) 2 -,
  • each R 4 , R 5 and R 7 is independently selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 8 is selected from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R 81 , -C(O)-O-R 81 , -C(O)-N-R 81 2 , -S(O) 2 -R 81 , and -S(O) 2 -N-R 81 2 , wherein each R 81 is independently chosen from the group consisting of hydrogen, Ci to C 8 alkyl, Ci to C 8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
  • R 7 and R 8 together form a 4-7 membered ring, each t is independently 0, 1, 2, 3, or 4, and
  • u 0, 1, or 2.
  • the compounds of the present invention include pharmaceutically acceptable salts of XII as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
  • the compounds of the invention are prepared by synthetic routes and procedures that are illustrated in the various synthetic schemes below.
  • the synthetic routes shown in schemes below are disclosed for the purpose of illustration and are not meant to be interpreted as limiting the processes to make the embodied compounds by any other methods. It will be appreciated by those skilled in the art that a number of methods are available for the preparation of the compounds of the present invention.
  • These compounds may be prepared by processes which include processes known in the chemical art for the production of structurally analogous compounds or by a novel process described herein.
  • One of the general strategies includes building the central scaffold followed by gradual functional group transformations of the two ends either simultaneously. In order to differentially functionalize the two ends, some orthogonal functional group protection and deprotection strategies are used (T.W. Greene & P. G.
  • IC 50 The concentration of an inhibitor that causes a 50 % reduction in a measured activity
  • Schemes 1-1 and 1-2 illustrate the various methods of preparing aryl-carbocyclic central scaffolds (Bs) and how the two ends of the molecule can be differentially constructed in order to allow for selective functionalization of either end of the molecule.
  • Scheme 1-3 outlines the preparation of core structures connected through a carbon-nitrogen bond.
  • the nitrogen arylation is achieved using one of the several methods.
  • the acetophenone moiety and the V group in A-17 can be sequentially converted to a bromoketone as in A-18 for further introduction of the A-19 moiety.
  • the coupling between A-15 and A-16 to A-17 represents a nucleophilic aromatic substitution method.
  • Other methodologies employed include Buchwald or Ma couplings (J. Org. Chem. 2005, 70, 164), such as the coupling of A-15 with A-20 to B-6, A-15 with A-22 to B-7, A-21 with A-22 to B-8.
  • V is a carboxylate, it can be extended via an amide linkage.
  • the carboxylate can undergo a Curtis rearrangement to an amine, which in turn can be transformed to an amide (B-6 to B-9).
  • the carboxylate can be hydrolyzed and converted to B-IO when reacts with a protected form of pyrrolidin-2- ylmethanamine.
  • the methodologies outlined in this scheme are further depicted in other schemes described herein.
  • Scheme 1-4 illustrates some of the ways for further functional group transformations using scaffold B-I as an example.
  • the nitrogen protecting groups P and P' can be removed simultaneously to give B-Ia.
  • B-Ia is treated together a suitably protected amino acid under standard peptide coupling conditions, such as HATU and a tertiary amine base, e.g. H ⁇ nig's base, the doubly coupled product B-Ib is obtained.
  • P refers to a protecting group such as Boc-, Cbz-, Troc-, etc.
  • P can also be other alkyl, acyl, alkoxylcarbonyl, alkylaminocarbonyl groups that are intended for this position.
  • the newly introduced amino acid in B-If can be the same as the residue on the left-hand side of the molecule or can be a different one. From B- If, a variety of compounds (with a general formula of B-Ig) are prepared with differentially functionalized end pieces.
  • the imidazole moiety is preferably protected with SEM or other protecting groups.
  • the protection process does generate a mixture of regioisomers of the protecting group. However, such a mixture does not usually affect the reactivity of the intermediates toward further reaction and will become one compound upon the removal of the protecting group.
  • the iodo- or bromo-imidazole intermediate A-27 is used converted to is the corresponding borate A-28 under the conditions shown, or using conditions that are known to promote similar transformations.
  • the acetylene compound A-28 is obtained after subsequent treatment with base.
  • Scheme 1-1 The use of intermediate as an alternative method of synthesizing arylimidazole intermediates such as A-I and B-3 is illustrated in Scheme 1-1. These versatile building blocks are used in many other manners as will be shown in the schemes to follow.
  • the aryl-imidazole and benzoimidazole building blocks are synthesized using the route described in Scheme 1-6 (Ref. J. Med. Chem. 2008, 51, 5109; 2006, 49, ZIlA; and 2002, 45, 5556).
  • Those in the art shall recognize that the phenyl, the proline and the protecting group on nitrogen may be replaced in order to achieve the desired functionality at a given position.
  • V for example can be an acetyl group or a masked form
  • OTf V can be a protected form of N
  • Scheme 1-7 [0207]
  • the building blocks used in Scheme 1-1 for the synthesis of scaffolds such as B-I to B-4 and others are synthesized using routes described in Scheme 1-7.
  • the preparation of A-Ia starts with the dimethyl bicyclo[2.2.2]octane-l,4-dicarboxylate, one of the methyl ester group is selectively hydro lyzed to the acid, which in turn is converted to a bromo group to give methyl 4-bromobicyclo[2.2.2]octane-l-carboxylate.
  • a Friedel- Crafts reaction between methyl 4-bromobicyclo[2.2.2]octane-l-carboxylate and a substituted benzene yields A-Ia (Ref. J. Org. Chem. 1970, 55, 917).
  • Compound A-Ib is prepared similarly.
  • Another method to prepare the cyclohexyl-containing compounds such as A-Ib and A-Ib' is through a cross coupling reaction between vinyltrifolate and a phenylboronate (or a boronic acid).
  • the letter V represents a carboxylate group, such as an ethoxylcarbonyl, or a protected amino group, or can be another functional group that can be further functionalized.
  • the resulted styrenyl group can be preserved (A- Ib') or can be saturated under hydrogenation condition to give A-Ib.
  • the cyclopentyl analog A-Ic may be made by similar route.
  • the four-carbon analog is made in sequence as shown.
  • Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA).
  • 1 H-NMR spectra were recorded on a Bruker 400 MHz or 500 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons.
  • Electrospray spray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard 1100 MSD electrospray mass spectrometer using the HPl 100 HPLC for sample delivery.
  • Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses) or a single m/z value for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 5 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using an acetonitrile/water gradient (10%-90%) acetonitrile in water with 0.1% formic acid as delivery solvent.
  • the compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH 4 OAc in acetonitrile/water as delivery solvent. Enantiomeric purity was determined using a Hewlett-Packard Series 1050 system equipped with a chiral HLPC column (ChiralPak AD, 4.6 mm x 150mm) and isocratic elution using 5:95 isopropanol-hexane as a mobile phase.
  • Step a Referring to Scheme 2-3, compound 1 was prepared following procedures described in J. Med. Chem. 2007, 50, 6706.
  • Step b A sample of compound 1 (1.Og, 2.82 mmol) in dichloromethane was treated with excess 4N HCl in dioxane. At the completion of removal of Boc group as indicated by LCMS, solvents were removed and the residue was dried under vaccum. This material was taken up in acetonitrile (6 mL) and treated with tert-butyi (lH-pyrazol-1- yl)methylenedicarbamate (2) (1.01 g, 3.2 mmol) and DIPEA (0.60 g, 4.65 mmol) at rt overnight. The solvents were evaporated off and the crude product was purified by silica gel column chromatography with a gradient eluent consisting various ratio of EtOAc and hexanes to give compound 3 (0.59 g, 71% yield).
  • Step c A solution of 3 (1.34 g, 2.69 mmol, from combined runs) in THF (5 mL) was treated with excess 4N HCl in dioxane at rt overnight. Solvents were removed by evaporation, and residue was further dried under high vacuum. A portion of this de-Boc material (0.3 g, 1.0 mmol) was taken up in THF (4 mL) and water (0.34 mL). To this mixture was added K2CO3 (0.27 g, 2.02 mmol) followed by bromoketone compound 4 (0.33 g, 1.01 mmol, prepared following published procedures). The entire mixture was heated at reflux overnight.
  • Step d A mixture of compound 5 (0.2 g, 0.38 mmol), bis(pinacolato)diboron (0.12 g, 0.46 mmol), potassium acetate (0.11 g, 1.1 mmol), and Pd(dppf)Cl 2 -CH 2 Cl2 (30 mg, 0.038 mmol) in dioxane (5 mL) was stirred at 80 0 C for 17 h under an atmosphere of Ar. Subsequently, the reaction mixture was filtered. The filtered cake was washed with EtOAc (5 mL x 3). The filtrate was washed with H 2 O and dried with anhydrous Na 2 SO 4 . The solvent was removed and the residue was purified by silica gel column chromatography to give compound 6 (0.14 g).
  • Step e A solution of compound 6 (0.640 g, 1.1 mmol) in dioxane (24 mL) and water (2.4 mL) was sequentially added ⁇ S)-tert-hvXy ⁇ 2-(5-iodo-l-((2-(trimethylsilyl) ethoxy)methyl)-lH-imidazol-2-yl)pyrrolidine-l-carboxylate (1.10 g, 2.22 mmol), NaHCO 3 (0.37 g, 3.66 mmol), and Pd(dppf)Cl 2 -CH 2 Cl 2 (90 mg, 0.11 mmol) at rt under an atmosphere of Ar.
  • Step f A sample of compound 8 (34 mg) was treated 4N HCl in dioxane (0.5 mL) at rt overnight to remove both the Boc group and the SEM group. The Cbz group was removed under hydrogeno lysis conditions (Pd/C, H 2 ).
  • Step g Compound 9 (29 mg, 0.05 mmol) was treated with N-Moc-D-Phg-OH (20.6 mg, 0.11 mmol), DMTMM (42 mg, 0.15 mmol) and DIPEA (52 mg, 0.42 mmol) in THF/DMF (0.5 mL /0.5 mL) to give compound 10.
  • Step a Referring to Scheme 2-4, to a stirred solution of 1 (1 eq., 0.2 M) in CH 2 Cl 2 was added DIPEA (1.2 eq.). The reaction flask was cooled with a water-ice bath, and TMSOTf (1.1 eq.) was slowly added over a 10 min period. The reaction was stirred at 0 0 C for 10 min, then at rt until silylation was complete, as determined by TLC (1.5 h). PTT (IM in THF, 1.05 eq) was added over 10 min. The reaction was stirred at rt until bromination was complete, as judged by TLC (30 min).
  • the reaction was partitioned between CH 2 Cl 2 and NaHCO 3 with a 1/1 (v/v) ratio.
  • the aqueous phase was extracted with CH 2 Cl 2 (2x).
  • the combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated.
  • the crude product 2 was used without further purification.
  • Step d A stream of nitrogen was bubbled through a solution of 5 (1 eq., 0.3M) in o-xylene in a sealable reaction tube for 10 min. NH 4 OAc (10 eq.) was added to the solution. The reaction tube was sealed and placed in a 150 0 C oil bath. The reaction was stirred at this temperature for 1 h then cooled to rt. The reaction tube was carefully opened, and its contents partitioned between aqueous Na 2 CO 3 and CH 2 Cl 2 /Me0H (10/1 (v/v)) with a 1 : 1 (v/v) ratio..
  • Step e To a solution of 6 (1 eq.) in EtOH/AcOH (1/1 , v/v) was added Pd(OH) 2 on carbon (10%). After sealing the reaction flask with a rubber septum, the system was evacuated and backfilled with 1 atm H 2 (2x). The vigorously stirred reaction was stirred at rt under H 2 (1 atm) for 16 h. The mixture was filtered through a pad of CELITETM545 (pre- washed with EtOH), and the separated solids were washed with EtOH (5x). The filtrate was concentrated to provide crude 7.
  • Residual AcOH was removed by dissolving the crude product in H 2 O then adjusting the pH to ⁇ 13 with 2N aqueous NaOH. The product was extracted with CH 2 Cl 2 until the extracts were free of 7. The crude product was used without further purification.
  • Step g A stream of nitrogen was bubbled through a solution of 8 (1 eq, 0.3M) in o-xylene in a sealable reaction tube for 10 min. NH 4 OAc (10 eq) was added to the solution. The reaction tube was sealed and placed in a 150 0 C oil bath. The reaction was stirred at this temperature for 1 h then cooled to rt. The reaction tube was carefully opened, and its contents were partitioned between aqueous Na 2 CO 3 and CH 2 Cl 2 /Me0H (10/1 (v/v)) with a 1 : 1 (v/v) ratio.
  • Step h To a solution of 9 (1 eq) in absolute EtOH was added Pd on carbon (10%, 50% H 2 O). After sealing the reaction flask with a rubber septum, the system was evacuated and backfilled with 1 atm H 2 (2x). The vigorously stirred reaction was stirred at rt under H 2 (1 atm) for 4 h. The mixture was filtered through a pad of CELITETM545 (pre -washed with EtOH), and the separated solids were washed with EtOH (5x). The filtrate was concentrated to provide crude 10 that was used without further purification.
  • Step i To a stirred solution of 10 (1 eq, 0. IM) and N-Moc-D-Phg-OH(1 eq.) in DMF, DMTMM (1 eq.) and DIPEA (1 eq.) were sequentially added. The reaction was stirred at rt for 1 h and partitioned between aqueous Na 2 CO 3 and CH 2 Cl 2 /Me0H (10/1) with a 1/1 (v/v) ratio. The layers were separated, and the aqueous phase was extracted with CH 2 Cl 2 ZMeOH (10/1) until the extracts were free of any uv-active component.
  • Step j Compound 11 (1 eq.) was treated with THF (7 mL/mmol 11) followed by slow addition of 4N HCl in dioxane (14 mL/1 mmol of 11). The reaction was stirred at rt for
  • Step k To a stirred solution of 12 (1 eq, 0. IM) and N-Boc-D-Phg-OH (1 eq.) in DMF were sequentially added DMTMM (1 eq.) and DIPEA (1 eq.). The reaction was stirred at rt for 1 h. The crude reaction mixture was purified on a C18-Luna preparative HPLC column (H 2 O-MeCN, 0.1% HCO 2 H) to give compound 13 as a white solid.
  • Step 1 Compound 13 (1 eq.) was treated with THF (7 mL/mmol) followed by slow addition of 4N HCl in dioxane (14 mL/1 mmol of 13). The reaction was stirred at rt for
  • Step m To a stirred solution of 14 (1 eq, 0.1M) and cyclopropane carboxylic acid (1 eq.) in DMF were sequentially added DMTMM (1 eq.) and DIPEA (1 eq.). The reaction was stirred at rt until complete, as determined by LC-MS. The crude reaction mixture was purified on a C18-Luna preparative HPLC column (H 2 O-MeCN, 0.1% HCO 2 H) to give compound 15 as a white solid.
  • Step b To a suspension OfAlCl 3 (5.9 g, 54 mmol) in DCM (200 mL) at 0 0 C was added l-(4-phenylcyclohexyl)ethanone (9 g in DCM), and acetyl chloride (10.4 mL, 146 mmol) dropwise over 30 min. The mixture was stirred to rt for 15 min. and heated at 45 0 C for 4h. After being cooled to rt, the mixture was poured it into ice-HCl (IN). The organic layer was collected, and the aqueous layer was extracted with ethyl acetate (3x).
  • Step c To a solution of l-(4-(4-acetylcyclohexyl)phenyl)ethanone (A2) (900 mg, 3.7 mmol) in MeOH (20 mL) at O 0 C was added bromine (993 ⁇ L, 8.1 mmol) drop-wise and the reaction mixture was stirred below 5 0 C for 3 h. The reaction was quenched by adding saturated aqueous NaHCO 3 solution and the mixture was extracted with ethyl acetate (3x). The extracts were combined and concentrated.
  • A2 l-(4-(4-acetylcyclohexyl)phenyl)ethanone
  • Step d To a solution of N-Cbz-L-Pro-OH (1.36 g, 5.47 mmol) in acetonitrile (10 mL) was added triethyl amine (762 ⁇ L, 5.47 mmol) and 2-bromo-l-(4-(4-(2- bromoacetyl)cyclo hexyl)phenyl)ethanone (A3) (1 g, 2.49 mmol) in acetonitrile. The reaction mixture was stirred at rt overnight. The solvent was removed and product was diluted with ethyl acetate (3x), washed with NaHCO 3 (100 mL) and brine, and dried with Na 2 SO 4 .
  • Step f (5)-benzyl 2-(4-(4-(4-(4-(4-(4-(4-((S)- 1 -(benzyloxycarbonyl)pyrrolidin-2-yl)- 1 H- imi-dazol-2-yl)phenyl)cyclohexyl)- 1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (A5) (200 mg) and Pd/C (20 mg) in MeOH (20 mL) was purged with H 2 . The reaction was stirred under hydrogen balloon for 48 h, filtered on CELITETMand concentrated.
  • Step g To a solution of 2-((5)-pyrrolidin-2-yl)-4-(4-(4-(4-((5)-pyrrolidin-2-yl)- lH-imidazol-2-yl) phenyl)cyclohexyl)-lH-imidazole (A6) (300 mg, 0.715 mmol) in DMF (20 mL) was added N-Boc-L- VaI-OH (432 mg, 1.72 mmol), HATU (654 mg, 1.72 mmol) and diisopropylethylamine (590 ⁇ L, 3.58 mmol). The reaction was stirred at rt overnight. The solvent was removed under reduced pressure.
  • Step a Referring to Scheme 2-7 to a suspension of AICI3 (1.58 g, 12 mmol) in DCM (30 niL) at -78 0 C was added l-(4-phenylcyclohexyl)ethanone (Al') (1 g in DCM, 5.0 mmol), and bromoacetyl bromide (0.65 mL, 7.5 mmol) dropwise over 10 min. The mixture was stirred to rt for 15 min and heated at 40-50 0 C for 3 h, cooled to rt and poured into a mixture of ice and HCl (IN).
  • Al' l-(4-phenylcyclohexyl)ethanone
  • Step c To a solution of A3' (20.0 g, 40.7 mmol) and diethylisopropylamine (20 mL) in DCM (200 mL) in a round bottom flask was added trimethylsilyl trifluoromethanesulfonate (TMSOTf, 20 mL, 122 mmol) at -78 0 C. The reaction was stirred at rt overnight. To the solution was added a solution of phenyltrimethylammonium tribromide (PTT, 16.8 g, 45 mmol) in THF (50 mL). The reaction was stirred at rt 2 h and quenched with saturated NaHCO 3 solution.
  • TMSOTf trimethylsilyl trifluoromethanesulfonate
  • Step e Following the deprotection and amide formation operations described for similar systems and repeated the process twice, the differentially functionalized compound A8' was obtained.
  • Step a Referring to Scheme 3-1, methyl S-phenylcyclobutanecarboxylate A2 was obtained by treating a solution of 3-phenylcyclobutanecarboxylic acid (5.3 g, 30 mmol, Reference: JOC, 1962, 27, 1647) in methanol (50 mL) and thionyl chloride (2.9 mL, 39 mmol) first at 0 0 C for 0.5 h and then at rt overnight. The solvent was removed, the residue was diluted with ethyl acetate (100 mL) and washed with brine and H 2 O, dried with Na 2 SO 4 .
  • 3-phenylcyclobutanecarboxylic acid 5.3 g, 30 mmol, Reference: JOC, 1962, 27, 1647
  • thionyl chloride 2.9 mL, 39 mmol
  • Step b To a solution of methyl S-phenylcyclobutanecarboxylate (A2) (5.41 g, 28 mmol) and AICI3 (9.5 g, 71 mmol) in methylene chloride (150 mL) at 0 0 C was added acetyl chloride (4 mL) dropwise and the reaction mixture was stirred at rt overnight. The reaction mixture was diluted with IN HCl (100 mL) and extracted with CH 2 Cl 2 , and the organic layer was dried with Na 2 SO 4 , filtered and concentrated.
  • A2 methyl S-phenylcyclobutanecarboxylate
  • AICI3 9 g, 71 mmol
  • Step c To a solution of methyl 3-(4-acetylphenyl)cyclobutanecarboxylate (A3) (6.56 g, 28.2 mmol) in methylene chloride (250 mL) at O 0 C was added PTT (10.6 g, 28.2 mmol) and the reaction mixture was stirred at rt overnight. The reaction was quenched with NaHCO 3 (100 mL), washed with brine, and dried with Na 2 SO 4 . After removal of the solvent, crude product A4 (7.2 g, 82% yield) was directly used for the next step.
  • A3 methyl 3-(4-acetylphenyl)cyclobutanecarboxylate
  • Step d A solution of crude methyl 3-(4-(2-bromoacetyl)phenyl) cyclobutanecarboxylate (A4) (8.8 g, 28.3 mmol), N-Boc-L-Pro-OH (6.7 g, 31.2 mmol) and triethylamine (4.34 mL) in CH 3 CN was stirred for 2 h. At the completion of reaction, the volatile components were removed in vacuo, and the residue was partitioned between H 2 O and CH 2 Cl 2 . The organic phase was dried, filtered and concentrated in vacuo.
  • Step e A mixture of ketoester (S)-l-tert-butyl 2-(2-(4-(3-(methoxycarbonyl) cyclobutyl) phenyl)-2-oxoethyl) pyrrolidine- 1 ,2-dicarboxylate (A5) (3.7 g, 8.76 mmol) and NH 4 OAc (6.75 g, 87.6 mmol) in o-xylenes (10 niL) was heated in a sealed tube at 140 0 C for 1 h. The volatile component was removed in vacuo, and the residue was partitioned between H 2 Oand CH 2 Cl 2 . Te organic phase was dried, filtered and concentrated in vacuo.
  • Step f To a solution of the compound (S)-tert-bv ⁇ y ⁇ 2-(4-(4-(3- (methoxycarbonyl)cyclobutyl) phenyl)- 1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (A6) (1.76 g, 41.5 mmol) in THF (10 mL) and MeOH (10 mL), LiOH (IM, 10.0 mL) was added at 0 0 C.
  • Step g The mixture of (5)-3-(4-(2-(l-(tert-butoxycarbonyl)pyrrolidin-2-yl)-lH- imidazol-4-yl) phenyl)cyclobutanecarboxylic acid (A7) (822 mg, 2 mmol), DPPA (0.53 mL, 2.4 mmol), and triethylamine (0.34 mL) in benzyl alcohol (10 mL) was heated at 95 0 C overnight. The volatile component was removed in vacuo, the residue was partitioned between H 2 O and CH 2 Cl 2 . The organic phase was dried, filtered and concentrated in vacuo.
  • Step h To a solution of (S)-tert-butyl 2-(4-(4-(3-(benzyloxycarbonylamino) cyclobutyl)phenyl)- lH-imidazol-2-yl)pyrrolidine-l -carboxylate (A8) (449 mg, 0.87 mmol) in methanol (10 mL) was added 10% Pd/C (50 mg) and the mixture was stirred overnight under H 2 atmosphere in a balloon.
  • Step i To a solution of (S)-tert-bv ⁇ yl 2-(4-(4-(3-aminocyclobutyl)phenyl)-7H- imidazol-2-yl)pyrrolidine-l -carboxylate (A9) (330 mg, 0.86mmol) in dichloromethane (60 mL), N-Boc-L-Pro-O ⁇ (204 mg, 0.95 mmol), and DIC (0.2 mL) were added at rt. After stirring overnight, the reaction mixture was diluted with methylene chloride (50 mL), and washed with saturated aqueous NaHCCh, dried with Na 2 SO 4 .
  • Step j To a solution of (S)-tert-butyl 2-(3-(4-(2-((S)-l-(tert- butoxycarbonyl)pyrrolidin- 2-yl)-7H-imidazol-4-yl)phenyl)cyclobutylcarbamoyl)pyrrolidine- 1-carboxylate (AlO) (100 mg, 0.173 mmol) in T ⁇ F (8 mL), 4N HCl in dioxane (2 mL) was added slowly at rt.
  • AlO 1-carboxylate
  • Step k To a solution of (5)-N-(3-(4-(2-((5)-pyrrolidin-2-yl)-lH-imidazol-4- yl)phenyl) cyclobutyl)pyrrolidine-2-carboxamide (All) (100 mg, 0.98 mmol) in dichloromethane (20 mL), N-Boc-D-Phg-OH (87mg, 0.35 mmol), DIPEA (144 ⁇ L, 0.34 mmol) and HATU (134 mg, 0.35 mmol) were added at rt. After stirring overnight, the reaction mixture was washed with brine and H 2 O, dried with Na 2 SO 4 .
  • Step a A sample of the product from Scheme 3-1, tert-butyl (R)-2-((S)-2-(3-(4- (2-((S)- 1 -((R)-2-( te/t-butoxycarbonyl amino)-2-phenylacetyl)pyrrolidin-2-yl)- 1 H-imidazol- 4-yl)phenyl)cyclobutylcarbamoyl)pyrrolidin- 1 -yl)-2-oxo- 1 -phenylethylcarbamate (A13) (222 mg, 0.262 mmol) in THF (10 niL) was treated with 4N HCl in dioxane (5 rnL) at rt for 8 h.
  • Step b To a solution of (5)-l-((i?)-2-amino-2-phenylacetyl)-N-(3-(4-(2-((5)-l- ((i?)-2-amino -2-phenylacetyl)pyrrolidin-2-yl)- 1 H-imidazol-4-yl)phenyl)cyclobutyl) pyrrolidine-2-carboxamide (80 mg, 0.124 mmol) in dichloromethane (20 mL), cyclopropyl carboxylic acid (22 mg, 0.26 mmol), DIPEA (0.5 mL) and HATU (94 mg, 0.26 mmol) were added at rt.
  • Step a Referring to Scheme 4-1, the starting building blocks, Al, Al, A3, and A4 can be prepared following published conditions in the literature. References: 1). Chang, H.; Fiesman, W. F. and Petter, R. C. Syn. Comm. 2007, 37, 1267. 2). Champans, N. B.; Sotheeswar, S. and Tonyne, K. J. J. Org. Chem. 1970, 35, 917. 3). Delia, E. W. and Tsanaktisidis, J. Aust. J. Chem. 1985, 38, 1705. [0260] Step b.
  • Step d To a solution of A3 (17.8 g) in dibromomethane (1200 mL) was added mercury(II) oxide at rt. The reaction was warmed up to 80 0 C and bromine (6.0 mL) was added dropwise during 25 min. After additional 3 h stirring, the reaction was cooled down to rt and filtered through a pad of CELITETM, washed with dichloromethane, concentrated to afford A4 (19.8 g). The crude product A4 was used without further purification.
  • Step e To a solution of A4 (19.8 g) in dichloromethane (500 mL) at -20 0 C was added aluminum chloride (43 g) in several portions. The reaction was then warmed up to O 0 C. After overnight stirring, the reaction was poured into a mixture of ethyl acetate (800 mL), IM HCl (800 mL) along with some ice. After separating the ethyl acetate layer, the aqueous layer was extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with brine, H 2 O, dried over Na 2 SO 4 , filtered, and concentrated to afford A5 (19.2 g), which was used without further purification.
  • Step f To a solution of A5 (19.2 g) in dichloromethane (500 mL) at -20 0 C was added acetyl chloride (16.8 mL), followed by aluminum chloride (43 g). The reaction was allowed to warm up to rt. After overnight stirring, the reaction was poured into a mixture of ethyl acetate (800 mL), IM HCl (800 mL) along with some ice. After separating the organic layer, the aqueous layer was extracted with ethyl acetate (3x300 mL). The combined organic layers were washed with brine, H 2 O, dried over Na 2 SO 4 , filtered, and concentrated to afford A6 (24 g), which was used for next reaction without further purification.
  • Step g To a solution of A6 (21 g) in MeOH (500 mL) and THF (500 mL) was added aqueous lithium hydroxide (IM, 365 mL) at rt. After overnight stirring, the reaction was concentrated. The residue was diluted with water (1400 mL) and extracted with diethyl ether (3 x 500 mL), ethyl acetate (2 x 400 mL). The combined organic layers were extracted with lithium hydroxide (IM, 500 mL). All aqueous basic layers were combined and acidified to pH 2 by concentrated HCl, extracted with ethyl acetate (3 x 800 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated to provide A7 (14.8 g).
  • IM lithium hydroxide
  • Step h To a solution of A7 (14.8 g) in dichloromethane (800 mL) was added oxalyl chloride (5.1 mL) at rt. DMF (209 ⁇ L) was added in three portions over 4 h. The reaction was concentrated and re-dissolved in dichloromethane (500 mL). The fresh made diazomethane (0.3M, 500 mL) was added at O 0 C. The reaction was slowly warmed up to rt. After overnight stirring, the reaction was concentrated to obtain the crude A8 (17.8 g).
  • Step j To a stirred solution of A9 (18.5 g) and Cbz-Pro-OH (14.5 g) in MeCN was added Et 3 N (8.1 mL). The reaction was stirred at rt overnight and concentrated. The resulting crude product was diluted by ethyl acetate (1000 mL) and washed with saturated sodium carbonate, brine, H 2 O, dried over sodium sulfate and concentrated to provide AlO (27 g)- [0269] Step k. To a stirred solution of AlO (10 g) in CH 2 Cl 2 (400 mL) was added DIPEA (3.4 mL).
  • Step 1 To a stirred solution of All (8.7 g) and N-Cbz-L-Pro-OH (3.45g) in MeCN was added Et 3 N (2.24 mL). The reaction was stirred at rt overnight and concentrated. The resulting crude product was diluted by ethyl acetate (500 mL) and washed with saturated sodium carbonate, brine, water, dried over sodium sulfate and concentrated to provide A12 (10.2 g).
  • Step n To a stirred solution of A13 (500 mg) in dichloromethane (50 mL) was added trifluoroacetic acid (5 mL). After 3 h, the reaction was concentrated to dryness to give a TFA salt, which was dissolved in DMF (20 mL). To the solution were added DIEA (490 ⁇ L), N-Moc-D-Phg-OH (98 mg) and 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4- methylmorpholinium chloride (DMTMM, 156 mg) subsequently. After one h stirring, the reaction was diluted with H 2 O. The suspension was filtered through a pad of CELITETM545 and washed with H 2 O. The filtrate cake was rinsed with dichloromethane and concentrated to provide A14 (380 mg) without further purification.
  • Step 13 To a stirred solution of A14 (8 mg) in methanol (3 mL) was added 10% Pd/C (4 mg) and one drop of concentrated HCl. The reaction was in a Parr shaker at rt and under 60 psi of hydrogen for 12 hours. The reaction was filtered through a pad of CELITETM545 and washed with methanol. The filtrate was concentrated to dryness to provide a free amine, which was dissolved in DMF (1 mL). Subsequently, the mixture was added DIEA (6 ⁇ L), N-Moc- VaI-OH (1.8 mg) and DMTMM (2.8 mg). After stirring for one h, the reaction was quenched by adding water.
  • the suspension was filtered through CELITETM545 and washed with water.
  • the filtrate cake was rinsed by dichloromethane and concentrated.
  • the residue was purified by prep-HPLC (Phenomenex, C18-Luna column, H 2 O-MeCN, 0.1% HCO 2 H) to provide A15 (3.0 mg, 98% purity).
  • Step a Referring to Scheme 5-4, a mixture of Inflate 2 (0.43 g, 2.34 mmol), borate 3 from above (1.01 g, 2.3 mmol) and Pd(PPh 3 ) 2 Cl 2 (160 mg, 0.23 mmol) in THF (12 mL) and aqueous Na 2 CO 3 (2 M, 2.4 mL) was degassed and filled with nitrogen. The mixture heated at 8O 0 C overnight. The reaction mixture was purified by column chromatography eluting with 1% methanol in ethyl acetate to give compound 4 (0.95 g, 70% yield).
  • Step b To a solution of 4 (0.95 g, 1.6 mmol) in DCM (32 mL) at O 0 C was add 4M HCl in dioxane. The mixture was stirred at O 0 C for 3 h and warmed to rt for 1 h. Solvent was removed to give a white solid 5.
  • Step c A mixture of 5 obtained above, DMTMM (0.89g, 3.2 mmol), triethylamine (1.12 mL, 8.0 mmol) and N-Boc-D-Phg-OH (0.8 g, 3.2 mmol) in THF (16 mL) was stirred at rt for 14 h. The reaction was diluted with H 2 O (50 mL), extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 , and then concentrated to give a residue.
  • Step d A mixture of 5 (400 mg, 1.0 mmol) and Pd/C ( 100 mg) in methanol ( 12 mL) was degassed, and filled with hydrogen (60 psi). The mixture was shaken for 16 h. The solution was filtered through a pad of CELITETM545. The filtrate was concentrated to give a pale yellow solid 7.
  • Step e A mixture of 7 (384 mg, 0.98 mmol), DMTMM (0.51g, 1.86 mmol), triethylamine (0.54 mL, 3.9 mmol) and Boc-D-Phg-OH (466 mg, 1.86 mmol) in THF (10 mL) was stirred at rt for 14 h. The reaction was diluted with H 2 O and extracted with ethyl acetate. The combined organic layers were washed with brine and dried over Na 2 SO 4 , concentrated to give a residue.
  • Step a Referring to Scheme 5-5, to a solution of 8 (0.86 g, 1.0 mmol) in DCM (10 mL) at O 0 C was add TFA (2 mL). The mixture was stirred at rt for 3 h. Solvent was removed to give a white solid 9.
  • Step b To a solution of 9 (90 mg, 0.14 mmol) and triethylamine (95 ⁇ L, 0.68 mmol) in THF/DMF (2 mL, 1/1 (v/v)) at -78 0 C was added morpholinyl chloroformate (30 ⁇ L, 0.26 mmol). The solution was stirred at rt overnight, diluted with H 2 Oand ethyl acetate. The organic layer was washed with H 2 O and brine, dried over sodium sulfate, and then concentrated to give a residue. The residue was purified with silica gel chromatography eluting with 5% methanol in DCM to afford 10 (40 mg).
  • Step a Referring to Scheme 5-6, to prepare compound 1, to a solution of quinoline-6-carboxylic acid methyl ester (5.61 g, 30 mmol) in 100 mL of dichloromethane was added mCPBA (8.1 g, 36 mmol, 77% maximum purity) in four portions in 5 min at 0 0 C. The resulting mixture was warmed to rt and stirred for 2 h. The reaction mixture was diluted with 300 mL of dichloromethane and washed with aqueous Na 2 S 2 O 3 solution, saturated NaHCO 3 solution, H 2 Oand brine.
  • Step b To the solution of quinoline iV-oxide (6.7 g, 33 mmol) in dichloromethane (60 mL) was added POCl 3 (30 mL) dropwise at rt. The reaction mixture was stirred for 16 h at 50 0 C in sealed vessel before it was concentrated to dryness. The residue was dissolved in dichloromethane and washed with saturated NaHCO 3 , H 2 Oand brine. The organic layer was dried over Na 2 SO 4 .
  • Step c The mixture of 1 (1.8 g, 8.1 mmol), methyl isonipecotate 2 (1.75 g, 12.2 mmol) and K 2 HPO 4 (5.64 g, 32.4 mmol) in 15 mL of DMSO was stirred at 80 0 C for 20 hours. After cooling down, the resulting mixture was partitioned between 500 mL of EtOAc and 500 mL of H 2 O. The organic layer was washed with H 2 O and brine, and dried (Na 2 SO 4 ).
  • Step d To the solution of 3 (1.81 g, 5.5 mmol) and chloroiodomethane (2.81 mL, 38.5 mmol) in THF (40 mL) was added LDA (pre-cooled to -78 0 C, freshly made from 10.9 mL of diisoproylamine and 28.6 mL of 2.5 M n-BuLi in hexanes in 40 mL of THF) at -78 0 C via cannula over 20 minutes. The reaction mixture was stirred for two hours at -78 0 C before it was quenched by dropwise addition of 60 niL AcOH/THF (v/v, 1/1).
  • Step e A solution of 4 (1.2 g, 3.3 mmol), N-Boc-L-Pro-OH (2.1 g, 9.9 mmol), DIPEA (2.96 mL, 19.8 mmol) and potassium iodide (1.66 g, 9.9 mmol) in MeCN (50 mL) was stirred at 40 0 C for 14 h. After removing all solvent in vacuo, the residue was partitioned in EtOAc and saturated NaHCO 3 . The organic layer was washed with H 2 O and brine and dried over Na 2 SO 4 .
  • Step f A mixture of 5 (723 mg, 1.0 mmol), ammonium acetate (2.31 g, 30 mmol) and Et 3 N (4.18 mL, 30 mmol) in xylene (30 mL) was stirred in sealed vessel at 140 0 C for 1.5 h. After removing all solvent in vacuo, the residue was partitioned in 5% MeOH in dichloromethane and water. The organic layer was washed with H 2 Oand brine. The aqueous layers were extracted with 5% MeOH in dichloromethane twice. The combined organic layers were dried over Na 2 SO 4 .
  • Step g The solution of 6 (320 mg) in 6 mL of dichloromethane and TFA (5 mL) was stirred at rt for 2 h. After removing solvent in vacuo, the residue was purified by reverse- phase preparative HPLC to afford compound 7 (120 mg) as a yellow solid.
  • Step h To a solution of N-Moc-L- VaI-OH (8) (77 mg, 0.44 mmol) and HATU (167 mg, 0.44 mmol) in 2 mL of DMF was added DIPEA (0.15 mL, 1.0 mmol). The resulting solution was stirred at rt for 20 min before 7 (97 mg, ca. 0.2 mmol) and DIPEA (0.15 mL, 1.0 mmol) in 3 mL of DMF was added. The reaction mixture was stirred at rt for another 2 h with determination of the completion of the reaction by LC-MS. The solution was partitioned between EtOAc and water and the organic layer was washed with H 2 Oand brine.
  • Step a Referring to Scheme 5-7, to a suspension of quinoline-6-carboxylic acid (13.2 g, 76.2 mmol) in MeOH (120 mL) was added thionyl chloride (16.6 mL, 229 mmol) dropwise at 0 0 C over 10 minutes. The resulting mixture was refluxed for 3 h, then concentrated to remove all solvents in vacuo. The residue was partitioned between 300 mL of EtOAc and 500 mL of saturated NaHCCh. The organic layer was washed with H 2 O followed by brine and dried with Na 2 SO 4 .
  • Step b To a solution of 4-hydroxy-cyclohexanecarboxylic acid (11.5 g, 80 mmol) in methanol (120 mL) was added thionyl chloride (16.5 mL, 224 mmol) dropwise at 0 0 C. The resulting mixture was then warmed to refluxing for 3 hours. All solvent was removed in vacuo and the residue was dissolved in EtOAc. The solution was washed with saturated aqueous NaHCO 3 solution, H 2 O and brine. Column chromatography (EtOAc/Hexanes, v/v, 1/1 to 2/1) gave 8.5 g methyl ester as colorless oil.
  • Step c To a solution of compound 1 (3.45 g, 18.4 mmol) in absolute ethanol (100 mL) was added TFA (1.42 mL, 18.4 mmol) dropwise at rt, followed by compound 2 (3.18 g, 15.3 mmol). The reaction mixture was heated to reflux. (TMS) 3 SiH (5.7 mL, 18.4 mmol) and AIBN (2.52 g, 15.3 mmol) were added into the mixture in four portions over a period of 6 h. After refluxing for 8 h, the resulting mixture was cooled down and all solvents were removed.
  • TMS TMS 3 SiH
  • AIBN (2.52 g, 15.3 mmol
  • Step d To a solution of Intermediate 3 (470 g, 1.5 mmol) in methanol (20 mL) was added thionyl chloride (0.55 mL, 7.5 mmol) dropwise at O 0 C. The resulting mixture was then heated to refluxing for 3 h. All solvent was removed in vacuo and the residue was dissolved in EtOAc. The solution was washed with saturated aqueous NaHCO 3 solution, water and brine, respectively. Column chromatography (EtOAc/Hexanes, v/v, 1/1) gave compound 4 (310 mg). LC-MS (ESI): m/z 328 (M+l) + . [0292] Step e.
  • Step f A solution of Intermediate 5 (330 mg, 0.91 mmol), N-Boc-L-Pro-OH (0.58 g, 2.73 mmol), DIPEA (0.81 mL, 5.46 mmol) and potassium iodide (0.45 g, 2.7 mmol) in MeCN (20 mL) was stirred at 40 0 C for 14 h. After removing all solvent in vacuo, the residue was partitioned in EtOAc and saturated NaHCO3. The organic layer was washed with H 2 O and brine and dried over Na 2 SO 4 .
  • Step g A mixture of Intermediate 6 (450 mg, 0.62 mmol), ammonium acetate (1.44 g, 18.7 mmol) and Et 3 N (2.6 mL, 18.7 mmol) in xylene (20 mL) was stirred in sealed vessel at 140 0 C for 1.5 h. After removing all solvent in vacuo, the residue was partitioned between 5% MeOH in dichloromethane and H 2 O. The organic layer was washed with H 2 O and brine. The aqueous layers were extracted with 5% MeOH in dichloromethane twice. The combined organic layers were dried over Na 2 SO 4 .
  • Step h A solution of Intermediate 6 (110 mg) in dichloromethane (3 mL) and TFA (2 mL) was stirred at rt for 2 h. After removing all solvent in vacuo, compound 8 (122 mg) was obtained as a yellow TFA salt.
  • Step i To a solution of N-Moc-D-Phg-OH (25 mg) and compound 8 (-40 mg) in 0.75 mL of THF and 1.5 mL of DMF was added DIPEA (0.01 mL). The resulting solution was stirred at rt for 20 min before DMTMM (33 mg) was added. The reaction mixture was stirred at rt for another 2 h as LC-MS indicating the completion of reaction. The solution was partitioned in EtOAc and water, the organic layer was washed with water and brine. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na 2 SO 4 before it was concentrated in vacuo.
  • Step a Referring to Scheme 5-8, to a suspension of quinoline-6-carboxylic acid (13.2 g, 76.2 mmol) in 120 mL MeOH was added thionyl chloride (16.6 mL, 229 mmol) dropwise at O 0 C in 10 min. After being heated at reflux for 3 h, the volatile solvents were removed by a rotary evaporator in vacuo. The residue was taken up in 300 mL EtOAc and was washed with 500 mL saturated NaHCO 3 , H 2 Oand brine sequentially. The organic layer was dried over anhydrous Na 2 SO 4 .
  • reaction mixture was kept at refluxing for another 12 h. After cooling down, the mixture was partitioned between EtOAc and water. The organic layer was washed with brine and dried over anhydrous Na 2 SO 4 . After filtration and concentration, the residue was purified by the flash column chromatography (silica, hexanes/ethyl acetate, v/v, 4/1 to 2/1) to afford compound C4 (4.6 g, 64 % yield) as a white solid. The product was further purified by recrystallization from a mixture of EtOAc and hexanes.
  • Step c 2-Chloro-l- ⁇ 2-[4-(2-chloro-acetyl)-bicyclo[2.2.2]oct-l-yl]-quinolin-6-yl ⁇ - ethanone.
  • C4 610 mg, 1.68 mmol
  • chloroiodomethane (0.74 mL, 10.1 mmol)
  • THF 10 mL
  • LDA pre-cooled to -78 0 C, freshly made from 3 mL of diisoproylamine and 8.06 mL of 2.5 M n-BuLi in hexanes in 10 mL of THF
  • Step e The mixture of C6 (700 mg, 0.94 mmol), ammonium acetate (2.16 g, 28 mmol) and Et 3 N (3.9 mL, 28 mmol) in xylene (30 mL) was stirred in sealed vessel at 140 0 C for 1.5 h. After removing all solvent in vacuo, the residue was partitioned in 5% MeOH in dichloromethane and water. The organic layer was washed with H 2 O and brine. The aqueous layers were extracted with 5% MeOH in dichloromethane twice. The combined organic layers were dried over Na 2 SO 4 .
  • Step a Referring to Scheme 5-9, a mixture of acetanilide 1 (3.28g, 24 mmol), 4- bromo-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (2) (5 g, 20 mmol), ZnCl 2 (13.1 g, 96 mmol) in 1 ,2-dichloroethane (2 mL) in a sealed Parr bottle was heated at 120 0 C for 16 h. The reaction mixture was dissolved in ethyl acetate (100 mL) and washed with H 2 O (50 mL) and brine (50 mL). The organic phase was dried over Na 2 SO 4 and concentrated under reduced pressure to give a mixture of ester 3 and acid 3'.
  • Step b The resulting mixture of ester 3 and acid 3' was dissolved in methanol (60 mL) and treated with aqueous lithium hydroxide (10 g in 20 mL of water, 240 mmol). The reaction mixture was refluxed for 4 h. Methanol was evaporated under reduced pressure and the resulting aqueous solution was washed with ethyl acetate (20 mL). The aqueous solution was adjusted to pH 2 by the addition of 1 N HCl (aq) and extracted with ethyl acetate (2 x 100 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated in vacuo to give 4 (5.3 g, 92% yield) as a yellow solid.
  • aqueous lithium hydroxide 10 g in 20 mL of water, 240 mmol
  • Step c A nitrating mixture [ 1.17 mL, prepared from 67% HNO 3 (3.52 mmol) and H 2 SO 4 ] was added dropwise to a cooled mixture of acid 4 (1.01 g, 3.52 mmol) in glacial acetic acid (8 mL) and acetic anhydride (4 mL). The mixture was stirred at rt for 12 h and poured into iced H 2 O. The precipitate was filtered off, washed with H 2 OtO neutral, and dried in vacuo to give 5 (0.72 g, 70% yield) as a yellow solid.
  • Step f A solution of N-Cbz-L-Pro-OH (2 g, 8 mmol), pentafluorophenol (1.48 g, 8 mmol) and DCC (1.82 g, 8.8 mmol) in ethyl acetate (20 mL) was stirred at rt for 2 h. The reaction solution was filtered and the filtrate was concentrated in vacuo to give compound 8 (3.2 g, 96% yield) as a white solid. The mixture of compound 7 (0.44 g, 1.61 mmol) and activated ester 8 (0.8 g, 1.93 mmol) in 2,2-dimethoxypropane (30 mL) was stirred at rt overnight. The reaction solution was concentrated to give crude compound 9.
  • Step g Compound 9 was dissolved in acetic acid (2 mL) and heated at 60 0 C for 5 h. The reaction solution was neutralized by saturated NaHCO 3 and extracted with ethyl acetate (2x20 mL). The combined organic phase was concentrated and the resulting crude product was purified by silica gel column chromatography (ethyl acetate/hexane, 65/35, v/v) to give compound 10 (0.4 g, 52% yield) as a yellow oil.
  • Step h To a solution of compound 10 (0.8 g, 1.68 mmol) in methanol (3 mL) was added aqueous lithium hydroxide (0.13 g in 1 mL of water, 3.4 mmol). The reaction mixture was then refluxed for 8 h. Methanol was evaporated and the resulting aqueous solution was washed by ethyl acetate and neutralized by 1 N HCl solution.
  • Step i A solution of acid obtained (0.57 g, 1.2 mmol) and oxalyl chloride (1.05 mL, 12 mmol) in dichloromethane (5 mL) was stirred at rt overnight. After concentrated under reduced pressure, the remaining residue was dissolved in ether (10 mL) followed by addition of diazomethane (20 mL, 0.33 N in ether, 6.8 mmol) at 0 0 C. The reaction mixture was stirred at O 0 C for 30 min.
  • Step k A solution of compounds 12 and 12' (0.37 g, 0.68 mmol), N-Boc-L-Pro-
  • Step m A mixture of compoundsl4 and 14' (83.3 mg, 0.13 mmol), Pd/C (53.4 mg, 5% on carbon, 0.025 mmol) and one drop concentrated HCl in ethanol (3 mL) under an atmosphere of hydrogen (15 psi) was stirred at rt for 6 h. The reaction solution was then concentrated in vacuo to give compounds 15 and 15' (75 mg, 90% yield). To a solution of the amines obtained above (75 mg, 0.14 mmol) in THF (4 mL) was added 4N HCl in dioxane (1 mL) at rt. The reaction mixture was stirred at rt for 2 h. The solvent was evaporated and the residue was dried in vacuo to give compounds 16 and 16' (50 mg, 83% yield) as a yellow solid.
  • Step n To a solution of compounds 16 and 16' (44 mg, 0.1 mmol), N-Moc-L-Val- OH (43 mg, 0.25 mmol) and DMTMM (68 mg, 0.25 mmol) in a solvent mixture of DMF- THF (2 mL, 1 :3) was added DIPEA (0.17 mL, 1.0 mmol) at rt. The reaction mixture was stirred at rt for 2 h. THF was evaporated and the remaining residue was purified by prep- HPLC to provide compounds 17 and 17' (4.6 mg, 5% yield).
  • Step a Referring to Scheme 6-1, to a solution of N-Cbz-L-Pro-OH (7.52 g, 30.0 mmol) and DIPEA (5.50 g, 54.0 mmol) in THF (200 niL) was added HATU (11.5 g, 30.0 mmol) at rt. After stirring for 10 min, 4-bromobenzene-l,2-diamine (1) (5.1O g, 27.0 mmol) was added and the reaction mixture was stirred at rt for 2 h. The mixture was concentrated and the residue was diluted with EtOAc (250 mL) and water (50 mL). The organic phase was washed with brine and dried with anhydrous Na 2 SO 4 . The solvent was removed and the residue was dried in vacuo to give crude compounds 2 and 2 ' (10.0 g), which were used for the next step without further purification. LC-MS (ESI) m/z 418.1 (M + H) + .
  • Step c To a mixture of compound 3 (5.05 g, 12.5 mmol), bis(pinacolato)diboron (7.10 g, 26.3 mmol), and KOAc (3.20 g, 32.5 mmol) in 1,4-dioxane (100 mL) was added Pd(dppf)Cl 2 (400 mg, 0.5 mmol) at rt under an atmosphere of N 2 . After stirring at 80 0 C for 3h under an atmosphere of N 2 , the reaction mixture was filtered through CELITETM545 and the filtered cake was washed with EtOAc (100 mL x 3). The filtrate was washed with brine and dried with anhydrous Na 2 SO 4 .
  • Step d To a mixture of compound 4 (1.04 g, 2.20 mmol), 1 ,4-diiodobenzene (360 mg, 1.1 mmol), and NaHCO 3 (650 mg, 7.7 mmol) in 1 ,2-dimethoxyethane (36 mL) and water (12 mL) was added Pd(dppf)Cl 2 (80.0 mg, 0.10 mmol) at rt under an atmosphere of N 2 . After stirring at 80 0 C overnight under an atmosphere of N 2 , the reaction mixture was concentrated and the residue was diluted with EtOAc (100 mL) and water (25 mL). The organic phase was washed with brine and dried with anhydrous Na 2 SO 4 .
  • Step e To a solution of compound 5 (200 mg, 0.28 mmol) in CHCl 3 (5 mL) was added TMSI (168 mg, 0.84 mmol) at rt. After stirring at rt overnight, the reaction was quenched by adding MeOH (3.0 mL), followed by 4N HCl in dioxane (2.0 mL). The resulting mixture was stirred at rt for 30 min and concentrated. The residue was washed with DCM (10 mL) and dried in vacuo to give crude compound 6 (220 mg), which was used for the next step without further purification. LC-MS (ESI) m/z 449.2 (M + H) + .
  • Step f To a solution of crude compound 6 (150 mg, 0.20 mmol) in DMF (2 mL) was added Et 3 N (0.22 mL, 2.10 mmol), followed by N-Moc-L-Val-OH (87.0 mg, 0.50 mmol) and HATU (190 mg, 0.50 mmol). After stirring at rt for 1 h, the reaction mixture was concentrated and the residue was diluted with DCM (50 mL) and water (10 mL). The organic phase was washed with brine and dried with anhydrous Na 2 SO 4 .
  • Step a Referring to Scheme 6-2, to a solution of veratrol (8) (40.Og, 0.29 mol) in anhydrous THF (100 mL) and TMEDA (40 mL) was added /?-BuLi (2.5 M in hexanes, 128 rnL, 0.32 mol) dropwise at rt under an atmosphere of N 2 . After stirring at rt for 28 h under an atmosphere of N 2 , the reaction mixture was cooled to -78 0 C, followed by adding TMSCl (45 mL). The reaction mixture was stirred at rt for 5 h and then added water (20 mL).
  • Step b To a solution of compound 9 (40 g, 0.20 mol) in anhydrous TMEDA (40 mL) was added n-BuLi in hexanes (2.5 M, 120 mL, 0.24 mol) dropwise at 0 0 C under an atmosphere of N 2 . After stirring at rt for 25 h, the reaction mixture was cooled to -78 0 C, followed by adding TMSCl (40 mL). The reaction mixture was stirred at rt for 5h and then added water (50 mL). The mixture was concentrated and the residue was extracted with hexanes (100 mL x 3). The extracts were combined, washed with brine, and dried with anhydrous Na 2 SO 4 . The solvent was removed and the residue was purified by silica gel column chromatography to give compound 10 (52 g, 85%) as colorless oil. LC-MS: (ESI) m/z 283.1 (M+H) + .
  • Step d To a solution of compound 11 (3.89g, 10.0 mmol) in CH 2 Cl 2 (20 mL) was added BBr 3 (2.5 M in DCM, 15 mL, 60 mmol) at -78 0 C. After stirring at rt for 14 h, the reaction mixture was poured into water and the aqueous layer was extracted with CH 2 Cl 2 (5OmL x 2). The organic phase was washed with brine and dried with anhydrous Na 2 SO 4 . The solvent was removed and the residue was purified by silica gel column chromatography to give compound 12 as a white solid (3.1 g, 85%).
  • Step e A mixture of compound 12 (1.5 g, 4.2 mmol), K 2 CO 3 (4.60 g, 33.2 mmol), and l-bromo-2-methoxyethane (2.30 g, 16.6 mmol) in acetone (100 mL) was refluxed overnight. The reaction mixture was concentrated and the residue was diluted with H 2 O (50 mL) and EtOAc (150 mL).
  • Step f To a solution of compound 13 (200 mg, 0.42 mmol) in 40 mL DME/H 2 O
  • Step g A mixture of compound 14 (150 mg, 0.21 mmol) in dioxane (2 mL) was added 4N HCl in dioxane (2 mL) at rt. After stirring at rt for 2 h, the reaction mixture was concentrated and the residue was dried in vacuo to give an HCl salt, which was used for the next step without further purification.
  • Step h Subsequently, the HCl salt was dissolved in DMF (2 mL) and the resulting solution was respectively added DIPEA (0.34 mL, 2.1 mmol), N-Boc-L- VaI-OH (90 mg, 0.51 mmol), and HATU (192 mg, 0.210 mmol). After stirring at rt for 30 min, the reaction mixture was poured into ice H 2 O. The solid was collected by filtration and purified by preparative HPLC to give compound 15. LC-MS (ESI): m/z 911.5 (M+H) + .
  • Step a To prepare compound 2 of Scheme 7-1, tert-Butyi 4- oxocyclohexylcarbamate (9.0 g, 42.5 mmol) was treated with HCl (4N in 1,4-dioxane, 60 mL) at rt. After 4 h stirring, the reaction was concentrated to obtain the crude product (6.3 g), which was dissolved in anhydrous DMF (200 mL). N-Boc-L-Pro-OH (9.1 g, 42.3 mmol)), HATU (17.7 g, 46.6 mmol) and DIEA (22.8 mL, 131 mmol) were added at rt.
  • Step b To a solution of ⁇ S)-tert-hvXy ⁇ 2-(4-oxocyclohexylcarbamoyl)pyrrolidine- 1-carboxylate (4.3 g, 13.87 mmol) in dichloromethane (350 mL) at -78 0 C was slowly added LHMDS (29.1 mL, IM in THF, 29.1 mmol). After stirring for 2 h, 1,1,1-trifluoro-N-phenyl- N-(trifluoromethylsulfonyl)methanesulfonamide (10.4 g, 29.1 mmol) was added as solid at - 78 0 C.
  • Step c To a solution of (2S)-tert-bv ⁇ y ⁇ 2-(4-(trifluoromethylsulfonyloxy) cyclohex-3-enyl carbamoyl)pyrrolidine-l-carboxylate (2) (1.65 g, 3.73 mmol) and (5)-tert- butyl 2-(5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)-lH-imidazol-2- yl)pyrrolidine-l-carboxylate (3) (1.95 g, 4.44 mmol) in THF (19 mL), Pd(PPh 3 ) 2 Cl 2 (130 mg, 0.185 mmol) and aqueous Na 2 CO 3 (2M, 7.5 mL, 15 mmol) were added under N 2 protection at rt.
  • Step d To a solution of (2S)-tert-buiyl 2-(4-(4-(2-((S)- 1 -(tert-butoxycarbonyl) pyrrolidin- 2-yl)- lH-imidazol-S-y ⁇ pheny ⁇ cyclohex-S-enylcarbamoy ⁇ pyrrolidine- 1 - carboxylate (50 mg, 0.082 mmol) in DCM (15 mL), was added TFA (1 mL) at rt. After 1.5 h stirring, the reaction was concentrated to give a TFA salt (5) (75 mg), which was dissolved in anhydrous T ⁇ F (5 mL).
  • Step e To a solution of the compound 6 (210 mg, 0.24 mmol) in DCM (10 mL) was added TFA (1 mL) at rt. After 1.5 h stirring, the reaction was concentrated to give the crude product, which was dissolved in anhydrous THF (20 mL). 4-Morpholinecarbonyl chloride (62 ⁇ L, 0.54 mmol) and Et 3 N (206 ⁇ L, 1.48 mmol) were added at rt. After overnight stirring, the reaction was quenched by water, extracted by ethyl acetate.
  • Step f A mixture of compound 7 (20 mg, 0.022mmol) and 10% Pd/C (5 mg) in MeOH (2 mL) was hydrogenated (60 psi) for 2 days. The reaction was filtered through a CELITETM pad and washed with MeOH.
  • Biological activity of the compounds of the invention was determined using an HCV replicon assay.
  • the lb_Huh-Luc/Neo-ET cell line persistently expressing a bicistronic genotype Ib replicon in Huh 7 cells was obtained from ReBLikon GMBH. This cell line was used to test compound inhibition using luciferase enzyme activity readout as a measurement of compound inhibition of replicon levels.
  • each compound is added in triplicate to the cells. Plates incubated for 72 h prior to running the luciferase assay. Enzyme activity was measured using a Bright-Glo Kit (cat. number E2620) manufactured by Promega Corporation. The following equation was used to generate a percent control value for each compound.
  • Example compounds of the disclosed invention are illustrated in Tables 1-9 attached as appendices.
  • the tables show inhibitory activity of many of the example compounds with respect to HCV Ib.
  • the biological activity is indicated as being *, ** , ***, or ****, which corresponds to EC50 ranges of > 1000 nM, 999 nM to 10 nM, 9.9 nM to 1 nM, or ⁇ 1 nM respectively.
  • the tables further provide mass spectrometry results for the synthesized example compounds.
  • compositions [0341] The sixteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention
  • the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients or vehicles, and optionally other therapeutic and/or prophylactic ingredients.
  • excipients are known to those of skill in the art.
  • the compounds of the present invention include, without limitation, basic compounds such as free bases. A thorough discussion of pharmaceutically acceptable excipients and salts is available in Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990)..
  • the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, creams, ointments, lotions or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
  • the compositions will include an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, may include other pharmaceutical agents, adjuvants, diluents, buffers, etc.
  • the invention includes a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention including isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof together with one or more pharmaceutically acceptable carriers and optionally other therapeutic and/or prophylactic ingredients.
  • conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and the like.
  • the composition will generally take the form of a tablet, capsule, a softgel capsule nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used carriers such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. When liquid suspensions are used, the active agent may be combined with emulsifying and suspending agents. If desired, flavoring, coloring and/or sweetening agents may be added as well. Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents and the like. [0347] The seventeenth aspect of the invention provides the use of the compounds of the invention in the manufacture of a medicament.
  • the medicament is for the treatment of hepatitis C.
  • the eighteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, optionally in a pharmaceutical composition.
  • a pharmaceutically or therapeutically effective amount of the composition will be delivered to the subject.
  • the precise effective amount will vary from subject to subject and will depend upon the species, age, the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. Thus, the effective amount for a given situation can be determined by routine experimentation.
  • the subject may be administered as many doses as is required to reduce and/or alleviate the signs, symptoms or causes of the disorder in question, or bring about any other desired alteration of a biological system.
  • One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of this invention for a given disease.
  • the compounds of the present invention and their isomeric forms and pharmaceutically acceptable salts thereof are useful in treating and preventing HCV infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the HCV lifecycle.
  • Classes of compounds useful in the invention may include, without limitation, all classes of HCV antivirals.
  • mechanistic classes of agents that may be useful when combined with the compounds of the present invention include, for example, nucleoside and non-nucleoside inhibitors of the HCV polymerase, protease inhibitors, helicase inhibitors, NS4B inhibitors and medicinal agents that functionally inhibit the internal ribosomal entry site (IRES) and other medicaments that inhibit HCV cell attachment or virus entry, HCV RNA translation, HCV RNA transcription, replication or HCV maturation, assembly or virus release.
  • IRS internal ribosomal entry site
  • telaprevir VX-950
  • boceprevir SCH-503034
  • narlaprevir SCH-9005178
  • ITMN-191 R-7227
  • TMC-435350 a.k.a.
  • Nucleosidic HCV polymerase (replicase) inhibitors useful in the invention include, but are not limited to, R7128, PSI-7851, IDX-184, IDX-102, R1479, UNX-08189, PSI-6130, PSI-938 and PSI-879 and various other nucleoside and nucleotide analogs and HCV inhibitors including (but not limited to) those derived as 2'-C-methyl modified nucleos(t)ides, 4'-aza modified nucleos(t)ides, and 7'-deaza modified nucleos(t)
  • Non-nuclosidic HCV polymerase (replicase) inhibitors useful in the invention include, but are not limited to , HCV-796, HCV-371, VCH-759, VCH-916, VCH- 222, ANA-598, MK-3281, ABT-333, ABT-072, PF-00868554, BI-207127, GS-9190, A- 837093, JKT-109, GL-59728 and GL-60667.
  • NS5A inhibitors of the present invention may be used in combination with cyclophyllin and immunophyllin antagonists (eg, without limitation, DEBIO compounds, NM-811 as well as cyclosporine and its derivatives), kinase inhibitors, , inhibitors of heat shock proteins (e.g., HSP90 and HSP70), other immunomodulatory agents that may include, without limitation, interferons (-alpha, -beta, -omega, -gamma, -lambda or synthetic) such as Intron ATM, Roferon-ATM, Canferon-A300TM, AdvaferonTM, InfergenTM, HumoferonTM, Sumiferon MPTM, AlfaferoneTM, IFN- ⁇ TM, FeronTM and the like; polyethylene glycol derivatized (pegylated) interferon compounds, such as PEG interferon- ⁇ -2a (PegasysTM), PEG interferon- ⁇ -2
  • ITCA-638 omega-interferon delivered by the DUROS TM subcutaneous delivery system
  • compounds that stimulate the synthesis of interferon in cells such as resiquimod and the like
  • interleukins compounds that enhance the development of type 1 helper T cell response, such as SCV-07 and the like
  • TOLL-like receptor agonists such as CpG-IOlOl (actilon), isotorabine, ANA773 and the like; thymosin ⁇ -1; ANA-245 and ANA-246; histamine dihydrochloride; propagermanium; tetrachlorodecaoxide; ampligen; IMP-321; KRN-7000; antibodies, such as civacir, XTL-6865 and the like and prophylactic and therapeutic vaccines such as InnoVac C, HCV E1E2/MF59 and the like.
  • any of the above-described methods involving administering an NS5A inhibitor, a Type I interferon receptor agonist (e.g., an IFN- ⁇ ) and a Type II interferon receptor agonist (e.g., an IFN- ⁇ ) can be augmented by administration of an effective amount of a TNF- ⁇ antagonist.
  • a Type I interferon receptor agonist e.g., an IFN- ⁇
  • a Type II interferon receptor agonist e.g., an IFN- ⁇
  • TNF- ⁇ antagonists that are suitable for use in such combination therapies include ENBREL TM, REMIC ADETM and HUMIRA TM.
  • NS5A inhibitors of the present invention may be used in combination with antiprotozoans and other antivirals thought to be effective in the treatment of HCV infection, such as, without limitation, the prodrug nitazoxanide.
  • Nitazoxanide can be used as an agent in combination the compounds disclosed in this invention as well as in combination with other agents useful in treating HCV infection such as peginterferon alfa-2a and ribavarin (see, for example,_Rossignol, JF and Keeffe, EB, Future Microbiol. 3:539-545, 2008).
  • NS5A inhibitors of the present invention may also be used with alternative forms of interferons and pegylated interferons, ribavirin or its analogs (e.g., tarabavarin, levoviron), microRNA, small interfering RNA compounds (e.g., SIRPLEX-140-N and the like), nucleotide or nucleoside analogs, immunoglobulins, hepatoprotectants, anti-inflammatory agents and other inhibitors of NS5A.
  • interferons and pegylated interferons e.g., tarabavarin, levoviron
  • microRNA e.g., small interfering RNA compounds
  • nucleotide or nucleoside analogs e.g., immunoglobulins, hepatoprotectants, anti-inflammatory agents and other inhibitors of NS5A.
  • Inhibitors of other targets in the HCV lifecycle include NS3 helicase inhibitors; NS4A co-factor inhibitors; antisense oligonucleotide inhibitors, such as ISIS- 14803, AVI-4065 and the like; vector-encoded short hairpin RNA (shRNA); HCV specific ribozymes such as heptazyme, RPI, 13919 and the like; entry inhibitors such as HepeX-C, HuMax-HepC and the like; alpha glucosidase inhibitors such as celgosivir, UT- 23 IB and the like; KPE-02003002 and BIVN 401 and IMPDH inhibitors.
  • NS3 helicase inhibitors such as ISIS- 14803, AVI-4065 and the like
  • antisense oligonucleotide inhibitors such as ISIS- 14803, AVI-4065 and the like
  • HCV inhibitor compounds include those disclosed in the following publications: U.S. Pat. No. 5,807,876; U.S. Pat. No. 6,498,178; U.S. Pat. No. 6,344,465; U.S. Pat. No.
  • combinations of, for example, ribavirin and interferon may be administered as multiple combination therapy with at least one of the compounds of the present invention.
  • the present invention is not limited to the aforementioned classes or compounds and contemplates known and new compounds and combinations of biologically active agents (see, Strader, D.B., Wright, T., Thomas, DX. and Seeff, L. B., AASLD Practice Guidelines. 1-22, 2009 and Manns, M.P., Foster, G. R., Rockstroh, J.K., Zeuzem, S., Zoulim, F. and Houghton, M., Nature Reviews Drug Discovery. 6:991-1000, 2007, Pawlotsky, J-M., Chevaliez, S.
  • combination therapies of the present invention include any chemically compatible combination of a compound of this inventive group with other compounds of the inventive group or other compounds outside of the inventive group, as long as the combination does not eliminate the anti-viral activity of the compound of this inventive group or the anti-viral activity of the pharmaceutical composition itself.
  • Combination therapy can be sequential, that is treatment with one agent first and then a second agent (for example, where each treatment comprises a different compound of the invention or where one treatment comprises a compound of the invention and the other comprises one or more biologically active agents) or it can be treatment with both agents at the same time (concurrently).
  • Sequential therapy can include a reasonable time after the completion of the first therapy before beginning the second therapy. Treatment with both agents at the same time can be in the same daily dose or in separate doses.
  • Combination therapy need not be limited to two agents and may include three or more agents. The dosages for both concurrent and sequential combination therapy will depend on absorption, distribution, metabolism and excretion rates of the components of the combination therapy as well as other factors known to one of skill in the art.
  • Dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules may be adjusted over time according to the individual's need and the professional judgment of the person administering or supervising the administration of the combination therapy. [0356] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to non-macrocyclic, non-peptidic, substituted heterocyclic compounds useful for inhibiting hepatitis C virus ("HCV") replication, particularly functions of the non-structural 5A ("NS5A") protein of HCV

Description

INHIBITORS OF HCV NS5A Inventors: Leping Li and Min Zhong Statement of Related Applications
[0001] This application claims the benefit of U.S. provisional applications 61/119,723 filed Dec. 3, 2008; 61/173,590 filed April 28, 2009; and 61/182,952 filed June 1, 2009. Field of the Invention
[0002] The invention relates to compounds useful for inhibiting hepatitis C virus ("HCV") replication, particularly functions of the non-structural 5 A ("NS5A") protein of HCV.
Background of the Invention
[0003] HCV is a single-stranded RNA virus that is a member of the Flaviviridae family. The virus shows extensive genetic heterogeneity as there are currently seven identified genotypes and more than 50 identified subtypes. In HCV infected cells, viral RNA is translated into a polyprotein that is cleaved into ten individual proteins. At the amino terminus are structural proteins: the core (C) protein and the envelope glycoproteins, El and E2. p7, an integral membrane protein, follows El and E2. Additionally, there are six nonstructural proteins, NS2, NS3, NS4A, NS4B, NS5A and NS5B, which play a functional role in the HCV lifecycle. (see, for example, Lindenbach, B.D. and CM. Rice, Nature. 436:933- 938, 2005).
[0004] Infection by HCV is a serious health issue. It is estimated that 170 million people worldwide are chronically infected with HCV. HCV infection can lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. Chronic HCV infection is thus a major worldwide cause of liver-related premature mortality.
[0005] The present standard of care treatment regimen for HCV infection involves interferon-alpha, alone, or in combination with ribavirin. The treatment is cumbersome and sometimes has debilitating and severe side effects and many patients do not durably respond to treatment. New and effective methods of treating HCV infection are urgently needed. Summary of the Invention
[0006] Essential features of the NS5A protein of HCV make it an ideal target for inhibitors. The present disclosure describes a class of compounds targeting the NS5A protein and methods of their use to treat HCV infection in humans. 7] In a first aspect, compounds of formula I are provided:
Figure imgf000003_0001
wherein,
A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p- -(CR2)n-O-(CR2)p- -(CR2)n-N(RN)-(CR2)p- -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
heteroaryl group selected from the group consisting of
Figure imgf000003_0002
Figure imgf000003_0003
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000004_0001
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3.
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that
in the example of A or A' being
Figure imgf000004_0002
, the A-B-A' can be any of:
Figure imgf000005_0001
B is Q or Q Q , wherein each Q is independently selected from the group consisting of a cycloalkyl group, cycloalkenyl group, heterocycle, aryl group or heteroaryl group, with the proviso that only one Q is a six member aromatic ring when B is Q Q and with the proviso that if B is Q Q , any Q is that is poly cyclic is connected to the remainder of the molecule through only one cycle of the poly cycle;
Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of Rc, Rd, Re and Rf may optionally be substituted by Ci to C8 alkyl, Ci to C8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently 0, 1, 2, 3, or 4, and
u is 0, 1, or 2.
[0008] In a first embodiment of the first aspect, each Q is independently optionally substituted with one or more substituents each independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and if Q is not aromatic, it is optionally substituted with oxo.
[0009] In a second embodiment of the first aspect, each Q is independently optionally substituted with -CN, -OCF3, -OCHF2, -CF3 or -F.
[0010] In a third embodiment of the first aspect, B is selected from the group consisting
Figure imgf000006_0001
Figure imgf000007_0001
, wherein:
Figure imgf000007_0002
is a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns;
V is -CH2-, -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or -(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0;
each r and s is independently 0, 1, 2, 3, or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
each Rb is independently Ci-Ci2 alkyl, hydroxyl, halogen, or oxo.
[0011] In a fourth embodiment of the first aspect,
Figure imgf000007_0003
, if present, is selected
Figure imgf000007_0004
from the group consisting of \==/
Figure imgf000008_0001
and wherein * indicates attachment points to the remainder of the compound, and each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
[0012] In a fifth embodiment of the first aspect, each Ra, if present, -CN, -OCF3, -OCHF2, -CF3, or -F.
[0013] In a sixth embodiment of the first aspect, A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
heteroaryl group selected from the group
Figure imgf000008_0002
consisting of -^^X1 ,
Figure imgf000008_0003
[0014] In a seventh embodiment of the first aspect, A and A' are independently selected
from the group consisting of a single bond,
Figure imgf000008_0004
Figure imgf000008_0005
Figure imgf000009_0001
[0015] In an eighth embodiment of the first aspect, Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl and Ci to Cg heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0016] In a ninth embodiment of the first aspect, one or both of Rc and Rd or Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0017] In a tenth embodiment of the first aspect, Rc and Rd are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000009_0002
Figure imgf000010_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0018] In an eleventh embodiment of the first aspect, Re and Rf are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000010_0002
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to
C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0019] In a second aspect of the invention, compounds have formula III:
Figure imgf000010_0003
wherein
Figure imgf000011_0001
A' is selected from the group consisting of single bond, H H
Figure imgf000011_0002
Figure imgf000012_0001
-(CR2)n-C(O)N(R >N>- (CR2)p- -(CR2)n-C(O)-(CR2)p- and -(CR2)n-N(RN)C(O)-(CR2)p- wherein RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
Figure imgf000012_0002
\=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
r is selected from the group consisting of 0, 1, 2, 3, or 4.
[0020] In a first embodiment of the second aspect, A'
Figure imgf000012_0003
-(CR2)n-C(O)-(CR2)p- -(CR2)n-C(O)N(RN)-(CR2)p- or -(CR2)n-N(RN)C(O)-(CR2)p-
[0021] In a second embodiment of the second aspect, A' is V H
[0022] In a third embodiment of the second aspect, compounds have formula Ilia:
Figure imgf000012_0004
wherein X and
X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0023] In a fourth embodiment of the second aspect, compounds have formula III
wherein A' is selected from the group consisting of
Figure imgf000013_0001
Figure imgf000013_0002
[0024] In a fifth embodiment of the second aspect, compounds have formula IHb:
Figure imgf000013_0003
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl. 5] In a third aspect of the invention, compounds have formula IV:
Figure imgf000014_0001
wherein
Il >
A and A' are independently selected from the group consisting of single bond, H
Figure imgf000014_0002
C(O)N(RN)-(CR2)P-, wherein: RN is selected from the group consisting of hydrogen, - OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide; \=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
r is O, 1, 2, 3 or 4;
each Rb is independently C1-C5 alkyl, hydroxyl, halogen, or oxo;
s is O, 1, 2, 3, 4, 5, or 6; and
each of X1 and X2 are independently C or N.
[0026] In a first embodiment of the third aspect, A and A' are each independently
Figure imgf000015_0001
or -(CR2)n-C(O)N(RN)-(CR2)p-.
[0027] In a second embodiment of the third aspect, compounds have formula IVa:
Figure imgf000015_0002
[0028] In a third embodiment of the third aspect, compounds have formula IVb:
Figure imgf000016_0001
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0029] In a fourth aspect of the invention, compounds have formula V:
Figure imgf000016_0002
wherein
A and A' are independently selected from the group consisting of single bond,
Figure imgf000016_0003
Figure imgf000016_0004
Figure imgf000017_0001
C(O)-N(RN)-(CR2)P-, wherein RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
X is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -O-, -S-, -S(O)i_2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, and Ci to Cs heteroalkyl;
Figure imgf000017_0002
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
r is O, 1, 2, 3 or 4. 30] In a first embodiment of the fourth aspect, A and A' are each independently
Figure imgf000017_0003
or -(CR2)n-C(O)N(RN)-(CR2)p-. [0031] In a second embodiment of the fourth aspect, compounds have formula Va:
Figure imgf000018_0001
[0032] In a third embodiment of the fourth aspect, compounds have formula Vb:
Figure imgf000018_0002
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0033] In a fifth aspect of the invention, compounds have formula VI:
Figure imgf000018_0003
, wherein
each -© \-=--v- 1 iSs 1 iTndependently a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns; each r is independently 0, 1, 2, 3, or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p- -(CR2)n-O-(CR2)p- -(CR2)n-N(RN)-(CR2)p- -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
heteroaryl group selected from the group
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
wherein:
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000020_0001
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3.
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that
in the example of A or A' being
Figure imgf000020_0002
the A-B-A' can be any of:
Figure imgf000021_0001
Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of Rc, Rd, Re and Rf may optionally be substituted by Ci to Cg alkyl, Ci to Cg heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2)t]u-U-(CR4 2)t-NR7-(CR4 2)t-R8, -U-(CR4 2)t-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R81 2, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, optionally, R7 and R8 together form a 4-7 membered ring, each t is independently 0, 1, 2, 3, or 4, and u is 0, 1, or 2.
[0034] In a first embodiment of the fifth aspect, each -©- IS 1 ndependently
selected from the group consisting of
Figure imgf000022_0001
Figure imgf000022_0002
and wherein * indicates attachment points to the remainder of the compound, and each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
[0035] In a second embodiment of the fifth aspect, A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
heteroaryl group selected from the group consisting of
Figure imgf000022_0003
Figure imgf000022_0004
[0036] In a third embodiment of the fifth aspect, A and A' are independently selected
from the group consisting of a single bond,
Figure imgf000023_0001
Figure imgf000023_0002
[0037] In a fourth embodiment of the fifth aspect, A and A' are each independently
Figure imgf000023_0003
or -(CR2)n-C(0)N(FO Nλ-(CR2)p-.
[0038] In a sixth aspect of the invention, in any compound of the second through fifth aspects, Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cs alkyl and Ci to Cs heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle. [0039] In a first embodiment of the sixth aspect, one of Rc and Rd or Re and Rf are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0040] In a second embodiment of the sixth aspect, both of Rc and Rd and Re and Rf are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0041] In a third embodiment of the sixth aspect, Rc and Rd are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000024_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0042] In a fourth embodiment of the sixth aspect, Re and Rf are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000024_0002
Figure imgf000025_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to
C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0043] In a seventh aspect of the invention, each Ra , if present in a compound of any of the second through sixth aspects, is independently -CN, -OCF3, -OCHF2, -CF3, or -F.
[0044] In an eighth aspect of the invention, if present in any compound of any of the previous aspects, one of Y and Y' is N.
[0045] In a first embodiment of the eighth aspect, both Y and Y' are N.
[0046] In a ninth aspect of the invention, Z and Z' in any of the previous aspects are each 1-3 amino acids.
[0047] In a first embodiment of the ninth aspect, the amino acids are in the D configuration.
[0048] In a tenth aspect of the invention, Z and Z' in any of the previous aspects are each independently selected from the group consisting of -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8.
[0049] In a first embodiment of the tenth aspect, one or both of Z and Z' are -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8.
[0050] In a second embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-NR7-(CR4 2),-R8.
[0051] In a third embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-NR7-(CR4 2),-R8. [0052] In a fourth embodiment of the tenth aspect, one or both of Z and Z' are -[C(O)-(CR4 2)t-NR5-(CR4 2)t]u-U-(CR4 2)t-NR7-(CR4 2)t-R8.
[0053] In a fifth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-NR7-(CR4 2),-R8.
[0054] In a sixth embodiment of the tenth aspect, one or both of Z and Z' are -[C(O)-(CR4 2)t-NR5-(CR4 2)t]u-C(O)-(CR4 2)t-NR7-(CR4 2)t-R8.
[0055] In a seventh embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-NR5-(CR4 2),-C(O)-(CR4 2),-NR7-(CR4 2),-R8.
[0056] In an eighth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-NR7-(CR4 2),-R8.
[0057] In a ninth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-(CR4 2)n-C(O)-R81.
[0058] In a tenth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-C(O)-R81.
[0059] In an eleventh embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-(CR4 2)n-C(O)-O-R81.
[0060] In a twelfth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-C(O)-O-R81.
[0061] In a thirteenth embodiment of the tenth aspect, one or both of Z and Z' are -U- (CR4 2)t-R8.
[0062] In a fourteenth embodiment of the tenth aspect, one or both of Z and Z' are - C(O)-(CR4 2)t-R8. [0063] In a fifteenth embodiment of the tenth aspect, one or both of Z and Z' are -[U-(CR4 2)t-NR5-(CR4 2)t]u-U-(CR4 2)t-O-(CR4 2)t-R8.
[0064] In a sixteenth embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-O-(CR4 2),-R8.
[0065] In a seventeenth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)t-NR5-(CR4 2)t-C(O)-(CR4 2)t-O-(CR4 2)t-R8.
[0066] In an eighteenth embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-O-(CR4 2),-R8.
[0067] In a nineteenth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)t-O-(CR4 2)t-R8.
[0068] In a twentieth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-R8 wherein R7 and R8 together form a 4-7 membered ring.
[0069] In an eleventh aspect of the invention, compounds have formula VII:
Figure imgf000027_0001
wherein,
\=/ may include 1 or 2 nitrogens as heteroatoms,
r is from 0 to 4,
each Ra is independently selected from the group consisting of -OH,
-CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; A and A' are independently selected from the group consisting of
Figure imgf000028_0001
Figure imgf000028_0002
-(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p- and -(CR2)n-C(O)N(RN)-(CR2)p-, wherein,
if A or A' is a heteroaryl group, it is optionally substituted with one or more of the substituents selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and
n and p are independently 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
for each A and A',
Figure imgf000028_0003
may be attached to either side of
A and A' so that in the example of A or A' being HN s the
Figure imgf000028_0004
Figure imgf000029_0001
B' is
Figure imgf000029_0002
wherein,
B' is optionally substituted with between 1 and 4 substituents, each independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino and oxo,
Xa is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -O-, -S-, -S(=O)2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, and Ci to Cs heteroalkyl, and
Xb is either C or N;
X and X' are each either present or absent and if present, independently selected from the group consisting of a bond, -CH2-, - CH2-CH2-, -CH=CH-, -0-, -S-, -S(O)2-, -CH2O-, -CH2S-, -CH2S(O)2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R81 2, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently O, 1, 2, 3, or 4, and
u is 0, 1, or 2. 70] In a twelfth aspect of the invention, compounds have formula VIII:
Figure imgf000030_0001
wherein:
B' is selected from the group consisting of
Figure imgf000030_0002
Figure imgf000030_0003
\=/ optionally includes 1 or 2 nitrogens as heteroatoms; each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)i_2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl; each R8 is independently chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl. 1] In a thirteenth aspect of the invention, compounds have formula IX:
Figure imgf000031_0001
wherein:
B' is selected from the group consisting of →© V_v- s →Θ N — /- ,- \ — / and
Figure imgf000031_0002
\=/ optionally includes 1, 2, 3, or 4 nitrogens as heteroatoms; each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)i_2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl; each R8 is independently chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl. 2] In a fourteenth aspect of the invention, compounds have formula X:
Figure imgf000032_0001
B' is selected from the group consisting of -©- -Θ- -
Figure imgf000032_0002
\=/ optionally includes 1 or 2 nitrogens as heteroatoms; each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)i_2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl; each R8 is independently chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl. 3] In a fifteenth aspect of the invention, compounds have formula XI:
Figure imgf000033_0001
wherein:
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
Xa is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -0-, -S-, -S(=0)2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, and Ci to Cg heteroalkyl, each R8 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl.
[0074] The sixteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention.
[0075] The seventeenth aspect of the invention provides the use of the compounds of the invention in the manufacture of a medicament.
[0076] In a first embodiment of the seventeenth aspect, the medicament is for the treatment of hepatitis C.
[0077] The eighteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention. Detailed Description
[0078] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Definition of standard chemistry terms may be found in reference works, including Carey and Sundberg (2007) "Advanced Organic Chemistry 5th Ed." VoIs. A and B, Springer Science+Business Media LLC, New York. The practice of the present invention will employ, unless otherwise indicated, conventional methods of synthetic organic chemistry, mass spectroscopy, preparative and analytical methods of chromatography, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology.
[0079] The term "alkanoyl" as used herein contemplates a carbonyl group with a lower alkyl group as a substituent.
[0080] The term "alkenyl" as used herein contemplates substituted or unsubstituted, straight and branched chain alkene radicals, including both the E- and Z-forms, containing from two to eight carbon atoms. The alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, -NO2, CO2R, C(O)R, -O-R, -N(RN)2, -N(RN)C(O)R, -N(RN)S(O)2R, -SR, -C(O)N(RN)2, -OC(O)R, -0C(0)N(RN)2, S(O)R, SO2R, -SO3R, -S(O)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0100] The term "alkoxy" as used herein contemplates an oxygen with a lower alkyl group as a substituent and includes methoxy, ethoxy, butoxy, trifluromethoxy and the like. It also includes divalent substituents linked to two separated oxygen atoms such as, without limitation, -O-(CH2)i.4-O-, -0-CF2-O-, -0-(CH2)L4-O-(CH2CH2-O)L4- and
Figure imgf000035_0001
[0081] The term "alkoxycarbonyl" as used herein contemplates a carbonyl group with an alkoxy group as a substituent.
[0082] The term "alkyl" as used herein contemplates substituted or unsubstituted, straight and branched chain alkyl radicals containing from one to fifteen carbon atoms. The term "lower alkyl" as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl and the like. The alkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -C(O)2R, -C(O)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(O)2R, -SR, -C(0)N(RN)2, -OC(O)R, -0C(0)N(RN)2, -SOR, -SO2R, -SO3R, -S(O)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0083] The term "alkylene," "alkenylene" and "alkynylene" as used herein refers to the groups "alkyl," "alkenyl" and "alkynyl" respectively, when they are divalent, ie, attached to two atoms.
[0084] The term "alkylsulfonyl" as used herein contemplates a sulfonyl group which has a lower alkyl group as a substituent.
[0085] The term "alkynyl" as used herein contemplates substituted or unsubstituted, straight and branched carbon chain containing from two to eight carbon atoms and having at least one carbon-carbon triple bond. The term alkynyl includes, for example ethynyl, 1- propynyl, 2- propynyl, 1-butynyl, 3 -methyl- 1-butynyl and the like. The alkynyl group may be optionally substituted with one or more substituents selected from halo, -CN, NO2, CO2R, C(O)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(O)2R, -SR, -C(0)N(RN)2, -OC(O)R, -0C(0)N(RN)2, -SOR, -SO2R, -SO3R, -S(O)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0086] The term "amino" as used herein contemplates a group of the structure -NRN 2.
[0087] The term "amino acid" as used herein contemplates a group of the structure
Figure imgf000036_0001
configuration and includes but is not limited to the twenty "standard" amino acids: isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine and histidine. The present invention also includes, without limitation, D-configuration amino acids, beta-amino acids, amino acids having side chains as well as all non-natural amino acids known to one skilled in the art.
[0088] The term "aralkyl" as used herein contemplates a lower alkyl group which has as a substituent an aromatic group, which aromatic group may be substituted or unsubstituted.
The aralkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -CO2R, -C(O)R, -O-R, -N(RN)2, -N(RN)C(O)R, -N(RN)S(O)2R, -SR, -
C(O)N(RN)2,
-OC(O)R, -OC(O)N(RN)2, -SOR, -SO2R, -SO3R, -S(O)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0089] The terms "aryl," "aromatic group" or "aromatic ring" as used herein contemplates substituted or unsubstituted single-ring and multiple aromatic groups (for example, phenyl, pyridyl and pyrazole, etc.) and polycyclic ring systems (naphthyl and quinolinyl, etc.). The polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls. The aryl group may be optionally substituted with one or more substituents selected from halogen, alkyl, -CN, -NO2, -CO2R, -C(O)R, -O-R, -N(RN)2, -N(RN)C(O)R, - N(RN)S(O)2R, -SR, -C(O)N(RN)2,
-OC(O)R, -OC(O)N(RN)2, -SOR, -SO2R, -SO3R, -S(O)2N(RN)2, -SiR3, -P(O)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl. [0090] The term "arylsulfonyl" as used herein contemplates a sulfonyl group which has as a substituent an aryl group. The term is meant to include, without limitation, monovalent as well as multiply valent aryls (eg, divalent aryls).
[0091] The term "carbamoyl" as used herein contemplates a group of the structure
Figure imgf000037_0001
[0092] The term "carbonyl" as used herein contemplates a group of the structure
Figure imgf000037_0002
[0093] The term "carboxyl" as used herein contemplates a group of the structure
Figure imgf000037_0003
[0094] The term "cycloalkyl" as used herein contemplates substituted or unsubstituted cyclic alkyl radicals containing from three to twelve carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl and the like. The term "cycloalkyl" also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused"). The cycloalkyl group may be optionally substituted with one or more substituents selected from halo, -CN, -NO2, -CO2R, -C(O)R, -O-R, -N(RN)2, -N(RN)C(O)R, -N(RN)S(O)2R, -SR, -C(O)N(RN)2, -OC(O)R, -OC(O)N(RN)2, -SOR, -SO2R, -S(O)2N(RN)2, phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
[0095] The term "cycloalkenyl" as used herein contemplates substituted or unsubstituted cyclic alkenyl radicals containing from four to twelve carbon atoms in which there is at least one double bond between two of the ring carbons and includes cyclopentenyl, cyclohexenyl and the like. The term "cycloalkenyl" also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused"). The cycloalkenyl group may be optionally substituted with one or more substituents selected from halo, -CN, -NO2, -CO2R, -C(O)R, -O-R, -N(RN)2, -N(RN)C(O)R, -N(RN)S(O)2R, -SR, -C(O)N(RN)2, -OC(O)R, -OC(O)N(RN)2, -SOR, -SO2R, -S(O)2N(RN)2, phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl. [0096] The term "halo" or "halogen" as used herein includes fluorine, chlorine, bromine and iodine.
[0097] The term "heteroalkyl" as used herein contemplates an alkyl with one or more heteroatoms.
[0098] The term "heteroatom", particularly within a ring system, refers to N, O and S.
[0099] The term "heterocyclic group," "heterocycle" or "heterocyclic ring" as used herein contemplates substituted or unsubstituted aromatic and non-aromatic cyclic radicals having at least one heteroatom as a ring member. Preferred heterocyclic groups are those containing five or six ring atoms which includes at least one hetero atom and includes cyclic amines such as morpholino, piperidino, pyrrolidino and the like and cyclic ethers, such as tetrahydrofuran, tetrahydropyran and the like. Aromatic heterocyclic groups, also termed "heteroaryl" groups, contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, oxodiazole, thiadiazole, pyridine, pyrazine, pyridazine, pyrimidine and the like. The term heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two or more atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls. Examples of polycyclic heteroaromatic systems include quinoline, isoquinoline, cinnoline, tetrahydroisoquinoline, quinoxaline, quinazoline, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, indazole, purine, benzotriazole, pyrrolepyridine, pyrrazolopyridine and the like. The heterocyclic group may be optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, -CN, -NO2, -CO2R, -C(O)R, -O-R, -N(RN)2, -N(RN)C(O)R, -N(RN)S(O)2R, -SR, -C(O)N(RN)2, -OC(O)R, -OC(O)N(RN)2, -SOR, -SO2R, -SO3R, -S(O)2N(RN)2, -SiR3, -P(O)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0101] The term "oxo" as used herein contemplates an oxygen atom attached with a double bond.
[0102] By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0103] "Pharmaceutically acceptable salt" refers to a salt of a compound of the invention which is made with counterions understood in the art to be generally acceptable for pharmaceutical uses and which possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, piperidine, dimethylamine, diethylamine and the like. Also included are salts of amino acids such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like (see, e.g., Berge et al, 1977, J. Pharm. Sci. 66:1-19).
[0104] The terms "phosphate" and "phosphonate" as used herein refer to the moieties having the following structures, respectively:
O I l O Il
— O-P-OR -P-OR OR OR
[0105] The terms "salts" and "hydrates" refers to the hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity, flowability and manufacturability of the resulting bulk drug.
[0106] The term sulfonamide as used herein contemplates a group having the structure
Figure imgf000040_0001
[0107] The term "sulfonate" as used herein contemplates a group having the structure
Figure imgf000040_0002
wherein Rs is selected from the group consisting of hydrogen, C1-C10 alkyl,
C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkanoyl, or C1-C10 alkoxycarbonyl.
[0108] The term "sulfonyl" as used herein contemplates a group having the structure
Figure imgf000040_0003
[0109] "Substituted sulfonyl" as used herein contemplates a group having the structure
Figure imgf000040_0004
including, but not limited to alkylsulfonyl and arylsulfonyl.
[0110] The term "thiocarbonyl," as used herein, means a carbonyl wherein an oxygen atom has been replaced with a sulfur.
[0111] Each R is independently selected from hydrogen, -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to C12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino, and oxo.
[0112] Each RN is independently selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to C12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide. Two RN may be taken together with C, O, N or S to which they are attached to form a five to seven membered ring which may optionally contain a further heteroatom.
[0113] The compounds of the present invention may be used to inhibit or reduce the activity of HCV, particularly HCVs NS5A protein. In these contexts, inhibition and reduction of activity of the NS5A protein refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound. In particular aspects, the inhibition or reduction in the measured activity is at least a 10% reduction or inhibition. One of skill in the art will appreciate that reduction or inhibition of the measured activity of at least 20%, 50%, 75%, 90% or 100%, or any number in between, may be preferred for particular applications.
[0114] In a first aspect, compounds of formula I are provided:
Figure imgf000041_0001
wherein,
A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p- -(CR2)n-O-(CR2)p- -(CR2)n-N(RN)-(CR2)p- -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
Figure imgf000041_0002
Figure imgf000042_0001
wherein:
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, -(CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000042_0002
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3.
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2, each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that
in the example of A or A' being HN , the A-B-A' can be any of:
*-BVy- A~B-iV -fV*-* YrB-
B is Q or Q Q , wherein each Q is independently selected from the group consisting of a cycloalkyl group, cycloalkenyl group, heterocycle, aryl group or heteroaryl group, with the proviso that only one Q is a six member aromatic ring when B is Q Q and with the proviso that if B is Q Q , any Q is that is poly cyclic is connected to the remainder of the molecule through only one cycle of the poly cycle;
Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to C8 alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein,
each hetero atom, if present, is independently N, O or S,
each of Rc, Rd, Re and Rf may optionally be substituted by Ci to C8 alkyl, Ci to C8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently O, 1, 2, 3, or 4, and
u is 0, 1, or 2.
[0115] The compounds of the present invention include pharmaceutically acceptable salts of I as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0116] In a first embodiment of the first aspect, each Q is independently optionally substituted with one or more substituents each independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and if Q is not aromatic, it is optionally substituted with oxo. [0117] In a second embodiment of the first aspect, each Q is independently optionally substituted with -CN, -OCF3, -OCHF2, -CF3, or -F.
[0118] In a third embodiment of the first aspect, B is selected from the group consisting
Figure imgf000045_0001
, wherein:
Figure imgf000045_0002
is a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns;
V is -CH2-, -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or -(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0;
each r and s is independently 0, 1, 2, 3, or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
each Rb is independently C1-C12 alkyl, hydroxyl, halogen or oxo.
[0119] In a fourth embodiment of the first aspect,
Figure imgf000046_0001
, if present, is selected
from the group consisting of
Figure imgf000046_0002
Figure imgf000046_0003
and wherein * indicates attachment points to the remainder of the compound, and each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
[0120] In a fifth embodiment of the first aspect, each Ra, if present, is independently -CN, -OCF3, -OCHF2, -CF3, or -F.
[0121] In a sixth embodiment of the first aspect, A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)P- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
heteroaryl group selected from the group
Figure imgf000046_0004
consisting of ^^X1
Figure imgf000046_0005
[0122] In a seventh embodiment of the first aspect, A and A' are independently selected
from the group consisting of a single bond,
Figure imgf000046_0006
Figure imgf000047_0001
[0123] In an eighth embodiment of the first aspect, Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl and Ci to Cg heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0124] In a ninth embodiment of the first aspect, one or both of Rc and Rd or Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0125] In a tenth embodiment of the first aspect, Rc and Rd are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000047_0002
Figure imgf000048_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0126] In an eleventh embodiment of the first aspect, Re and Rf are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000048_0002
wherein R1N is selected from the group consisting of hydrogen, -OH, Ci to
Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0127] In a second aspect of the invention, compounds have formula III:
Figure imgf000048_0003
wherein
Figure imgf000048_0004
A' is selected from the group consisting of single bond, H , H
Figure imgf000049_0001
-(CR2)n-O-(CR2)p-, -(CR2X-C(O)N(R >N1Xλ CR2)P- and -(CR2)n-N(RN)C(O)-(CR2)p- wherein RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide; \=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
r is selected from the group consisting of 0, 1, 2, 3, or 4.
[0128] The compounds of the present invention include pharmaceutically acceptable salts of III as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
11 / \ Ji
[0129] In a first embodiment of the second aspect, A' is H , H , -(CR2)n-C(O)-(CR2)p- -(CR2)n-C(O)N(RN)-(CR2)p- or -(CR2)n-N(RN)C(O)-(CR2)p-.
[0130] In a second embodiment of the second aspect, A' is V H
[0131] In a third embodiment of the second aspect, compounds have formula Ilia:
Figure imgf000050_0001
wherein X and
X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0132] The compounds of the present invention include pharmaceutically acceptable salts of Ilia as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. [0133] In a fourth embodiment of the second aspect, compounds have formula III
Figure imgf000051_0001
[0134] In a fifth embodiment of the second aspect, compounds have formula IHb:
Figure imgf000051_0002
A' is selected from the group consisting of
Figure imgf000051_0003
Figure imgf000051_0004
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0135] The compounds of the present invention include pharmaceutically acceptable salts of IHb as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. 6] In a third aspect of the invention, compounds have formula IV:
Figure imgf000052_0001
wherein
Il >
-N
A and A' are independently selected from the group consisting of single bond, H
Figure imgf000052_0002
C(O)N(RN)-(CR2)P-, wherein: RN is selected from the group consisting of hydrogen, - OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
\=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
r is O, 1, 2, 3 or 4;
each Rb is independently C1-C5 alkyl, hydroxyl, halogen, or oxo;
s is O, 1, 2, 3, 4, 5, or 6; and
each of X1 and X2 are independently C or N.
[0137] The compounds of the present invention include pharmaceutically acceptable salts of IV as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0138] In a first embodiment of the third aspect, A and A' are each independently χy H ~ or -(CR2)n-C(O)N(RN)-(CR2)p-.
[0139] In a second embodiment of the third aspect, compounds have formula IVa:
Figure imgf000053_0001
[0140] The compounds of the present invention include pharmaceutically acceptable salts of IVa as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0141] In a third embodiment of the third aspect, compounds have formula IVb:
Figure imgf000054_0001
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0142] The compounds of the present invention include pharmaceutically acceptable salts of IVb as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0143] In a fourth aspect of the invention, compounds have formula V:
Figure imgf000054_0002
wherein
A and A' are independently selected from the group consisting of single bond,
Figure imgf000054_0003
Figure imgf000054_0004
Figure imgf000055_0001
-(CR2)n-C(O)-N(RN)-(CR2)p-, wherein RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
X3 is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -O-, -S-, -S(O)i_2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, and Ci to Cs heteroalkyl;
\=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
r is O, 1, 2, 3 or 4.
[0144] The compounds of the present invention include pharmaceutically acceptable salts of V as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0145] In a first embodiment of the fourth aspect, A and A' are each independently
Figure imgf000055_0002
[0146] In a second embodiment of the fourth aspect, compounds have formula Va:
Figure imgf000056_0001
[0147] The compounds of the present invention include pharmaceutically acceptable salts of Va as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0148] In a third embodiment of the fourth aspect, compounds have formula Vb:
Figure imgf000056_0002
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
[0149] The compounds of the present invention include pharmaceutically acceptable salts of Vb as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0150] In a fifth aspect of the invention, compounds have formula VI:
Figure imgf000056_0003
, wherein
each -O- IS l independently a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns;
each r is independently 0, 1, 2, 3, or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
A and A' are independently selected from the group consisting of a single bond, -(CR2)n-C(O)-(CR2)p- -(CR2)n-O-(CR2)p- -(CR2)n-N(RN)-(CR2)p- -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
Figure imgf000057_0001
heteroaryl group selected from the group consisting of ^ JL^X1 — , / J^LY1
Figure imgf000057_0002
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000058_0001
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3.
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that in the example of A or A' being
Figure imgf000059_0001
the A-B-A' can be any of:
Figure imgf000059_0002
Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein,
each hetero atom, if present, is independently N, O or S,
each of Rc, Rd, Re and Rf may optionally be substituted by Ci to Cs alkyl, Ci to Cs heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4 , R5 and R7 is independently selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently 0, 1, 2, 3, or 4, and
u is 0, 1, or 2.
[0151] The compounds of the present invention include pharmaceutically acceptable salts of VI as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0152] In a first embodiment of the fifth aspect, each -©- IS 1 ndependently
selected from the group consisting of
Figure imgf000060_0001
Figure imgf000060_0002
and wherein * indicates attachment points to the remainder of the compound and each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
[0153] In a second embodiment of the fifth aspect, A and A' are independently selected from the group consisting of a single bond, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p- -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a heteroaryl group selected from the group consisting
Figure imgf000060_0003
Figure imgf000061_0001
[0154] In a third embodiment of the fifth aspect, A and A' are independently selected
from the group consisting of a single bond,
Figure imgf000061_0002
Figure imgf000061_0003
[0155] In a fourth embodiment of the fifth aspect, A and A' are each independently χy H ~ or -(CR2)n-C(O)N(RN)-(CR2)p-.
[0156] In a sixth aspect of the invention, in any compound of the second through fifth aspects, Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl and Ci to Cg heteroalkyl, wherein, each hetero atom, if present, is independently N, O or S, Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0157] In a first embodiment of the sixth aspect, one of Rc and Rd or Re and Rf are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0158] In a second embodiment of the sixth aspect, both of Rc and Rd and Re and Rf are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
[0159] In a third embodiment of the sixth aspect, Rc and Rd are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000062_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0160] In a fourth embodiment of the sixth aspect, Re and Rf are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000062_0002
Figure imgf000063_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to
C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
[0161] In a seventh aspect of the invention, each Ra , if present in a compound of any of the second through sixth aspects, is independently -CN, -OCF3, -OCHF2, -CF3, or -F.
[0162] In an eighth aspect of the invention, if present in any compound of any of the previous aspects, one of Y and Y' is N.
[0163] In a first embodiment of the eighth aspect, both Y and Y' are N.
[0164] In a ninth aspect of the invention, Z and Z' in any of the previous aspects are each 1-3 amino acids.
[0165] In a first embodiment of the ninth aspect, the amino acids are in the D configuration.
[0166] In a tenth aspect of the invention, Z and Z' in any of the previous aspects are each independently selected from the group consisting of -[U-(CR4 2)t-NR5-(CR4 2)t]u-U-(CR4 2)t-NR7-(CR4 2)t-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8.
[0167] In a first embodiment of the tenth aspect, one or both of Z and Z' are -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8.
[0168] In a second embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-NR5-(CR4 2)t-U-(CR4 2)t-NR7-(CR4 2)t-R8.
[0169] In a third embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-NR7-(CR4 2),-R8.
[0170] In a fourth embodiment of the tenth aspect, one or both of Z and Z' are -[C(O)-(CR4 2)t-NR5-(CR4 2)t]u-U-(CR4 2)t-NR7-(CR4 2)t-R8.
[0171] In a fifth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-NR7-(CR4 2),-R8.
[0172] In a sixth embodiment of the tenth aspect, one or both of Z and Z' are -[C(O)-(CR4 2)t-NR5-(CR4 2)t]u-C(O)-(CR4 2)t-NR7-(CR4 2)t-R8. [0173] In a seventh embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-NR5-(CR4 2),-C(O)-(CR4 2),-NR7-(CR4 2),-R8.
[0174] In an eighth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-NR7-(CR4 2),-R8.
[0175] In a ninth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-(CR4 2)n-C(O)-R81.
[0176] In a tenth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-C(O)-R81.
[0177] In an eleventh embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-(CR4 2)n-C(O)-O-R81.
[0178] In a twelfth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-C(O)-O-R81.
[0179] In a thirteenth embodiment of the tenth aspect, one or both of Z and Z' are -U- (CR4 2)t-R8.
[0180] In a fourteenth embodiment of the tenth aspect, one or both of Z and Z' are - C(O)-(CR4 2)t-R8.
[0181] In a fifteenth embodiment of the tenth aspect, one or both of Z and Z' are -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8.
[0182] In a sixteenth embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-O-(CR4 2),-R8.
[0183] In a seventeenth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)t-NR5-(CR4 2)t-C(O)-(CR4 2)t-O-(CR4 2)t-R8.
[0184] In an eighteenth embodiment of the tenth aspect, one or both of Z and Z' are -U-(CR4 2),-O-(CR4 2),-R8.
[0185] In a nineteenth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2),-O-(CR4 2),-R8.
[0186] In a twentieth embodiment of the tenth aspect, one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-R8 wherein R7 and R8 together form a 4-7 membered ring.
[0187] In an eleventh aspect of the invention, compounds have formula VII:
Figure imgf000065_0001
wherein,
\=/ may include 1 or 2 nitrogens as heteroatoms,
r is from 0 to 4,
each Ra is independently selected from the group consisting of -OH,
-CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
A and A' are independently selected from the group consisting of
Figure imgf000065_0002
H
Figure imgf000065_0003
-(CR2)n-O-(CR2)p- and -(CR2)n-C(O)N(R N>λ (CR2)p- wherein,
if A or A' is a heteroaryl group, it is optionally substituted with one or more of the substituents selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and
n and p are independently O, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
for each A and A',
Figure imgf000066_0001
may be attached to either side of
A and A' so that in the example of A or A' being HN s the
Figure imgf000066_0002
s
Figure imgf000066_0003
wherein,
B' is optionally substituted with between 1 and 4 substituents, each independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino and oxo,
Xa is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -O-, -S-, -S(=O)2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, and Ci to Cs heteroalkyl, and
Xb is either C or N; X and X' are each either present or absent and if present, independently selected from the group consisting of a bond, -CH2-, - CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)2-, -CH2O-, -CH2S-, -CH2S(O)2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4 , R5 and R7 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently O, 1, 2, 3, or 4, and
u is O, 1, or 2.
[0188] The compounds of the present invention include pharmaceutically acceptable salts of VII as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0189] In a twelfth aspect of the invention, compounds have formula VIII:
Figure imgf000068_0001
wherein:
B' is selected from the group consisting of -©- -©- -
Figure imgf000068_0002
1 or 2 nitrogens as heteroatoms; each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -0-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)i_2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl; each R8 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl.
[0190] The compounds of the present invention include pharmaceutically acceptable salts of IX as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0191] In a thirteenth aspect of the invention, compounds have formula IX:
Figure imgf000069_0001
wherein:
B' is selected from the group consisting of -©- -Θ- -
Figure imgf000069_0002
\=/ optionally includes 1 or 2 nitrogens as heteroatoms; each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)i_2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl; each R8 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl.
[0192] The compounds of the present invention include pharmaceutically acceptable salts of IX as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. 3] In a fourteenth aspect of the invention, compounds have formula X:
Figure imgf000070_0001
wherein:
B' is selected from the group consisting of -©- -Θ- -
Figure imgf000070_0002
\=/ optionally includes 1 or 2 nitrogens as heteroatoms; each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)i_2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl; each R8 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl,
Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R 81 , -C(S)-R81, -C(O)-O-R81, -C(O)-N-R81 2, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl. [0194] The compounds of the present invention include pharmaceutically acceptable salts of X as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0195] In a fifteenth aspect of the invention, compounds have formula XI:
Figure imgf000071_0001
wherein: each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; r is O, 1, 2, 3 or 4;
Xa is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -O-, -S-, -S(=O)2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cs alkyl, and Ci to Cs heteroalkyl, each R8 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl; and each R4 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl.
[0196] The compounds of the present invention include pharmaceutically acceptable salts of XI as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof. 7] In an additional aspect of the invention, compounds of formula XII are provided:
Figure imgf000072_0001
wherein,
A and A' are independently selected from the group consisting of a single bond,
-(CR2)n-C(O)-(CR2)p- -(CR2)n-O-(CR2)p- -(CR2)n-N(R NN λ)-(CR2)p-,
-(CR2)n-S(O)k-N(R >NN λ)-(CR2)p- -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a
Figure imgf000072_0002
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000073_0001
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3,
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that
in the example of A or A' being
Figure imgf000073_0002
, the A-B-A' can be any of: B is selected f
Figure imgf000074_0001
rom the group consisting of v 's ,
Figure imgf000074_0002
Figure imgf000074_0003
, wherein:
-©- i,s a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns;
V is -CH2-, -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or -(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0;
X1 is CH2, NH, O or S,
each Y1 is independently CH or N,
each r and s is independently 0, 1, 2, 3 or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
each Rb is independently selected from the group consisting of Ci-Ci2 alkyl, hydroxyl, halogen and oxo;
Rc, Rd, Re, and Rf are each independently selected from the group consisting of: hydrogen, Ci to C8 alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of Rc, Rd, Re, and Rf may optionally be substituted by Ci to C8 alkyl, Ci to C8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8, and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)-, and -S(O)2-,
each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R81 2, -S(O)2-R81, and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring, each t is independently 0, 1, 2, 3, or 4, and
u is 0, 1, or 2.
[0198] The compounds of the present invention include pharmaceutically acceptable salts of XII as well as an optically pure enantiomer, racemate or diastereomeric mixtures thereof.
[0199] The compounds of the invention are prepared by synthetic routes and procedures that are illustrated in the various synthetic schemes below. The synthetic routes shown in schemes below are disclosed for the purpose of illustration and are not meant to be interpreted as limiting the processes to make the embodied compounds by any other methods. It will be appreciated by those skilled in the art that a number of methods are available for the preparation of the compounds of the present invention. These compounds may be prepared by processes which include processes known in the chemical art for the production of structurally analogous compounds or by a novel process described herein. One of the general strategies includes building the central scaffold followed by gradual functional group transformations of the two ends either simultaneously. In order to differentially functionalize the two ends, some orthogonal functional group protection and deprotection strategies are used (T.W. Greene & P. G. M. Wutts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999). Another synthetic strategy entails the construction of the two halves of the molecule separately and coupling them toward the end of the synthesis. The cross coupling techniques employ conditions such as the Sonogashira, Suzuki-Miayura, or Stille reaction for connecting carbon-carbon bonds. For scaffold cores linked via a carbon-nitrogen bond, their syntheses typically utilize a nucleophilic aromatic substitution reaction, a Buchwald or a Ma cross coupling reaction. The functional groups, typically amines and carboxyl groups on either ends of the cores are generally orthogonally protected to allow for selective further manipulations as needed.
following abbreviations are used throughout this application:
ACN Acetonitrile aq Aqueous
Bn Benzyl
BnOH Benzyl alcohol
Boc t-butoxycarbonyl
DCE Dichloroethane
DCM Dichloromethane
DIEA(DIPEA) Diisopropylethylamine
DMA N, iV-Dimethy lacetamide
DME 1 ,2-Dimethoxyethane
DMF N, iV-Dimethy lformamide
DMSO Dimethylsulfoxide
DMTMM 4-(4,6-Dimethoxy-l,3,5-triazin-2-yl)-4- methylmorpholinium chloride
DPPA Diphenylphosphoryl azide
DTT Dithiothreitol
EDC Ethylcarbodiimide hydrochloride
EDCl 1 -Ethyl-3-[3-(dimethylamino) propyl]carbodiimide hydrochloride
EDTA Ethylene diamine tetraacetic acid
ESI Electrospray Ionization
Et3N, TEA Triethylamine
EtOAc, EtAc Ethyl acetate
EtOH Ethanol g Gram(s) h Hour(s)
HBTU O-Benzotriazol- 1 -yl-N,N,N ' ,N ' -tetramethyluronium hexafluorophosphate
HOBt 1 -Hydroxybenzotriazole
IC50 The concentration of an inhibitor that causes a 50 % reduction in a measured activity
LAH Lithium aluminum hydride LDA Lithium diisopropylamide
LCMS Liquid Chramatography Mass Spectrometry
MeI Methyl Iodide
MeOH Methanol min Minute(s) mmol Millimole(s)
NMM 4-Methylmorpholine
NMP N-methylpyrrolidinone
PG Protective Group
PTT Phenyl trimethyl tribromide
Py Pyridine rt Room temperature
TEA Triethylamine
Tf Trifluoromethanesulfonate
TFA Trifluoroacetic acid
TFAA Trifluoroacetic anhydride
THF Tetrahydrofuran
TLC Thin Layer Chramatography
EXAMPLE 1 - General Synthesis
Figure imgf000079_0001
Figure imgf000079_0002
Scheme 1-1
[0201] Schemes 1-1 and 1-2 illustrate the various methods of preparing aryl-carbocyclic central scaffolds (Bs) and how the two ends of the molecule can be differentially constructed in order to allow for selective functionalization of either end of the molecule.
Figure imgf000080_0001
Scheme 1-2
Figure imgf000081_0001
A-17 A-16 A15
Figure imgf000081_0002
B-8
B-6
V = NH-P' V = CO2Et
Figure imgf000081_0003
Scheme 1-3
[0202] Scheme 1-3 outlines the preparation of core structures connected through a carbon-nitrogen bond. The nitrogen arylation is achieved using one of the several methods. In one embodiment, the acetophenone moiety and the V group in A-17 can be sequentially converted to a bromoketone as in A-18 for further introduction of the A-19 moiety. The coupling between A-15 and A-16 to A-17 represents a nucleophilic aromatic substitution method. Other methodologies employed include Buchwald or Ma couplings (J. Org. Chem. 2005, 70, 164), such as the coupling of A-15 with A-20 to B-6, A-15 with A-22 to B-7, A-21 with A-22 to B-8. When V is a carboxylate, it can be extended via an amide linkage. Taking B-6 as an example, the carboxylate can undergo a Curtis rearrangement to an amine, which in turn can be transformed to an amide (B-6 to B-9). Alternatively, the carboxylate can be hydrolyzed and converted to B-IO when reacts with a protected form of pyrrolidin-2- ylmethanamine. The methodologies outlined in this scheme are further depicted in other schemes described herein.
Figure imgf000082_0001
Scheme 1-4
[0203] Scheme 1-4 illustrates some of the ways for further functional group transformations using scaffold B-I as an example. Starting from a properly protected B-I, the nitrogen protecting groups P and P' can be removed simultaneously to give B-Ia. When B-Ia is treated together a suitably protected amino acid under standard peptide coupling conditions, such as HATU and a tertiary amine base, e.g. Hϋnig's base, the doubly coupled product B-Ib is obtained. Typically, P refers to a protecting group such as Boc-, Cbz-, Troc-, etc. P can also be other alkyl, acyl, alkoxylcarbonyl, alkylaminocarbonyl groups that are intended for this position. When P is one of the removable groups, upon its removal, the free the amino group can be further derivatized to B-Ic. The definition of Cap group is P and P'. The protecting groups P and P' can be removed selectively to free one of the two amino groups in B-I as in the case of B-I to B-Id. These skilled in the art will understand that the P' group can be deprotected while the P group is preserved to give an alternative structure such as B-Id. The free amino group of B-Id is coupled with another properly functionalized amino acid to give B-Ie. When this process of selective deprotection and functionalization is repeated, compound B-If is obtained. The newly introduced amino acid in B-If can be the same as the residue on the left-hand side of the molecule or can be a different one. From B- If, a variety of compounds (with a general formula of B-Ig) are prepared with differentially functionalized end pieces.
[0204] In another embodiment, several key intermediates used in the construction of claimed scaffolds are depicted in the following schemes.
Figure imgf000083_0001
A-23 A-24 A-25 A-26
Figure imgf000083_0002
Scheme 1-5
[0205] Scheme 1-5 using an L-pro line-based structure as an example describes the synthesis of several key imidazole intermediates that are used for the construction of various more advanced intermediates in this invention. (References: a. Polyhedron 2005, 24, 2625, b. WO2008/021927). The readily available L-prolinaldehyde is converted to imidazole A-24 by reacting with glyoxal in the presence of ammonium hydroxide. The monohalogenation (bromination or iodination) is best achieved via a two-step sequence, i.e. non-selective dihalogenation followed by a selective removal of one of the two halogen atoms to A-26. To facilitate the further functionalization, the imidazole moiety is preferably protected with SEM or other protecting groups. The protection process does generate a mixture of regioisomers of the protecting group. However, such a mixture does not usually affect the reactivity of the intermediates toward further reaction and will become one compound upon the removal of the protecting group. The iodo- or bromo-imidazole intermediate A-27 is used converted to is the corresponding borate A-28 under the conditions shown, or using conditions that are known to promote similar transformations. When the same intermediate A-27 is subjected to Sonogoshira coupling conditions, the acetylene compound A-28 is obtained after subsequent treatment with base. The use of intermediate as an alternative method of synthesizing arylimidazole intermediates such as A-I and B-3 is illustrated in Scheme 1-1. These versatile building blocks are used in many other manners as will be shown in the schemes to follow.
Figure imgf000084_0001
Ref. J. Med. Chem.2008, 51, 5109; 2006, 49, 3774; and 2002, 45, 5556
Scheme 1-6
[0206] In another embodiment, the aryl-imidazole and benzoimidazole building blocks are synthesized using the route described in Scheme 1-6 (Ref. J. Med. Chem. 2008, 51, 5109; 2006, 49, ZIlA; and 2002, 45, 5556). Those in the art shall recognize that the phenyl, the proline and the protecting group on nitrogen may be replaced in order to achieve the desired functionality at a given position.
Figure imgf000084_0002
R2 = H, or Ac V = Ac A-1 b
V for example can be an acetyl group or a masked form,
OTf
Figure imgf000084_0003
V can be a protected form of N
A-I b1
R2
EtO2C EtO2C LiOH,
HO2C
EtO2C EtO2C ^ // and thenheating V //
A-1d
Scheme 1-7 [0207] In another embodiment, the building blocks used in Scheme 1-1 for the synthesis of scaffolds such as B-I to B-4 and others are synthesized using routes described in Scheme 1-7. The preparation of A-Ia starts with the dimethyl bicyclo[2.2.2]octane-l,4-dicarboxylate, one of the methyl ester group is selectively hydro lyzed to the acid, which in turn is converted to a bromo group to give methyl 4-bromobicyclo[2.2.2]octane-l-carboxylate. A Friedel- Crafts reaction between methyl 4-bromobicyclo[2.2.2]octane-l-carboxylate and a substituted benzene yields A-Ia (Ref. J. Org. Chem. 1970, 55, 917). Compound A-Ib is prepared similarly. Another method to prepare the cyclohexyl-containing compounds such as A-Ib and A-Ib' is through a cross coupling reaction between vinyltrifolate and a phenylboronate (or a boronic acid). The letter V represents a carboxylate group, such as an ethoxylcarbonyl, or a protected amino group, or can be another functional group that can be further functionalized. Following the coupling step, the resulted styrenyl group can be preserved (A- Ib') or can be saturated under hydrogenation condition to give A-Ib. The cyclopentyl analog A-Ic may be made by similar route. The four-carbon analog is made in sequence as shown.
Synthesis of Example Compounds
[0208] The examples below provide exemplary synthetic methods for the preparation of the compounds of the present invention. One of skill in the art will understand that additional methods are also useful. The compounds of the invention can be made using conventional organic synthesis using starting materials, reagents and reactions well known in the art.
[0209] Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). 1H-NMR spectra were recorded on a Bruker 400 MHz or 500 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons. Electrospray spray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard 1100 MSD electrospray mass spectrometer using the HPl 100 HPLC for sample delivery. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses) or a single m/z value for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 5 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using an acetonitrile/water gradient (10%-90%) acetonitrile in water with 0.1% formic acid as delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH4OAc in acetonitrile/water as delivery solvent. Enantiomeric purity was determined using a Hewlett-Packard Series 1050 system equipped with a chiral HLPC column (ChiralPak AD, 4.6 mm x 150mm) and isocratic elution using 5:95 isopropanol-hexane as a mobile phase.
[0210] The compounds were named using ChemDraw program from Cambridge Soft Inc. EXAMPLE 2 - Synthesis of compounds of Formula IVb
[0211] Compounds of formula IVb can be made by schemes 2-1 and 2-2.
Figure imgf000087_0001
Pd(dppf)CI2, Pd(OAc)2 KOAc, dioxane, 1000C
1. N-Boc-D-amino acid, EDC, THF
1
Figure imgf000087_0002
2. 4 N HCI in dioxane
Pd(PPh3)4, 2.0N Na2CO3ZDME, 800C 3. R2COOH, EDC, THF 2. 4 N HCI in dioxane
Figure imgf000087_0003
OO
Figure imgf000087_0004
Scheme 2-1
Figure imgf000088_0001
3. 4 N HCI in dioxane
4. R2COOH, EDC, THF
Figure imgf000088_0002
Pd(PPh3)4, 2 N Na2CO3/DME, 800C
Figure imgf000088_0003
Scheme 2-2
Figure imgf000089_0001
[0212] Step a. Referring to Scheme 2-3, compound 1 was prepared following procedures described in J. Med. Chem. 2007, 50, 6706.
[0213] Step b. A sample of compound 1 (1.Og, 2.82 mmol) in dichloromethane was treated with excess 4N HCl in dioxane. At the completion of removal of Boc group as indicated by LCMS, solvents were removed and the residue was dried under vaccum. This material was taken up in acetonitrile (6 mL) and treated with tert-butyi (lH-pyrazol-1- yl)methylenedicarbamate (2) (1.01 g, 3.2 mmol) and DIPEA (0.60 g, 4.65 mmol) at rt overnight. The solvents were evaporated off and the crude product was purified by silica gel column chromatography with a gradient eluent consisting various ratio of EtOAc and hexanes to give compound 3 (0.59 g, 71% yield).
[0214] Step c. A solution of 3 (1.34 g, 2.69 mmol, from combined runs) in THF (5 mL) was treated with excess 4N HCl in dioxane at rt overnight. Solvents were removed by evaporation, and residue was further dried under high vacuum. A portion of this de-Boc material (0.3 g, 1.0 mmol) was taken up in THF (4 mL) and water (0.34 mL). To this mixture was added K2CO3 (0.27 g, 2.02 mmol) followed by bromoketone compound 4 (0.33 g, 1.01 mmol, prepared following published procedures). The entire mixture was heated at reflux overnight. After cooling, the reaction mixture was added CH2Cl2 and washed with H2O and brine, respectively. After drying over Na2SO4, the solvent was removed and the residue was purified by silica gel column chromatography, eluted with 1-3% MeOH in EtOAc to afford 5 (0.32 g).
[0215] Step d. A mixture of compound 5 (0.2 g, 0.38 mmol), bis(pinacolato)diboron (0.12 g, 0.46 mmol), potassium acetate (0.11 g, 1.1 mmol), and Pd(dppf)Cl2-CH2Cl2 (30 mg, 0.038 mmol) in dioxane (5 mL) was stirred at 80 0C for 17 h under an atmosphere of Ar. Subsequently, the reaction mixture was filtered. The filtered cake was washed with EtOAc (5 mL x 3). The filtrate was washed with H2O and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 6 (0.14 g).
[0216] Step e. A solution of compound 6 (0.640 g, 1.1 mmol) in dioxane (24 mL) and water (2.4 mL) was sequentially added {S)-tert-hvXy\ 2-(5-iodo-l-((2-(trimethylsilyl) ethoxy)methyl)-lH-imidazol-2-yl)pyrrolidine-l-carboxylate (1.10 g, 2.22 mmol), NaHCO3 (0.37 g, 3.66 mmol), and Pd(dppf)Cl2-CH2Cl2 (90 mg, 0.11 mmol) at rt under an atmosphere of Ar. After stirring at 80 0C overnight under an atmosphere of Ar, the reaction mixture was diluted with EtOAc (100 niL). The organic layer was isolated, washed with brine, and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 8 (0.2 g mg) as a yellow solid.
[0217] Step f. A sample of compound 8 (34 mg) was treated 4N HCl in dioxane (0.5 mL) at rt overnight to remove both the Boc group and the SEM group. The Cbz group was removed under hydrogeno lysis conditions (Pd/C, H2).
[0218] Step g. Compound 9 (29 mg, 0.05 mmol) was treated with N-Moc-D-Phg-OH (20.6 mg, 0.11 mmol), DMTMM (42 mg, 0.15 mmol) and DIPEA (52 mg, 0.42 mmol) in THF/DMF (0.5 mL /0.5 mL) to give compound 10. LC-MS (ESI): m/z 829 (M+H)+.
Figure imgf000091_0001
Scheme 2-4 [0219] Step a. Referring to Scheme 2-4, to a stirred solution of 1 (1 eq., 0.2 M) in CH2Cl2 was added DIPEA (1.2 eq.). The reaction flask was cooled with a water-ice bath, and TMSOTf (1.1 eq.) was slowly added over a 10 min period. The reaction was stirred at 0 0C for 10 min, then at rt until silylation was complete, as determined by TLC (1.5 h). PTT (IM in THF, 1.05 eq) was added over 10 min. The reaction was stirred at rt until bromination was complete, as judged by TLC (30 min). The reaction was partitioned between CH2Cl2and NaHCO3 with a 1/1 (v/v) ratio. The aqueous phase was extracted with CH2Cl2 (2x). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude product 2 was used without further purification.
[0220] Step b. To a stirred solution of 2 (1 eq., 0.3M) and N-Cbz-L-Pro-OH (1 eq.) in MeCN was added DIPEA (1.2 eq.). The reaction was stirred at rt for 16 h. The reaction was concentrated to dryness. The resulting crude product was purified by silica gel column chromatography (hexanes/EtOAc = 100/0 to 70/30 (v/v), 5 step gradient) to provide 3.
[0221] Step c. To a stirred solution of 4 (1 eq, 0.3M) and N-Boc-L-Pro-OH (1 eq.) in MeCN was added DIPEA (1.2 eq.). The reaction was stirred at rt for 16 h. The reaction was concentrated to dryness. The resulting crude product was purified by silica gel flash column chromatography (hexanes/EtOAc = 100/0 to70/30 (v/v), 5 step gradient) to provide 5.
[0222] Step d. A stream of nitrogen was bubbled through a solution of 5 (1 eq., 0.3M) in o-xylene in a sealable reaction tube for 10 min. NH4OAc (10 eq.) was added to the solution. The reaction tube was sealed and placed in a 150 0C oil bath. The reaction was stirred at this temperature for 1 h then cooled to rt. The reaction tube was carefully opened, and its contents partitioned between aqueous Na2CO3 and CH2Cl2/Me0H (10/1 (v/v)) with a 1 : 1 (v/v) ratio.. The layers were separated, and the aqueous phase was extracted with CH2Cl2/Me0H (10/1) until the extracts were free of any uv-active component (as determined by TLC). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The resulting crude product was purified by silica gel column chromatography (hexanes/EtOAc = 50/50, 20/80, and 0/100, then MeOH/EtOAc = 1/99 (v/v)) to provide 6.
[0223] Step e. To a solution of 6 (1 eq.) in EtOH/AcOH (1/1 , v/v) was added Pd(OH)2 on carbon (10%). After sealing the reaction flask with a rubber septum, the system was evacuated and backfilled with 1 atm H2 (2x). The vigorously stirred reaction was stirred at rt under H2 (1 atm) for 16 h. The mixture was filtered through a pad of CELITE™545 (pre- washed with EtOH), and the separated solids were washed with EtOH (5x). The filtrate was concentrated to provide crude 7. Residual AcOH was removed by dissolving the crude product in H2O then adjusting the pH to ~13 with 2N aqueous NaOH. The product was extracted with CH2Cl2 until the extracts were free of 7. The crude product was used without further purification.
[0224] Step f. To a solution of 7 (1 eq., 0.3M) and 3 (1 eq.) in DMSO was added DIPEA (1.2 eq). The reaction was stirred at rt for 4 h then at 30 0C for 16 h. The reaction was then partitioned between aqueous Na2CO3 and CH2Cl2/Me0H (10/1 (v/v)) with a 1 : 1 (v/v) ratio. The layers were separated, and the aqueous phase was extracted with CH2Cl2/Me0H (10/1 (v/v)) until the extracts were free of any UV-active component. The combined organic layers were dried over Na2SO4, filtered, and concentrated by rotary evaporation. The resulting crude product was purified by silica gel column chromatography (hexanes/EtOAc = 33/67 to 0/100 (v/v), 5 step gradient) to provide 8.
[0225] Step g. A stream of nitrogen was bubbled through a solution of 8 (1 eq, 0.3M) in o-xylene in a sealable reaction tube for 10 min. NH4OAc (10 eq) was added to the solution. The reaction tube was sealed and placed in a 150 0C oil bath. The reaction was stirred at this temperature for 1 h then cooled to rt. The reaction tube was carefully opened, and its contents were partitioned between aqueous Na2CO3 and CH2Cl2/Me0H (10/1 (v/v)) with a 1 : 1 (v/v) ratio. The layers were separated, and the aqueous phase was extracted with CH2Cl2ZMeOH (10/1 (v/v)) until the extracts were free of any UV-active component. The combined organic layers were dried over Na2SO4, filtered, and concentrated by rotary evaporation. The resulting crude product was purified by silica gel flash column chromatography (hexanes/EtOAc = 25/75 to 0/100 (v/v), then MeOH/EtOAc 1/99 to3/97 (v/v)) to provide 9.
[0226] Step h. To a solution of 9 (1 eq) in absolute EtOH was added Pd on carbon (10%, 50% H2O). After sealing the reaction flask with a rubber septum, the system was evacuated and backfilled with 1 atm H2 (2x). The vigorously stirred reaction was stirred at rt under H2 (1 atm) for 4 h. The mixture was filtered through a pad of CELITE™545 (pre -washed with EtOH), and the separated solids were washed with EtOH (5x). The filtrate was concentrated to provide crude 10 that was used without further purification.
[0227] Step i. To a stirred solution of 10 (1 eq, 0. IM) and N-Moc-D-Phg-OH(1 eq.) in DMF, DMTMM (1 eq.) and DIPEA (1 eq.) were sequentially added. The reaction was stirred at rt for 1 h and partitioned between aqueous Na2CO3 and CH2Cl2/Me0H (10/1) with a 1/1 (v/v) ratio. The layers were separated, and the aqueous phase was extracted with CH2Cl2ZMeOH (10/1) until the extracts were free of any uv-active component. The combined organic layers were dried over Na2SO4, filtered, and concentrated by rotary evaporation. Residual DMF was removed by bulb-to-bulb distillation using gentle heating. The remaining crude product was purified by silica gel column chromatography (hexanes/EtOAc = 25/75, 10/90, 0/100 (v/v), then MeOH/EtOAc = 1/99 to 3/97 (v/v)) to provide 11.
[0228] Step j. Compound 11 (1 eq.) was treated with THF (7 mL/mmol 11) followed by slow addition of 4N HCl in dioxane (14 mL/1 mmol of 11). The reaction was stirred at rt for
2 h. The reaction mixture was concentrated to dryness to provide 12.
[0229] Step k. To a stirred solution of 12 (1 eq, 0. IM) and N-Boc-D-Phg-OH (1 eq.) in DMF were sequentially added DMTMM (1 eq.) and DIPEA (1 eq.). The reaction was stirred at rt for 1 h. The crude reaction mixture was purified on a C18-Luna preparative HPLC column (H2O-MeCN, 0.1% HCO2H) to give compound 13 as a white solid.
[0230] Step 1. Compound 13 (1 eq.) was treated with THF (7 mL/mmol) followed by slow addition of 4N HCl in dioxane (14 mL/1 mmol of 13). The reaction was stirred at rt for
3 h. The reaction mixture was concentrated to dryness to provide 14.
[0231] Step m. To a stirred solution of 14 (1 eq, 0.1M) and cyclopropane carboxylic acid (1 eq.) in DMF were sequentially added DMTMM (1 eq.) and DIPEA (1 eq.). The reaction was stirred at rt until complete, as determined by LC-MS. The crude reaction mixture was purified on a C18-Luna preparative HPLC column (H2O-MeCN, 0.1% HCO2H) to give compound 15 as a white solid. 1H NMR (CDCl3, 300 MHz) 57.37-7.49 (m, 12H), 7.22 (br s, IH), 7.19 (br s, IH), 7.16 (s, IH), 6.84 (d, J= 6.0 Hz, IH), 6.27 (d, J= 0.5 Hz, IH), 5.94 (br d, J= 6.0 Hz, IH), 5.58 (d, J= 6.0 Hz, IH), 5.39 (d, J= 6.5 Hz, IH), 5.24-5.30 (m, 2H), 3.70-3.82 (m, 2H), 3.68 (s, 3H), 3.14-3.35 (m, 6H), 2.88 (br m, IH), 2.65-2.78 (m, 2H), 1.75- 2.15 (m, 10H), 1.47 (m, IH), 0.97 (m, 2H), 0.79 (m, 2H). LC/MS (ESI) m/z 430.9 [(M+2H)/2]+. HPLC: Agilent Eclipse XDB-C18 4.6x150 mm, 5μm; 5%-100% B over 15 min; A = H2O+TFA (0.1%), B = MeCN+TFA (0.1%); 254 nm; 20 μL injection volume. RT=8.17 min; 97% pure.
Figure imgf000095_0001
[0232] Step a. Referring to Scheme 2-6 to a suspension of AICI3 (19.5 g, 146 mmol) in CS2 (40 rnL) at -78 0C was added acetyl chloride (10.4 mL, 146 mmol) slowly over 10 min. The mixture was stirred vigorously for 15 min and cyclohexene (1O g, 122 mmol) was added dropwise over 20 min. The mixture was stirred below -2O0C for 30 min. The solvent was removed and the residue was re-dissolved in benzene. The mixture was heated at 40-500C 3-4 h, cooled to rt and poured into a mixture of ice and HCl (IN). The organic layer was collected, and aqueous layer was extracted with ethyl acetate (3X). The combined organic layers were concentrated and purified on a column (hexane: ethyl acetate, 8:2) to give l-(4- phenylcyclohexyl)ethanone (Al) (9 g, 37% yield).
[0233] Step b. To a suspension OfAlCl3 (5.9 g, 54 mmol) in DCM (200 mL) at 0 0C was added l-(4-phenylcyclohexyl)ethanone (9 g in DCM), and acetyl chloride (10.4 mL, 146 mmol) dropwise over 30 min. The mixture was stirred to rt for 15 min. and heated at 45 0C for 4h. After being cooled to rt, the mixture was poured it into ice-HCl (IN). The organic layer was collected, and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were combined, concentrated and purified on column (hexane: ethyl acetate, 8:2) to give l-(4-(4-acetylcyclohexyl)phenyl)ethanone (A2) as a mixture of two isomers (5g, 46% yield).
[0234] Step c. To a solution of l-(4-(4-acetylcyclohexyl)phenyl)ethanone (A2) (900 mg, 3.7 mmol) in MeOH (20 mL) at O0C was added bromine (993 μL, 8.1 mmol) drop-wise and the reaction mixture was stirred below 5 0C for 3 h. The reaction was quenched by adding saturated aqueous NaHCO3 solution and the mixture was extracted with ethyl acetate (3x). The extracts were combined and concentrated. The residue was purified by silica gel column chromatography (n-hexane/ethyl acetate = 5/1 (v/v)) to afford 2-bromo-l-(4-(4-(2- bromoacetyl)cyclohexyl)phenyl)ethanone (A3) (400 mg, 27% yield).
[0235] Step d. To a solution of N-Cbz-L-Pro-OH (1.36 g, 5.47 mmol) in acetonitrile (10 mL) was added triethyl amine (762 μL, 5.47 mmol) and 2-bromo-l-(4-(4-(2- bromoacetyl)cyclo hexyl)phenyl)ethanone (A3) (1 g, 2.49 mmol) in acetonitrile. The reaction mixture was stirred at rt overnight. The solvent was removed and product was diluted with ethyl acetate (3x), washed with NaHCO3 (100 mL) and brine, and dried with Na2SO4. After removal of the solvent, the crude product (S)- 1 -benzyl 2-(2-(4-(4-(2-((5)-l- (benzyloxycarbonyl) pyrrolidine-2-carbonyloxy)acetyl)cyclohexyl)phenyl)-2-oxoethyl) pyrrolidine- 1,2-dicar boxylate (A4) (2.5 g) was used for the next step directly. [0236] Step e. A solution of (S)- 1 -benzyl 2-(2-(4-(4-(2-((S)-l-(benzyloxycarbonyl) pyrrolidine-2-carbonyloxy)acetyl)cyclohexyl)phenyl)-2-oxoethyl) pyrrolidine- 1 ,2-dicar boxylate (A4) (3.0 g, 4.06 mmol) in o-xylene (25 niL), ammonium acetate (3.76 g, 48.7 mmol) and diisopropylethylamine (48.7 mmol) was placed in a pressure resistant tube. The tube was sealed and heated to 140 0C for 4 h, cooled to rt. The volatile component was removed in vacuo and the residue was partitioned between water and CH2Cl2. The organic phase was dried, filtered and concentrated in vacuo. The resulting crude material was purified by a flash chromatography (CH2Cl2/Me0H = 9/1 (v/v)) to provide (5)-benzyl 2-(4-(4-(4-(4- ((S)- 1 -(benzyloxycarbonyl)pyrrolidin-2-yl)- 1 H-imidazol-2-yl)phenyl)cyclohexyl)- 1 H- imidazol-2-yl)pyrrolidine-l-carboxylate (A5) as yellow residue (200 mg).
[0237] Step f. (5)-benzyl 2-(4-(4-(4-(4-((S)- 1 -(benzyloxycarbonyl)pyrrolidin-2-yl)- 1 H- imi-dazol-2-yl)phenyl)cyclohexyl)- 1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (A5) (200 mg) and Pd/C (20 mg) in MeOH (20 mL) was purged with H2. The reaction was stirred under hydrogen balloon for 48 h, filtered on CELITE™and concentrated. The residue 2-((5)- pyrrolidin-2-yl)-4-(4-(4-(4-((5)-pyrrolidin-2-yl)- 1 H-imidazol-2-yl)phenyl)cyclohexyl)- 1 H- imidazole (A6) was directly used for next step without further purification.
[0238] Step g. To a solution of 2-((5)-pyrrolidin-2-yl)-4-(4-(4-(4-((5)-pyrrolidin-2-yl)- lH-imidazol-2-yl) phenyl)cyclohexyl)-lH-imidazole (A6) (300 mg, 0.715 mmol) in DMF (20 mL) was added N-Boc-L- VaI-OH (432 mg, 1.72 mmol), HATU (654 mg, 1.72 mmol) and diisopropylethylamine (590 μL, 3.58 mmol). The reaction was stirred at rt overnight. The solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography (CH2Cl2/Me0H = 9/1 (v/v)) and preparative TLC to give A7 (500 mg) as a white solid. LC-MS (ESI): m/z 829 (M+H)+.
Figure imgf000098_0001
[0239] Step a. Referring to Scheme 2-7 to a suspension of AICI3 (1.58 g, 12 mmol) in DCM (30 niL) at -78 0C was added l-(4-phenylcyclohexyl)ethanone (Al') (1 g in DCM, 5.0 mmol), and bromoacetyl bromide (0.65 mL, 7.5 mmol) dropwise over 10 min. The mixture was stirred to rt for 15 min and heated at 40-500C for 3 h, cooled to rt and poured into a mixture of ice and HCl (IN). The organic layer was collected, and the aqueous layer was extracted with ethyl acetate (3 x). The combined organic layers were concentrated on rotovap and purified silica gel column chromatography (Hexanes / EtOAc = 8 / 2 (v/v)) to give the desired trans- isomer A2' (I g, 62% yield) along with a small amount of cώ-isomer.
[0240] Step b. To a solution of the N-Cbz-L-Pro-OH (7.4 g, 29.7 mmol) in acetonitrile (30 mL) was added triethylamine (5.2 mL, 37 mmol) and A2' (8 g, 24.8 mmol) in acetonitrile. The reaction mixture was stirred at rt overnight. The solvent was removed and product was extracted with ethyl acetate (3x), washed with NaHCO3 (200 mL) and brine, dried with Na2SO4. After removal of the solvent, the crude product was purified silica gel column chromatography (Hexanes/EtOAc = 1/1 (v/v)) to give pure A3' as a light yellow oil (8 g, 66% yield).
[0241] Step c. To a solution of A3' (20.0 g, 40.7 mmol) and diethylisopropylamine (20 mL) in DCM (200 mL) in a round bottom flask was added trimethylsilyl trifluoromethanesulfonate (TMSOTf, 20 mL, 122 mmol) at -78 0C. The reaction was stirred at rt overnight. To the solution was added a solution of phenyltrimethylammonium tribromide (PTT, 16.8 g, 45 mmol) in THF (50 mL). The reaction was stirred at rt 2 h and quenched with saturated NaHCO3 solution. The mixture was partitioned between water and CH2Cl2 (3x), and the organic layers were washed with brine, dried, filtered and concentrated in vacuum. The resulting crude material was purified by silica gel column chromatography (Hexanes/EtOAc = 1/1 (v/v)) to provide A4' as yellow residue (17g, 73% yield).
[0242] Using similar procedure as for compound A3' from A2', compound A5' was prepared from the corresponding bromide A4' in 80% yield.
[0243] Step d. To a solution of A5' (2.5 g, 3.5 mmol) in o-xylene (25 mL) in a sealed tube was added ammonium acetate (4.1 g, 53 mmol). The mixture was sealed and heated at 140 0C for 3 h and then cooled to rt. The volatile component was removed in vacuo, and the residue was partitioned between H2O and CH2Cl2, and the organic phase was dried, filtered and concentrated in vacuo. The resulting crude material was purified by silica gel column chromatography (CH2Cl2/ MeOH = 9/1 (v/v)) to provide A6' as a yellow solid (250 mg, 10% yield).
[0244] Step e. Following the deprotection and amide formation operations described for similar systems and repeated the process twice, the differentially functionalized compound A8' was obtained. LC-MS (ESI): m/z 789 (M+H)+.
Figure imgf000101_0001
EXAMPLE 3 - Synthesis of compounds of Formula IX
[0245] Step a. Referring to Scheme 3-1, methyl S-phenylcyclobutanecarboxylate A2 was obtained by treating a solution of 3-phenylcyclobutanecarboxylic acid (5.3 g, 30 mmol, Reference: JOC, 1962, 27, 1647) in methanol (50 mL) and thionyl chloride (2.9 mL, 39 mmol) first at 0 0C for 0.5 h and then at rt overnight. The solvent was removed, the residue was diluted with ethyl acetate (100 mL) and washed with brine and H2O, dried with Na2SO4. After removal of the solvent, the crude product was purified by silica gel column chromatography (n-hexane/ethyl acetate = 10/1 (v/v)) to afford methyl 3- phenylcyclobutanecarboxylate (A2) (5.41 g, 95% yield).
[0246] Step b. To a solution of methyl S-phenylcyclobutanecarboxylate (A2) (5.41 g, 28 mmol) and AICI3 (9.5 g, 71 mmol) in methylene chloride (150 mL) at 0 0C was added acetyl chloride (4 mL) dropwise and the reaction mixture was stirred at rt overnight. The reaction mixture was diluted with IN HCl (100 mL) and extracted with CH2Cl2, and the organic layer was dried with Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (n-hexane/ethyl acetate = 5:1) to afford methyl 3-(4- acetylphenyl)cyclobutanecarboxylate (A3) (6.O g, 94% yield).
[0247] Step c. To a solution of methyl 3-(4-acetylphenyl)cyclobutanecarboxylate (A3) (6.56 g, 28.2 mmol) in methylene chloride (250 mL) at O0C was added PTT (10.6 g, 28.2 mmol) and the reaction mixture was stirred at rt overnight. The reaction was quenched with NaHCO3 (100 mL), washed with brine, and dried with Na2SO4. After removal of the solvent, crude product A4 (7.2 g, 82% yield) was directly used for the next step.
[0248] Step d. A solution of crude methyl 3-(4-(2-bromoacetyl)phenyl) cyclobutanecarboxylate (A4) (8.8 g, 28.3 mmol), N-Boc-L-Pro-OH (6.7 g, 31.2 mmol) and triethylamine (4.34 mL) in CH3CN was stirred for 2 h. At the completion of reaction, the volatile components were removed in vacuo, and the residue was partitioned between H2O and CH2Cl2. The organic phase was dried, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography to provide (S)-l-tert-butyl 2-(2-(4-(3- (methoxycarbonyl)cyclobutyl)phenyl)-2-oxoethyl) pyrrolidine- 1 ,2-dicarboxylate (A5) as a colorless oil (10.6 g, 84% yield).
[0249] Step e. A mixture of ketoester (S)-l-tert-butyl 2-(2-(4-(3-(methoxycarbonyl) cyclobutyl) phenyl)-2-oxoethyl) pyrrolidine- 1 ,2-dicarboxylate (A5) (3.7 g, 8.76 mmol) and NH4OAc (6.75 g, 87.6 mmol) in o-xylenes (10 niL) was heated in a sealed tube at 140 0C for 1 h. The volatile component was removed in vacuo, and the residue was partitioned between H2Oand CH2Cl2. Te organic phase was dried, filtered and concentrated in vacuo. The resulting crude material was purified by silica gel column chromatography to provide (S)- tert-butyi 2-(4-(4-(3 -(methoxycarbonyl)cyclobutyl)phenyl)- 1 H-imidazol-2-yl)pyrrolidine- 1 - carboxylate (A6) as a colorless oil (1.76 g, 47.4% yield).
[0250] Step f. To a solution of the compound (S)-tert-bvΛy\ 2-(4-(4-(3- (methoxycarbonyl)cyclobutyl) phenyl)- 1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate (A6) (1.76 g, 41.5 mmol) in THF (10 mL) and MeOH (10 mL), LiOH (IM, 10.0 mL) was added at 0 0C. After 30 min of stirring, the reaction was quenched with saturated solution OfNH4Cl, extracted with EtOAc, dried over Na2SO4, and concentrated to obtain the crude product (S)-3- (4-(2-( 1 -(te/t-butoxycarbonyl)pyrrolidin-2-yl)- 1 H-imidazol-4-yl)phenyl) cyclobutanecarboxylic acid (A7) (1.4 g, 82.4% yield), which was used without further purification.
[0251] Step g. The mixture of (5)-3-(4-(2-(l-(tert-butoxycarbonyl)pyrrolidin-2-yl)-lH- imidazol-4-yl) phenyl)cyclobutanecarboxylic acid (A7) (822 mg, 2 mmol), DPPA (0.53 mL, 2.4 mmol), and triethylamine (0.34 mL) in benzyl alcohol (10 mL) was heated at 95 0C overnight. The volatile component was removed in vacuo, the residue was partitioned between H2O and CH2Cl2. The organic phase was dried, filtered and concentrated in vacuo. The resulting crude material was purified by a flash chromatography on silica gel to provide (S)-tert-butyl 2-(4-(4-(3-(benzyloxycarbonylamino)cyclobutyl)phenyl)-lH-imidazol-2- yl)pyrrolidine-l-carboxylateas (A8) as a yellow solid (449 mg, 44% yield).
[0252] Step h. To a solution of (S)-tert-butyl 2-(4-(4-(3-(benzyloxycarbonylamino) cyclobutyl)phenyl)- lH-imidazol-2-yl)pyrrolidine-l -carboxylate (A8) (449 mg, 0.87 mmol) in methanol (10 mL) was added 10% Pd/C (50 mg) and the mixture was stirred overnight under H2 atmosphere in a balloon. The mixture was filtrated and concentrated to obtain the crude product (S)-tert-bvXyl 2-(4-(4-(3-aminocyclobutyl)phenyl)-lH-imidazol-2- yl)pyrrolidine-l -carboxylate (A9) (330 mg, 99% yiled) without further purification.
[0253] Step i. To a solution of (S)-tert-bvΛyl 2-(4-(4-(3-aminocyclobutyl)phenyl)-7H- imidazol-2-yl)pyrrolidine-l -carboxylate (A9) (330 mg, 0.86mmol) in dichloromethane (60 mL), N-Boc-L-Pro-OΗ (204 mg, 0.95 mmol), and DIC (0.2 mL) were added at rt. After stirring overnight, the reaction mixture was diluted with methylene chloride (50 mL), and washed with saturated aqueous NaHCCh, dried with Na2SO4. After removal of the solvent, the crude product was purified by silica gel column chromatography (n-hexane/ethyl acetate = 2:1) to afford the product (S)-tert-bvΛy\ 2-(3-(4-(2-((5)-l-(tert-butoxycarbonyl)pyrrolidin-2- yl)-7H-imidazol-4-yl)phenyl)cyclobutylcarbamoyl)pyrrolidine-l-carboxylate (AlO) (294 mg, 59% yield).
[0254] Step j. To a solution of (S)-tert-butyl 2-(3-(4-(2-((S)-l-(tert- butoxycarbonyl)pyrrolidin- 2-yl)-7H-imidazol-4-yl)phenyl)cyclobutylcarbamoyl)pyrrolidine- 1-carboxylate (AlO) (100 mg, 0.173 mmol) in TΗF (8 mL), 4N HCl in dioxane (2 mL) was added slowly at rt. After stirring for 1.5 h, the solvent was removed to give (5)-N-(3-(4-(2- ((iS)-pyrrolidin-2-yl)- 1 Η-imidazol-4-yl) phenyl)cyclobutyl)pyrrolidine-2-carboxamide (Al 1) as an HCl salt. The white solid was used for the next step without further purification.
[0255] Step k. To a solution of (5)-N-(3-(4-(2-((5)-pyrrolidin-2-yl)-lH-imidazol-4- yl)phenyl) cyclobutyl)pyrrolidine-2-carboxamide (All) (100 mg, 0.98 mmol) in dichloromethane (20 mL), N-Boc-D-Phg-OH (87mg, 0.35 mmol), DIPEA (144 μL, 0.34 mmol) and HATU (134 mg, 0.35 mmol) were added at rt. After stirring overnight, the reaction mixture was washed with brine and H2O, dried with Na2SO4. After removal of the solvent, the crude product was purified by silica gel column chromatography (DCM /MeOH = 10/1 (v/v)) to afford tert-butyl (R)-2-((S)-2-(3-(4-(2-((S)-l-((R)-2-( tert- butoxycarbonylamino)-2-phenylacetyl) pyrrolidin-2-yl)- 1 H-imidazol-4-yl)phenyl) cyclobutylcarbamoyl)pyrrolidin-l-yl)-2-oxo-l-phenylethylcarbamate (A12) (50 mg, 34% yield). LC-MS (ESI): m/z 846 (M+H)+.
Figure imgf000104_0001
Scheme 3-2
[0256] Additional examples of formula IX bearing varying capping groups were prepared following procedures described below, such as in the synthesis of compound A14, shown in Scheme 3-2.
[0257] Step a. A sample of the product from Scheme 3-1, tert-butyl (R)-2-((S)-2-(3-(4- (2-((S)- 1 -((R)-2-( te/t-butoxycarbonyl amino)-2-phenylacetyl)pyrrolidin-2-yl)- 1 H-imidazol- 4-yl)phenyl)cyclobutylcarbamoyl)pyrrolidin- 1 -yl)-2-oxo- 1 -phenylethylcarbamate (A13) (222 mg, 0.262 mmol) in THF (10 niL) was treated with 4N HCl in dioxane (5 rnL) at rt for 8 h. At the completion of the reaction, solvent was removed and the resulting white solid, (5)-l-((i?)- 2-amino-2-phenylacetyl)-N-(3-(4-(2-((5)-l-((i?)-2-amino-2-phenylacetyl)pyrrolidin-2-yl)-lH- imidazol-4-yl)phenyl)cyclobutyl)pyrrolidine-2-carboxamide (300 mg) was used for the next step without further purification.
[0258] Step b. To a solution of (5)-l-((i?)-2-amino-2-phenylacetyl)-N-(3-(4-(2-((5)-l- ((i?)-2-amino -2-phenylacetyl)pyrrolidin-2-yl)- 1 H-imidazol-4-yl)phenyl)cyclobutyl) pyrrolidine-2-carboxamide (80 mg, 0.124 mmol) in dichloromethane (20 mL), cyclopropyl carboxylic acid (22 mg, 0.26 mmol), DIPEA (0.5 mL) and HATU (94 mg, 0.26 mmol) were added at rt. After stirring overnight, the reaction was washed with brine and H2O, dried with Na2SO4. After removal of the solvent, the crude product was purified by silica gel column chromatography (DCM /MeOH = 10 /1 (v/v)) to afford (S)-l-((R)-2- (cyclopropanecarboxamido)-2-phenylacetyl)-N-(3-(4-(2-((5)-l-((i?)-2- (cyclopropanecarboxamido)-2-phenylacetyl)pyrrolidin-2-yl)-lH-imidazol-4- yl)phenyl)cyclobutyl)pyrrolidine-2-carboxamide (A14) (25 mg).
EXAMPLE 4 - Synthesis of compounds of Formula V
O / — v 9 O LDA, BrCH2CH2CI, O J, / v U o X1 KOH/MeOH HgO/Br2
MeO OMe LDA MeO ^ — ' OMe MeO n N N —— ' ' n OH CH2Br2
A1 A2 A3
Figure imgf000106_0001
A4 A5 A6
Figure imgf000106_0002
NH4OAc, Hunig's base 2) MeOCO-N-Phg-OH, DMTMM, DMF xylene, 14O 0 C
Figure imgf000106_0003
Figure imgf000106_0004
Scheme 4-1
[0259] Step a. Referring to Scheme 4-1, the starting building blocks, Al, Al, A3, and A4 can be prepared following published conditions in the literature. References: 1). Chang, H.; Fiesman, W. F. and Petter, R. C. Syn. Comm. 2007, 37, 1267. 2). Champans, N. B.; Sotheeswar, S. and Tonyne, K. J. J. Org. Chem. 1970, 35, 917. 3). Delia, E. W. and Tsanaktisidis, J. Aust. J. Chem. 1985, 38, 1705. [0260] Step b. To a solution of freshly prepared LDA (132 mL of n-butyl lithium, 2.5 M in hexane, 51 mL of diisopropylamine) in THF (anhydrous, 420 mL), DMPU (200 mL) at -78 0C was added a solution of Al (60 g, 300 mmol) in THF (60 mL) at -78 0C. After stirring for 40 min, l-bromo-2-chloroethane (24.9 mL, 300 mmol) was added. After stirring for another 20 min at -78 0C, the dry ice-acetone bath was removed and the reaction was slowly warmed up to rt. After stirring for an additional hour, the reaction mixture was cooled back to -78 0C and a solution of DMPU (200 mL) in THF (420 mL) was added. Another portion of freshly prepared LDA (120 mL of n-butyl lithium, 2.5 M in hexane, 47 mL of di-isopropylamine in THF (anhydrous, 420 ml)) was added into the reaction mixture by cannula at -78 0C. After stirring for 1.5 h at -78 0C, the dry ice-acetone bath was removed and the reaction was slowly warmed up to rt. After 5-6 h, the reaction was quenched with saturated aqueous ammonium chloride (300 mL) and concentrated. The residue was diluted with H2O (480 mL) and extracted with ethyl acetate/hexane (1 :5 (v/v), 3 x 360 mL). The combined organic layers were washed with brine (500 mL) and then dried, filtered, and concentrated. The resulting crude product was purified by silica gel flash column chromatography (Hexanes / EtOAc = 10 / 1 (v/v)) to provide A2 (35 g).
[0261] Step c. To a solution of A2 (24.7 g) in MeOH (310 mL) was added potassium hydroxide (6.12 g) in H2O (62 mL) at rt. The reaction was warmed up to 95 0C and stirred overnight. The reaction was cooled to rt and concentrated. The residue was diluted with H2O (1000 mL) and extracted with ethyl acetate/hexane (1 : 10, 3 x 400 mL), which provided recycled A2 (4.8 g) after concentration. The remaining aqueous layer was acidified to pH = 3 by concentrated HCl and then was extracted with ethyl acetate/methanol (10:1 (v/v), 3 x 500 mL). The combined organic layers were dried with sodium sulfate, filtered and concentrated to provide A3 (17.8 g).
[0262] Step d. To a solution of A3 (17.8 g) in dibromomethane (1200 mL) was added mercury(II) oxide at rt. The reaction was warmed up to 80 0C and bromine (6.0 mL) was added dropwise during 25 min. After additional 3 h stirring, the reaction was cooled down to rt and filtered through a pad of CELITE™, washed with dichloromethane, concentrated to afford A4 (19.8 g). The crude product A4 was used without further purification.
[0263] Step e. To a solution of A4 (19.8 g) in dichloromethane (500 mL) at -20 0C was added aluminum chloride (43 g) in several portions. The reaction was then warmed up to O0C. After overnight stirring, the reaction was poured into a mixture of ethyl acetate (800 mL), IM HCl (800 mL) along with some ice. After separating the ethyl acetate layer, the aqueous layer was extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with brine, H2O, dried over Na2SO4, filtered, and concentrated to afford A5 (19.2 g), which was used without further purification.
[0264] Step f. To a solution of A5 (19.2 g) in dichloromethane (500 mL) at -20 0C was added acetyl chloride (16.8 mL), followed by aluminum chloride (43 g). The reaction was allowed to warm up to rt. After overnight stirring, the reaction was poured into a mixture of ethyl acetate (800 mL), IM HCl (800 mL) along with some ice. After separating the organic layer, the aqueous layer was extracted with ethyl acetate (3x300 mL). The combined organic layers were washed with brine, H2O, dried over Na2SO4, filtered, and concentrated to afford A6 (24 g), which was used for next reaction without further purification.
[0265] Step g. To a solution of A6 (21 g) in MeOH (500 mL) and THF (500 mL) was added aqueous lithium hydroxide (IM, 365 mL) at rt. After overnight stirring, the reaction was concentrated. The residue was diluted with water (1400 mL) and extracted with diethyl ether (3 x 500 mL), ethyl acetate (2 x 400 mL). The combined organic layers were extracted with lithium hydroxide (IM, 500 mL). All aqueous basic layers were combined and acidified to pH 2 by concentrated HCl, extracted with ethyl acetate (3 x 800 mL). The combined organic layers were dried over Na2SO4 , filtered and concentrated to provide A7 (14.8 g).
[0266] Step h. To a solution of A7 (14.8 g) in dichloromethane (800 mL) was added oxalyl chloride (5.1 mL) at rt. DMF (209 μL) was added in three portions over 4 h. The reaction was concentrated and re-dissolved in dichloromethane (500 mL). The fresh made diazomethane (0.3M, 500 mL) was added at O0C. The reaction was slowly warmed up to rt. After overnight stirring, the reaction was concentrated to obtain the crude A8 (17.8 g).
[0267] Step i. To a suspension of A8 (17.8 g) in acetic acid (250 mL), hydrogen bromide (33% in acetic acid, 25 mL) was added dropwise at rt. After stirring for an additional hour, the reaction was filtered though a pad of CELITE™454, washed with ethyl acetate, concentrated to afford the crude product, which was purified by silica gel flash column chromatography (Hexanes /EtOAc = 3 / 1 (v/v)) to provide A9 (18.5 g).
[0268] Step j. To a stirred solution of A9 (18.5 g) and Cbz-Pro-OH (14.5 g) in MeCN was added Et3N (8.1 mL). The reaction was stirred at rt overnight and concentrated. The resulting crude product was diluted by ethyl acetate (1000 mL) and washed with saturated sodium carbonate, brine, H2O, dried over sodium sulfate and concentrated to provide AlO (27 g)- [0269] Step k. To a stirred solution of AlO (10 g) in CH2Cl2 (400 mL) was added DIPEA (3.4 mL). The reaction flask was cooled down to -20 0C and TMSOTf (3.5 mL) was slowly added. The reaction was warmed up to rt and stirred for 2 h, then cooled back to -20 0C. PTT (8.0 g) in THF (30 mL) was added over 10 min. The reaction was slowly warmed up to rt and stirred overnight. The reaction was poured into a mixture of dichloromethane (500 mL) and sodium disulfϊte (10% in H2O, 500 mL). The organic layer was separated and washed with brine, H2O, dried over sodium sulfate and concentrated to provide the crude product, which was purified by silica gel flash column chromatography (hexanes /EtOAc = 4/1 (v/v)) to provide All (8.7 g).
[0270] Step 1. To a stirred solution of All (8.7 g) and N-Cbz-L-Pro-OH (3.45g) in MeCN was added Et3N (2.24 mL). The reaction was stirred at rt overnight and concentrated. The resulting crude product was diluted by ethyl acetate (500 mL) and washed with saturated sodium carbonate, brine, water, dried over sodium sulfate and concentrated to provide A12 (10.2 g).
[0271] Step m. A12 (6.5 g) was dissolved in xylene (100 mL) in a sealed bottle. NH4OAc (14.5 g) and N,N-diisopropylethylamine (33 mL) were added to the solution. The reaction tube was sealed and placed in an 14O0C oil bath. The reaction was stirred at this temperature for 1.5 h, then cooled to rt. The reaction tube was carefully opened, and reaction mixture was diluted with dichloromethane. The combine organic solution was washed with brine and H2O, dried over Na2SO4, filtered, and concentrated. The resulting crude product was purified by silica gel flash column chromatography (EtO Ac/Acetone/ 28% NH4OH = 100/1/1 (v/v/v)) to provide A13 (3.0 g).
[0272] Step n. To a stirred solution of A13 (500 mg) in dichloromethane (50 mL) was added trifluoroacetic acid (5 mL). After 3 h, the reaction was concentrated to dryness to give a TFA salt, which was dissolved in DMF (20 mL). To the solution were added DIEA (490 μL), N-Moc-D-Phg-OH (98 mg) and 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4- methylmorpholinium chloride (DMTMM, 156 mg) subsequently. After one h stirring, the reaction was diluted with H2O. The suspension was filtered through a pad of CELITE™545 and washed with H2O. The filtrate cake was rinsed with dichloromethane and concentrated to provide A14 (380 mg) without further purification.
Step 13. Step o. To a stirred solution of A14 (8 mg) in methanol (3 mL) was added 10% Pd/C (4 mg) and one drop of concentrated HCl. The reaction was in a Parr shaker at rt and under 60 psi of hydrogen for 12 hours. The reaction was filtered through a pad of CELITE™545 and washed with methanol. The filtrate was concentrated to dryness to provide a free amine, which was dissolved in DMF (1 mL). Subsequently, the mixture was added DIEA (6 μL), N-Moc- VaI-OH (1.8 mg) and DMTMM (2.8 mg). After stirring for one h, the reaction was quenched by adding water. The suspension was filtered through CELITE™545 and washed with water. The filtrate cake was rinsed by dichloromethane and concentrated. The residue was purified by prep-HPLC (Phenomenex, C18-Luna column, H2O-MeCN, 0.1% HCO2H) to provide A15 (3.0 mg, 98% purity). 1H NMR (CDCl3, 300 MHz), δ 8.01 (br s, IH), 7.57 (d, J= 8.0 Hz, 2H), 7.44-7.39 (m, 5H), 7.31 (d, J= 8.0 Hz, 2H), 7.24 (s, IH), 6.75 (s, IH), 6.02 (br d, J= 7.1 Hz, IH), 5.48 (br d, J= 5.8 Hz, IH), 5.43-5.40 (m, 2H), 5.34 (br d, J= 5.5 Hz, IH), 4.15-4.10 (m, IH), 3.97-3.95 (m, IH), 3.83-3.80 (m, IH), 3.71 (s, 3H), 3.65(s, 3H), 3.25-3.22 (m, IH), 2.77-2.62 (m, 2H), 2.35-2.20 (m, IH), 2.20-2.00 (m, 4H), 2.05-1.85(br m, 16H), 1.03 (d, J= 4.4 Hz, 6H).
LLC-MS (ESI) m/z: 805.3 (M+H)+, 803.3 (M-H)". HPLC: Agilent Eclipse XDB-C18 4.6x150 mm, 5μm; 5%-100% B over 15 min; A=H2O+TFA (0.1%), B=MeCN+TFA (0.1%); 254 nm; 20 μL injection volume. RT=8.86 min; 98%. EXAMPLE 5 - Synthesis of additional compounds of Formula I
Figure imgf000110_0001
Scheme 5-1
Figure imgf000111_0001
JOC 2005, 70, 164
Figure imgf000111_0002
Scheme 5-2 Na2CO3,
Figure imgf000111_0003
Scheme 5-3 no
Figure imgf000112_0001
4 M HCI/Dioxane
Figure imgf000112_0003
Figure imgf000112_0002
Scheme 5-4
[0273] Step a. Referring to Scheme 5-4, a mixture of Inflate 2 (0.43 g, 2.34 mmol), borate 3 from above (1.01 g, 2.3 mmol) and Pd(PPh3)2Cl2 (160 mg, 0.23 mmol) in THF (12 mL) and aqueous Na2CO3 (2 M, 2.4 mL) was degassed and filled with nitrogen. The mixture heated at 8O0C overnight. The reaction mixture was purified by column chromatography eluting with 1% methanol in ethyl acetate to give compound 4 (0.95 g, 70% yield).
[0274] Step b. To a solution of 4 (0.95 g, 1.6 mmol) in DCM (32 mL) at O0C was add 4M HCl in dioxane. The mixture was stirred at O0C for 3 h and warmed to rt for 1 h. Solvent was removed to give a white solid 5.
[0275] Step c. A mixture of 5 obtained above, DMTMM (0.89g, 3.2 mmol), triethylamine (1.12 mL, 8.0 mmol) and N-Boc-D-Phg-OH (0.8 g, 3.2 mmol) in THF (16 mL) was stirred at rt for 14 h. The reaction was diluted with H2O (50 mL), extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, and then concentrated to give a residue. The residue was purified with silica gel chromatography eluting with hexane/ethyl acetate (1/1 to 1/2 (v/v)) to afford 6 (32 mg, 14% yield). LCMS (ESI): m/z 858 (M+H)+.
[0276] Step d. A mixture of 5 (400 mg, 1.0 mmol) and Pd/C ( 100 mg) in methanol ( 12 mL) was degassed, and filled with hydrogen (60 psi). The mixture was shaken for 16 h. The solution was filtered through a pad of CELITE™545. The filtrate was concentrated to give a pale yellow solid 7.
[0277] Step e. A mixture of 7 (384 mg, 0.98 mmol), DMTMM (0.51g, 1.86 mmol), triethylamine (0.54 mL, 3.9 mmol) and Boc-D-Phg-OH (466 mg, 1.86 mmol) in THF (10 mL) was stirred at rt for 14 h. The reaction was diluted with H2O and extracted with ethyl acetate. The combined organic layers were washed with brine and dried over Na2SO4, concentrated to give a residue. The residue was purified by silica gel column chromatography eluting with hexane/ethyl acetate (1/1 to 1/2 (v/v)) to afford 8 (0.24 g, 29% yield). LC-MS (ESI): m/z 860 (M+H)+.
4 M HCI/Dioxane
Figure imgf000113_0001
Figure imgf000113_0002
Figure imgf000113_0003
Scheme 5-5
[0278] Step a. Referring to Scheme 5-5, to a solution of 8 (0.86 g, 1.0 mmol) in DCM (10 mL) at O0C was add TFA (2 mL). The mixture was stirred at rt for 3 h. Solvent was removed to give a white solid 9.
[0279] Step b. To a solution of 9 (90 mg, 0.14 mmol) and triethylamine (95 μL, 0.68 mmol) in THF/DMF (2 mL, 1/1 (v/v)) at -78 0C was added morpholinyl chloroformate (30 μL, 0.26 mmol). The solution was stirred at rt overnight, diluted with H2Oand ethyl acetate. The organic layer was washed with H2O and brine, dried over sodium sulfate, and then concentrated to give a residue. The residue was purified with silica gel chromatography eluting with 5% methanol in DCM to afford 10 (40 mg). LC-MS (ESI): m/z 884 (M-H)".
Figure imgf000114_0001
[0280] Step a. Referring to Scheme 5-6, to prepare compound 1, to a solution of quinoline-6-carboxylic acid methyl ester (5.61 g, 30 mmol) in 100 mL of dichloromethane was added mCPBA (8.1 g, 36 mmol, 77% maximum purity) in four portions in 5 min at 0 0C. The resulting mixture was warmed to rt and stirred for 2 h. The reaction mixture was diluted with 300 mL of dichloromethane and washed with aqueous Na2S2O3 solution, saturated NaHCO3 solution, H2Oand brine. After the organic layer was dried and concentrated, an intermediate was obtained as yellow solid (6.2 g, 100% yield), which was used for next step without further purification. 1U NMR (300 MHz, CDCl3) δ 8.81 (d, IH), 8.59 - 8.65 (m, 2H), 8.36 (d, IH), 7.86 (d, IH), 7.40 (d, IH), 3.98 (s, 3H) ppm.
[0281] Step b. To the solution of quinoline iV-oxide (6.7 g, 33 mmol) in dichloromethane (60 mL) was added POCl3 (30 mL) dropwise at rt. The reaction mixture was stirred for 16 h at 50 0C in sealed vessel before it was concentrated to dryness. The residue was dissolved in dichloromethane and washed with saturated NaHCO3, H2Oand brine. The organic layer was dried over Na2SO4. After concentration, the residue was purified by the flash column chromatography (silica, hexanes/ethyl acetate, v/v, 3/1 to 1/1) to afford the title compound (1.75 g, 24% yield) as white solid which contained some unknown impurity. Pure product was obtained by recrystallization from EtOAc and hexanes for analytical purpose. 1H NMR (300 MHz, CDCl3) δ 8.58 (d, IH), 8.31 (d, IH), 8.20 (d, IH), 8.06 (d, IH), 7.46 (d, IH), 4.00 (s, 3H) ppm.
[0282] Step c. The mixture of 1 (1.8 g, 8.1 mmol), methyl isonipecotate 2 (1.75 g, 12.2 mmol) and K2HPO4 (5.64 g, 32.4 mmol) in 15 mL of DMSO was stirred at 80 0C for 20 hours. After cooling down, the resulting mixture was partitioned between 500 mL of EtOAc and 500 mL of H2O. The organic layer was washed with H2O and brine, and dried (Na2SO4). After concentration, the residue was purified by the flash column chromatography (silica, hexanes/ethyl acetate, v/v, 3/1 to 1/1) to afford compound 3 (1.95 g, 70 % yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.32 (d, IH), 8.11 (dd, IH), 7.92 (d, IH), 7.65 (d, IH), 7.01 (d, IH), 4.45 - 4.55 (m, 2H), 3.93 (s, 3H), 3.70 (s, 3H), 3.10- 3.24 (td, 2H), 2.58 - 2.68 (m, IH), 2.00 - 2.10 (m, 2H), 1.75 - 1.87 (m, 2H) ppm.
[0283] Step d. To the solution of 3 (1.81 g, 5.5 mmol) and chloroiodomethane (2.81 mL, 38.5 mmol) in THF (40 mL) was added LDA (pre-cooled to -78 0C, freshly made from 10.9 mL of diisoproylamine and 28.6 mL of 2.5 M n-BuLi in hexanes in 40 mL of THF) at -78 0C via cannula over 20 minutes. The reaction mixture was stirred for two hours at -78 0C before it was quenched by dropwise addition of 60 niL AcOH/THF (v/v, 1/1). The resulting mixture was warmed up and partitioned in EtOAc and saturated NaHCO3. The organic layer was washed with H2O and dried over Na2SO4. After concentration, the residue was purified by the flash column chromatography (silica, hexanes/ethyl acetate, v/v, 2/1 to 1/1) to afford the title compound 4 (1.48 g, 74% yield) as a yellow solid. 1U NMR (300 MHz, CDCl3) δ 8.22 (d, IH), 8.15 (dd, IH), 7.94 (d, IH), 7.68 (d, IH), 7.01 (d, IH), 4.78 (s, 2H), 4.61 - 4.72 (m, 2H), 4.20 (s, 2H), 3.10 - 3.22 (td, 2H), 2.98 - 3.12 (m, IH), 1.96 - 2.08 (m, 2H), 1.67 - 1.85 (m, 2H) ppm.
[0284] Step e. A solution of 4 (1.2 g, 3.3 mmol), N-Boc-L-Pro-OH (2.1 g, 9.9 mmol), DIPEA (2.96 mL, 19.8 mmol) and potassium iodide (1.66 g, 9.9 mmol) in MeCN (50 mL) was stirred at 40 0C for 14 h. After removing all solvent in vacuo, the residue was partitioned in EtOAc and saturated NaHCO3. The organic layer was washed with H2O and brine and dried over Na2SO4. After concentration, the residue was purified by silica gel column chromatography (hexanes/ethyl acetate, v/v, 1/1 to 1/2) to afford compound 5 (2.21 g, 93% yield) as a yellow solid. LC-MS (ESI): m/z (M+H)+ 723.75; (M-H)" 721.85.
[0285] Step f. A mixture of 5 (723 mg, 1.0 mmol), ammonium acetate (2.31 g, 30 mmol) and Et3N (4.18 mL, 30 mmol) in xylene (30 mL) was stirred in sealed vessel at 140 0C for 1.5 h. After removing all solvent in vacuo, the residue was partitioned in 5% MeOH in dichloromethane and water. The organic layer was washed with H2Oand brine. The aqueous layers were extracted with 5% MeOH in dichloromethane twice. The combined organic layers were dried over Na2SO4. After concentration, the residue was purified by the flash column chromatography (silica, NH4OH/acetone/ethyl acetate, v/v, 1/3/100) to afford compound 6 (320 mg). LC-MS (ESI): m/z (M+H)+ 683.7; (M-H)" 681.8.
[0286] Step g. The solution of 6 (320 mg) in 6 mL of dichloromethane and TFA (5 mL) was stirred at rt for 2 h. After removing solvent in vacuo, the residue was purified by reverse- phase preparative HPLC to afford compound 7 (120 mg) as a yellow solid. LC-MS (ESI): m/z (M+H)+ 483.5; (M-H)" 481.6.
[0287] Step h. To a solution of N-Moc-L- VaI-OH (8) (77 mg, 0.44 mmol) and HATU (167 mg, 0.44 mmol) in 2 mL of DMF was added DIPEA (0.15 mL, 1.0 mmol). The resulting solution was stirred at rt for 20 min before 7 (97 mg, ca. 0.2 mmol) and DIPEA (0.15 mL, 1.0 mmol) in 3 mL of DMF was added. The reaction mixture was stirred at rt for another 2 h with determination of the completion of the reaction by LC-MS. The solution was partitioned between EtOAc and water and the organic layer was washed with H2Oand brine. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4 before it was concentrated in vacuo. The residue was purified by reverse phase prep- HPLC to afford the title compound 9 (70 mg) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.22 (d, IH), 8.18 (d, IH), 7.96 (d, IH), 7.86 (dd, IH), 7.55 (s, IH), 7.24 (d, IH), 6.96 (s, IH), 5.10 (t, IH), 5.01 (t, IH), 4.38 - 4.52 (m, 2H), 4.19 (dd, 2H), 3.60 - 4.00 (m, 6H), 3.57 (s, 3H), 3.56 (s, 3H), 3.32 - 3.48 (m, 3H), 3.08 - 3.24 (m, IH), 1.90 - 2.44 (m, 12H), 1.65 - 1.90 (m, 3H), 0.81 (t, 6H), 0.69 (t, 6H) ppm. LC-MS (ESI): m/z 399.7 (M+2H)++; 795.9 (M- H)-.
Figure imgf000117_0001
SOCI2, MeOH 48% HBr
HO COOH Br COOH reflux 1000C
Figure imgf000117_0002
Scheme 5-7
[0288] Step a. Referring to Scheme 5-7, to a suspension of quinoline-6-carboxylic acid (13.2 g, 76.2 mmol) in MeOH (120 mL) was added thionyl chloride (16.6 mL, 229 mmol) dropwise at 00C over 10 minutes. The resulting mixture was refluxed for 3 h, then concentrated to remove all solvents in vacuo. The residue was partitioned between 300 mL of EtOAc and 500 mL of saturated NaHCCh. The organic layer was washed with H2O followed by brine and dried with Na2SO4. After concentration, the residue was purified by silica gel column chromatography (hexanes/ethyl acetate, v/v, 1/1 to 1/2) to afford the compound 1 (11.2 g, 79 % yield) as a yellow solid. 1H NMR (300 MHz, CDCl3) 9.01 (dd, IH), 8.60 (d, IH), 8.24 - 8.34 (m, 2H), 8.15 (d, IH), 7.48 (dd, IH), 4.00 (s, 3H) ppm.
[0289] Step b. To a solution of 4-hydroxy-cyclohexanecarboxylic acid (11.5 g, 80 mmol) in methanol (120 mL) was added thionyl chloride (16.5 mL, 224 mmol) dropwise at 00C. The resulting mixture was then warmed to refluxing for 3 hours. All solvent was removed in vacuo and the residue was dissolved in EtOAc. The solution was washed with saturated aqueous NaHCO3 solution, H2O and brine. Column chromatography (EtOAc/Hexanes, v/v, 1/1 to 2/1) gave 8.5 g methyl ester as colorless oil. The methyl ester (6.2 g) was mixed with 60 mL of 48% HBr in sealed flask and heated up to 100 0C. After 30 minutes, the clear solution was cooled down and partitioned between EtOAc and H2O. The organic layer was washed with H2Oand dried over Na2SO4. After removing all solvent and cooling down, some crystal formed. Compound 2 (2.4 g) was obtained after filtration. 1H NMR (300 MHz, CDCl3) 3.98 - 4.08 (m, IH), 2.25 - 2.45 (m, 3H), 1.99 - 2.16 (m, 2H), 1.72 - 1.94 (m, 2H), 1.50 - 1.65 (m, IH) ppm.
[0290] Step c. To a solution of compound 1 (3.45 g, 18.4 mmol) in absolute ethanol (100 mL) was added TFA (1.42 mL, 18.4 mmol) dropwise at rt, followed by compound 2 (3.18 g, 15.3 mmol). The reaction mixture was heated to reflux. (TMS)3SiH (5.7 mL, 18.4 mmol) and AIBN (2.52 g, 15.3 mmol) were added into the mixture in four portions over a period of 6 h. After refluxing for 8 h, the resulting mixture was cooled down and all solvents were removed. The residue was purified by silica gel column chromatography (isopropyl alcohol/dichloromethane, v/v, 1/20 to 1/10) to afford compound 3 (470 mg) as a yellow solid. LC-MS (ESI): m/z 314 (M+ 1)+.
[0291] Step d. To a solution of Intermediate 3 (470 g, 1.5 mmol) in methanol (20 mL) was added thionyl chloride (0.55 mL, 7.5 mmol) dropwise at O0C. The resulting mixture was then heated to refluxing for 3 h. All solvent was removed in vacuo and the residue was dissolved in EtOAc. The solution was washed with saturated aqueous NaHCO3 solution, water and brine, respectively. Column chromatography (EtOAc/Hexanes, v/v, 1/1) gave compound 4 (310 mg). LC-MS (ESI): m/z 328 (M+l)+. [0292] Step e. To a solution of Intermediate 4 (310 mg, 0.95 mmol) and chloroiodomethane (0.42 rnL, 5.7 mmol) in THF (10 mL) was added LDA (precooled to -78 0C, freshly made from 1.75 mL of diisoproylamine and 4.56 mL of 2.5 M n-BuLi in hexanes in 20 mL of THF) at -78 0C via cannula for 20 min. The reaction mixture was stirred for 2 h at -78 0C before it was quenched by dropwise addition of 3 mL of AcOH/THF (v/v, 1/1). The resulting mixture was warmed up and partitioned bewteen EtOAc and saturated NaHCO3. The organic layer was washed with H2O and dried over Na2SO4. After concentration, the residue was purified by silica gel column chromatography (hexanes/ethyl acetate, v/v, 2/1 to 1/1) to afford compound 5 (330 mg) as a yellow solid. LC-MS (ESI): m/z 364 (M+l)+.
[0293] Step f. A solution of Intermediate 5 (330 mg, 0.91 mmol), N-Boc-L-Pro-OH (0.58 g, 2.73 mmol), DIPEA (0.81 mL, 5.46 mmol) and potassium iodide (0.45 g, 2.7 mmol) in MeCN (20 mL) was stirred at 40 0C for 14 h. After removing all solvent in vacuo, the residue was partitioned in EtOAc and saturated NaHCO3. The organic layer was washed with H2O and brine and dried over Na2SO4. After concentration, the residue was purified by silica gel column chromatography (hexanes/ethyl acetate, v/v, 1/1 to 1/2) to afford compound 6 (450 mg) as yellow solid. LC-MS (ESI): m/z 722.75 (M+l)+.
[0294] Step g. A mixture of Intermediate 6 (450 mg, 0.62 mmol), ammonium acetate (1.44 g, 18.7 mmol) and Et3N (2.6 mL, 18.7 mmol) in xylene (20 mL) was stirred in sealed vessel at 140 0C for 1.5 h. After removing all solvent in vacuo, the residue was partitioned between 5% MeOH in dichloromethane and H2O. The organic layer was washed with H2O and brine. The aqueous layers were extracted with 5% MeOH in dichloromethane twice. The combined organic layers were dried over Na2SO4. After concentration, the residue was purified by silica gel column chromatography (isopropyl alcohol/dichloromethane, v/v, 1/10 to 1/7) to afford compound 7 (110 mg) as a yellow solid. LC-MS (ESI): m/z 682.7 (M+l)+.
[0295] Step h. A solution of Intermediate 6 (110 mg) in dichloromethane (3 mL) and TFA (2 mL) was stirred at rt for 2 h. After removing all solvent in vacuo, compound 8 (122 mg) was obtained as a yellow TFA salt. LC-MS (ESI): m/z 482.5 (M+l)+.
[0296] Step i. To a solution of N-Moc-D-Phg-OH (25 mg) and compound 8 (-40 mg) in 0.75 mL of THF and 1.5 mL of DMF was added DIPEA (0.01 mL). The resulting solution was stirred at rt for 20 min before DMTMM (33 mg) was added. The reaction mixture was stirred at rt for another 2 h as LC-MS indicating the completion of reaction. The solution was partitioned in EtOAc and water, the organic layer was washed with water and brine. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4 before it was concentrated in vacuo. The residue was purified by reverse phase prep- HPLC to afford compound 9 (8.8 mg) as yellow solid. 1U NMR (300 MHz, CDCl3) δ 8.00 - 8.30 (m, 4H), 7.93 (br, 2H), 7.16 - 7.42 (m, 13H), 6.84 (s, IH), 6.64 (s, IH), 5.06 - 5.44 (m, 4H), 3.40 - 3.98 (m, 10H), 2.85 - 3.35 (m, 2H), 1.30 - 2.60 (m, 16H) ppm. LC-MS (ESI): m/z 433.15 (M+2)2+, 863.0 (M-I)".
Figure imgf000120_0001
Scheme 5-8
[0297] Step a. Referring to Scheme 5-8, to a suspension of quinoline-6-carboxylic acid (13.2 g, 76.2 mmol) in 120 mL MeOH was added thionyl chloride (16.6 mL, 229 mmol) dropwise at O0C in 10 min. After being heated at reflux for 3 h, the volatile solvents were removed by a rotary evaporator in vacuo. The residue was taken up in 300 mL EtOAc and was washed with 500 mL saturated NaHCO3, H2Oand brine sequentially. The organic layer was dried over anhydrous Na2SO4. After filtration and concentration, the residue was purified by silica gel column chromatography (hexanes/ethyl acetate, v/v, 1/1 to 1/2) to afford compound C2 (11.2 g, 79 % yield) as yellow solid. 1H NMR (300 MHz, CDCl3) δ 9.01 (dd, IH), 8.60 (d, IH), 8.24 - 8.34 (m, 2H), 8.15 (d, IH), 7.48 (dd, IH), 4.00 (s, 3H) ppm. [0298] Step b. 2-(4-Methoxycarbonyl-bicyclo[2.2.2]oct-l-yl)-quinoline-6-carboxylic acid methyl ester. To a solution of quinoline-6-carboxylic acid methyl ester C2 (9.5 g, 50.7 mmol) in 150 mL EtOH was added TFA (3.91 mL, 50.7 mmol) dropwise at 0 0C. To the resulting mixture was added 4-bromo-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (5.02 g, 20.3 mmol, this compound was prepared according to steps and conditions described previously) and tris(trimethylsilyl)silane (13.8 mL, 44.7 mmol) and heated to refluxing. To the refluxing mixture was added AIBN (2.67 g, 24.4 mmol) in four portions over 6 h. After the completion of addition, the reaction mixture was kept at refluxing for another 12 h. After cooling down, the mixture was partitioned between EtOAc and water. The organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration and concentration, the residue was purified by the flash column chromatography (silica, hexanes/ethyl acetate, v/v, 4/1 to 2/1) to afford compound C4 (4.6 g, 64 % yield) as a white solid. The product was further purified by recrystallization from a mixture of EtOAc and hexanes. 1H NMR (300 MHz, CDCl3) δ 8.52 (d, IH), 8.22 (dd, IH), 8.15 (d, IH), 8.04 (d, IH), 7.48 (d, IH), 3.98 (s, 3H), 3.69 (s, 3H), 1.88 - 2.18 (m, 12H) ppm.
[0299] Step c. 2-Chloro-l-{2-[4-(2-chloro-acetyl)-bicyclo[2.2.2]oct-l-yl]-quinolin-6-yl}- ethanone. To a solution of C4 (610 mg, 1.68 mmol) and chloroiodomethane (0.74 mL, 10.1 mmol) in THF (10 mL) was added LDA (pre-cooled to -78 0C, freshly made from 3 mL of diisoproylamine and 8.06 mL of 2.5 M n-BuLi in hexanes in 10 mL of THF) at -78 0C via a cannula over 20 min. The reaction mixture was stirred for two h at -78 0C before it was quenched by dropwise addition of 12 mL of AcOH/THF (v/v, 1/1). The resulting mixture was warmed up and partitioned in EtOAc and saturated NaHCO3. The organic layer was washed with water and dried over Na2SO4. After concentration, the residue was purified by the flash column chromatography (silica, hexanes/ethyl acetate, v/v, 8/1 to 2/1) to afford the compound C5 (445 mg, 68% yield) as a brown solid. 1H NMR (300 MHz, CDCl3) δ 8.42 (d, IH), 8.18 - 8.23 (m, 2H), 8.12 (d, IH), 7.55 (d, IH), 4.82 (s, 2H), 4.39 (s, 2H), 1.90 - 2.22 (m, 12H) ppm.
[0300] Step d. The solution of compound C5 (445 mg, 1.14 mmol), N-Boc-L-Pro-OH
(762 mg, 3.42 mmol), DIPEA (1.01 mL, 6.84 mmol) and potassium iodide (568 mg, 3.42 mmol) in MeCN (20 mL) was stirred at 50 0C for 4 h. After removing all solvent in vacuo, the residue was partitioned between EtOAc and saturated NaHCO3. The organic layer was washed with H2O and brine, and dried over Na2SO4. After concentration, the residue was purified by silica gel column chromatography (hexanes/ethyl acetate, v/v, 1/1 to 1/2) to afford compound C6 (620 mg, 73% yield) as yellow solid. LC-MS (ESI) m/z: IAl (M-H)".
[0301] Step e. The mixture of C6 (700 mg, 0.94 mmol), ammonium acetate (2.16 g, 28 mmol) and Et3N (3.9 mL, 28 mmol) in xylene (30 mL) was stirred in sealed vessel at 140 0C for 1.5 h. After removing all solvent in vacuo, the residue was partitioned in 5% MeOH in dichloromethane and water. The organic layer was washed with H2O and brine. The aqueous layers were extracted with 5% MeOH in dichloromethane twice. The combined organic layers were dried over Na2SO4. After concentration, the residue was purified by the flash column chromatography (silica, NH4θH/acetone/ethyl acetate, v/v, 1/3/100) to afford compound C7-1 (300 mg, 47% yield) as yellow solid. LC-MS (ESI) m/z: 707 (M-H)".
Figure imgf000122_0001
Scheme 5-9 [0302] Step a. Referring to Scheme 5-9, a mixture of acetanilide 1 (3.28g, 24 mmol), 4- bromo-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (2) (5 g, 20 mmol), ZnCl2 (13.1 g, 96 mmol) in 1 ,2-dichloroethane (2 mL) in a sealed Parr bottle was heated at 120 0C for 16 h. The reaction mixture was dissolved in ethyl acetate (100 mL) and washed with H2O (50 mL) and brine (50 mL). The organic phase was dried over Na2SO4 and concentrated under reduced pressure to give a mixture of ester 3 and acid 3'.
[0303] Step b. The resulting mixture of ester 3 and acid 3' was dissolved in methanol (60 mL) and treated with aqueous lithium hydroxide (10 g in 20 mL of water, 240 mmol). The reaction mixture was refluxed for 4 h. Methanol was evaporated under reduced pressure and the resulting aqueous solution was washed with ethyl acetate (20 mL). The aqueous solution was adjusted to pH 2 by the addition of 1 N HCl (aq) and extracted with ethyl acetate (2 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo to give 4 (5.3 g, 92% yield) as a yellow solid.
[0304] Step c. A nitrating mixture [ 1.17 mL, prepared from 67% HNO3 (3.52 mmol) and H2SO4] was added dropwise to a cooled mixture of acid 4 (1.01 g, 3.52 mmol) in glacial acetic acid (8 mL) and acetic anhydride (4 mL). The mixture was stirred at rt for 12 h and poured into iced H2O. The precipitate was filtered off, washed with H2OtO neutral, and dried in vacuo to give 5 (0.72 g, 70% yield) as a yellow solid.
[0305] Step d. A solution of 5 (2.7 g, 9.8 mmol) and 4 N HCl in dioxane (20 mL) in methanol (30 mL) was stirred at rt overnight. The solvent was evaporated, and the resulting residue was dissolved in ethyl acetate (50 mL) and washed with saturated NaHCO3 and brine. The organic phase was concentrated and the resulting crude product was purified by silica gel column chromatography (ethyl acetate/hexane= 15/85 (v/v)) to give 6 (1.64 g, 60% yield) as a yellow solid.
[0306] Step e. A solution of 6 (1.64 g, 5.4 mmol) and Raney nickel (0.63 g, 10.8 mmol) in absolute ethanol (20 mL) was stirred under an atmosphere of hydrogen (15 psi) at rt for 12 h. The mixture was filtered and the filtrate was concentrated followed by purification silica gel column chromatography (ethyl acetate/hexane=75/25 (v/v)) to give compound 7 as an HCl salt (0.8 g, 49% yield).
[0307] Step f. A solution of N-Cbz-L-Pro-OH (2 g, 8 mmol), pentafluorophenol (1.48 g, 8 mmol) and DCC (1.82 g, 8.8 mmol) in ethyl acetate (20 mL) was stirred at rt for 2 h. The reaction solution was filtered and the filtrate was concentrated in vacuo to give compound 8 (3.2 g, 96% yield) as a white solid. The mixture of compound 7 (0.44 g, 1.61 mmol) and activated ester 8 (0.8 g, 1.93 mmol) in 2,2-dimethoxypropane (30 mL) was stirred at rt overnight. The reaction solution was concentrated to give crude compound 9.
[0308] Step g. Compound 9 was dissolved in acetic acid (2 mL) and heated at 60 0C for 5 h. The reaction solution was neutralized by saturated NaHCO3 and extracted with ethyl acetate (2x20 mL). The combined organic phase was concentrated and the resulting crude product was purified by silica gel column chromatography (ethyl acetate/hexane, 65/35, v/v) to give compound 10 (0.4 g, 52% yield) as a yellow oil.
[0309] Step h. To a solution of compound 10 (0.8 g, 1.68 mmol) in methanol (3 mL) was added aqueous lithium hydroxide (0.13 g in 1 mL of water, 3.4 mmol). The reaction mixture was then refluxed for 8 h. Methanol was evaporated and the resulting aqueous solution was washed by ethyl acetate and neutralized by 1 N HCl solution. After extraction with ethyl acetate (2x20 ml), concentration under reduced pressure, the crude product was purified by silica gel column chromatography (ethyl acetate/hexane = 80/20 (v/v)) to give a free acid (0.32 g, 40% yield) as a yellow oil.
[0310] Step i. A solution of acid obtained (0.57 g, 1.2 mmol) and oxalyl chloride (1.05 mL, 12 mmol) in dichloromethane (5 mL) was stirred at rt overnight. After concentrated under reduced pressure, the remaining residue was dissolved in ether (10 mL) followed by addition of diazomethane (20 mL, 0.33 N in ether, 6.8 mmol) at 0 0C. The reaction mixture was stirred at O0C for 30 min. The reaction solution was concentrated and purified by silica gel column chromatography (ethyl acetate/hexane=75/25 (v/v)) to give an isomeric mixture (as a result of methylation on one of the benzimidazole nitrogens) of diazoketones 11 and 11' (0.2 g, 35% yield).
[0311] Step j. Diazoketones 11 and 11' (0.2 g, 0.42 mmol) were dissolved in acetic acid (1 mL) followed by treatment with HBr (48% in water, 168 mg, 1.0 mmol) at 0 0C. The reaction mixture was stirred at rt for 1 h. Saturated NaHCO3 was added slowly into the reaction solution followed by extraction with ethyl acetate (2 x 10 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (ethyl acetate/hexane = 25/75 (v/v)) to give 12 and 12' (0.15 g, 65% yield).
[0312] Step k. A solution of compounds 12 and 12' (0.37 g, 0.68 mmol), N-Boc-L-Pro-
OH (0.29 g, 1.35 mmol) and DIPEA (0.47 mL, 2.7 mmol) in acetonitrile (3 mL) was stirred at rt overnight. Acetonitrile was evaporated and the remaining residue was dissolved in ethyl acetate (20 rnL). The solution was washed with saturated NaHCO3 and brine and then dried over Na2SO4. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography (ethyl acetate/hexane = 75/35 (v/v)) to give compounds 13 and 13' (0.3 g, 65% yield).
[0313] Step 1. A mixture of compounds 13 and 13' (140 mg, 0.2 mmol) and ammonium acetate (0.47 g, 6.14 mmol) in xylene (1.5 mL) in a sealed bottle was stirred at 140 0C for 90 min. After concentration, the reaction mixture was purified by silica gel column chromatography (ethyl acetate 100%, then ethyl acetate/methanol = 90/10 (v/v)) to give compounds 14 and 14' (83.3 mg) as yellow solid in 59% yield.
[0314] Step m. A mixture of compoundsl4 and 14' (83.3 mg, 0.13 mmol), Pd/C (53.4 mg, 5% on carbon, 0.025 mmol) and one drop concentrated HCl in ethanol (3 mL) under an atmosphere of hydrogen (15 psi) was stirred at rt for 6 h. The reaction solution was then concentrated in vacuo to give compounds 15 and 15' (75 mg, 90% yield). To a solution of the amines obtained above (75 mg, 0.14 mmol) in THF (4 mL) was added 4N HCl in dioxane (1 mL) at rt. The reaction mixture was stirred at rt for 2 h. The solvent was evaporated and the residue was dried in vacuo to give compounds 16 and 16' (50 mg, 83% yield) as a yellow solid.
[0315] Step n. To a solution of compounds 16 and 16' (44 mg, 0.1 mmol), N-Moc-L-Val- OH (43 mg, 0.25 mmol) and DMTMM (68 mg, 0.25 mmol) in a solvent mixture of DMF- THF (2 mL, 1 :3) was added DIPEA (0.17 mL, 1.0 mmol) at rt. The reaction mixture was stirred at rt for 2 h. THF was evaporated and the remaining residue was purified by prep- HPLC to provide compounds 17 and 17' (4.6 mg, 5% yield). 1H NMR (300 MHz, CD3OD) δ 7.33 (m, 4H), 6.92 (s, IH), 5.30 (t, J = 6.9 Hz, IH), 5.12 (t, J=6.9 Hz, IH), 4.22 (m, 2H), 3.99 (m, 4H), 3.94 (s, 3 H), 3.64 (s, 3H), 3.59 (s, 3H), 2.36 (m, 4H), 2.03 (m, 4 H), 1.93 (m, 12H), 0.92 (m, 12H) ppm.LC-MS (ESI): m/z 757 (M-H)".
Figure imgf000126_0001
EXAMPLE 6 - Synthesis of compounds of Formula IHb
[0316] Step a. Referring to Scheme 6-1, to a solution of N-Cbz-L-Pro-OH (7.52 g, 30.0 mmol) and DIPEA (5.50 g, 54.0 mmol) in THF (200 niL) was added HATU (11.5 g, 30.0 mmol) at rt. After stirring for 10 min, 4-bromobenzene-l,2-diamine (1) (5.1O g, 27.0 mmol) was added and the reaction mixture was stirred at rt for 2 h. The mixture was concentrated and the residue was diluted with EtOAc (250 mL) and water (50 mL). The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was dried in vacuo to give crude compounds 2 and 2 ' (10.0 g), which were used for the next step without further purification. LC-MS (ESI) m/z 418.1 (M + H)+.
[0317] Step b. A mixture of compounds 2 and V (10.0 g) in AcOH (100 mL) was stirred at 40 0C for 12 h. The reaction mixture was then neutralized by carefully adding saturated aqueous Na2CO3 to adjust the pH value to 8. Subsequently, the reaction mixture was extracted with EtOAc (150 mL x 3). The extracts were combined, washed with brine, and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 4/1 (v/v)) to give compound 3 (5.6 g, 70%) as a yellow solid. LC-MS (ESI) m/z 400.1 (M + H)+.
[0318] Step c. To a mixture of compound 3 (5.05 g, 12.5 mmol), bis(pinacolato)diboron (7.10 g, 26.3 mmol), and KOAc (3.20 g, 32.5 mmol) in 1,4-dioxane (100 mL) was added Pd(dppf)Cl2 (400 mg, 0.5 mmol) at rt under an atmosphere of N2. After stirring at 80 0C for 3h under an atmosphere of N2, the reaction mixture was filtered through CELITE™545 and the filtered cake was washed with EtOAc (100 mL x 3). The filtrate was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 2/1 (v/v)) to give compound 4 (3.0 g, 53%) as a gray solid: LC-MS (ESI) m/z 448.2 (M + H)+.
[0319] Step d. To a mixture of compound 4 (1.04 g, 2.20 mmol), 1 ,4-diiodobenzene (360 mg, 1.1 mmol), and NaHCO3 (650 mg, 7.7 mmol) in 1 ,2-dimethoxyethane (36 mL) and water (12 mL) was added Pd(dppf)Cl2 (80.0 mg, 0.10 mmol) at rt under an atmosphere of N2. After stirring at 800C overnight under an atmosphere of N2, the reaction mixture was concentrated and the residue was diluted with EtOAc (100 mL) and water (25 mL). The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (DCM/MeOH = 50/1 (v/v)) to give compound 5 (350 mg, 44%) as a yellow solid. LC-MS (ESI) m/z 111.3 (M + H)+.
[0320] Step e. To a solution of compound 5 (200 mg, 0.28 mmol) in CHCl3 (5 mL) was added TMSI (168 mg, 0.84 mmol) at rt. After stirring at rt overnight, the reaction was quenched by adding MeOH (3.0 mL), followed by 4N HCl in dioxane (2.0 mL). The resulting mixture was stirred at rt for 30 min and concentrated. The residue was washed with DCM (10 mL) and dried in vacuo to give crude compound 6 (220 mg), which was used for the next step without further purification. LC-MS (ESI) m/z 449.2 (M + H)+.
[0321] Step f. To a solution of crude compound 6 (150 mg, 0.20 mmol) in DMF (2 mL) was added Et3N (0.22 mL, 2.10 mmol), followed by N-Moc-L-Val-OH (87.0 mg, 0.50 mmol) and HATU (190 mg, 0.50 mmol). After stirring at rt for 1 h, the reaction mixture was concentrated and the residue was diluted with DCM (50 mL) and water (10 mL). The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (DCM/MeOH = 50/1 (v/v)) to give compound 7 (40 mg, 26%) as a white powder. 1H NMR (500 MHz, CDCl3) δ 7.68- 7.26 (m, 10H), 5.55-5.45 (m, 4H), 4.41-4.38 (m, 2H), 3.93-3.90 (m, 2H), 3.85-3.77 (m, 2H), 3.72 (s, 6H), 2.97-2.95 (m, 2H), 2.43-2.41 (m, 2H), 2.28-2.00 (m, 2H), 2.18-2.14 (m, 2H), 2.08-2.06 (m, 2H), 0.93-0.89 (m, 12H) ppm; LC-MS (ESI) m/z 763.4 (M + H)+
Figure imgf000129_0001
[0322] Step a. Referring to Scheme 6-2, to a solution of veratrol (8) (40.Og, 0.29 mol) in anhydrous THF (100 mL) and TMEDA (40 mL) was added /?-BuLi (2.5 M in hexanes, 128 rnL, 0.32 mol) dropwise at rt under an atmosphere of N2. After stirring at rt for 28 h under an atmosphere of N2, the reaction mixture was cooled to -78 0C, followed by adding TMSCl (45 mL). The reaction mixture was stirred at rt for 5 h and then added water (20 mL). The reaction mixture was concentrated and the residue was extracted with hexane (100 mL x 3). The extracts were combined, washed with brine, and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 9 (42g, 69%) as a colorless oil. LC-MS: (ESI) m/z 211.1 (M+H)+.
[0323] Step b. To a solution of compound 9 (40 g, 0.20 mol) in anhydrous TMEDA (40 mL) was added n-BuLi in hexanes (2.5 M, 120 mL, 0.24 mol) dropwise at 0 0C under an atmosphere of N2. After stirring at rt for 25 h, the reaction mixture was cooled to -78 0C, followed by adding TMSCl (40 mL). The reaction mixture was stirred at rt for 5h and then added water (50 mL). The mixture was concentrated and the residue was extracted with hexanes (100 mL x 3). The extracts were combined, washed with brine, and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 10 (52 g, 85%) as colorless oil. LC-MS: (ESI) m/z 283.1 (M+H)+.
[0324] Step c. A mixture of compound 10 (19.0 g, 68.1 mmol) in dichloromethane (100 mL) was added a solution of ICl (23.0 g, 142mmol) in dichloromethane (100 mL) at 0 0C. After stirring at rt for 30 min, the reaction was quenched by adding saturated aqueous Na2S2O3. The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (CH2Cl2/petroleum ether = 1/10 (v/v)) to give compound 11 (18.0 g, 75%). 1H NMR (CDCl3, 500 MHz): δ 7.24 (s, 2H), 3.87 (s, 6H) ppm. LC-MS: (ESI) m/z 390.9 (M+H)+.
[0325] Step d.. To a solution of compound 11 (3.89g, 10.0 mmol) in CH2Cl2 (20 mL) was added BBr3 (2.5 M in DCM, 15 mL, 60 mmol) at -78 0C. After stirring at rt for 14 h, the reaction mixture was poured into water and the aqueous layer was extracted with CH2Cl2 (5OmL x 2). The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 12 as a white solid (3.1 g, 85%). 1H NMR (CDCl3, 500 MHz): δ 7.00 (s, 2H), 5.61 (s, 2H) ppm. LC-MS: (ESI) m/z 362.8 (M+H)+. [0326] Step e. A mixture of compound 12 (1.5 g, 4.2 mmol), K2CO3 (4.60 g, 33.2 mmol), and l-bromo-2-methoxyethane (2.30 g, 16.6 mmol) in acetone (100 mL) was refluxed overnight. The reaction mixture was concentrated and the residue was diluted with H2O (50 mL) and EtOAc (150 mL). The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (DCM/petroleum ether = 1/10 (v/v)) to give compound 13 (1.5 g, 65%). 1H NMR (CDCl3, 500 MHz): δ 7. 23 (s, 2H), 3.99 (t, J = 6.8 Hz, 4H), 1.81 (m, 4H), 1.55 (m, 4H), 1.28 (m, 32H), 3.99 (t, J = 6.8 Hz, 6H). LC-MS: (ESI) m/z 478.9 (M+H)+.
[0327] Step f. To a solution of compound 13 (200 mg, 0.42 mmol) in 40 mL DME/H2O
(3/1 (v/v)), (5)-tert-butyl 2-(6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- benzo[<i]imidazol-2-yl)pyrrolidine-l-carboxylate (434 mg, 1.05 mmol), Pd(dppf)Cl2 (69 mg, 0.084 mmol), and NaHCO3 (212 mg, 2.52 mmol) were respectively added at rt under an atmosphere of N2. After stirring at 80 0C for 17 h, the reaction mixture was concentrated and the residue was diluted with EtOAc (100 mL) and water (20 mL). The organic phase was washed with brine and dried with anhydrous Na2SO4. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 2/1 (v/v)) to give compound 14 (250 mg, 75%) as a yellowish solid. LC-MS: (ESI) m/z 191.4 (M+H)+.
[0328] Step g. A mixture of compound 14 (150 mg, 0.21 mmol) in dioxane (2 mL) was added 4N HCl in dioxane (2 mL) at rt. After stirring at rt for 2 h, the reaction mixture was concentrated and the residue was dried in vacuo to give an HCl salt, which was used for the next step without further purification. LC-MS: (ESI) m/z 597.3 (M+H)+.
[0329] Step h. Subsequently, the HCl salt was dissolved in DMF (2 mL) and the resulting solution was respectively added DIPEA (0.34 mL, 2.1 mmol), N-Boc-L- VaI-OH (90 mg, 0.51 mmol), and HATU (192 mg, 0.210 mmol). After stirring at rt for 30 min, the reaction mixture was poured into ice H2O. The solid was collected by filtration and purified by preparative HPLC to give compound 15. LC-MS (ESI): m/z 911.5 (M+H)+. EXAMPLE 7 - Synthesis of compounds of Formula X
Figure imgf000132_0001
Scheme 7-1
[0330] Step a. To prepare compound 2 of Scheme 7-1, tert-Butyi 4- oxocyclohexylcarbamate (9.0 g, 42.5 mmol) was treated with HCl (4N in 1,4-dioxane, 60 mL) at rt. After 4 h stirring, the reaction was concentrated to obtain the crude product (6.3 g), which was dissolved in anhydrous DMF (200 mL). N-Boc-L-Pro-OH (9.1 g, 42.3 mmol)), HATU (17.7 g, 46.6 mmol) and DIEA (22.8 mL, 131 mmol) were added at rt. After stirring overnight, the reaction was quenched by brine, extracted by ethyl acetate. The combined organic phases were washed with brine and H2O, dried with Na2SO4. After removal of the solvents, the crude product was purified by silica gel column chromatography (ethyl acetate) to afford {S)-tert-hvXy\ 2-(4-oxocyclohexylcarbamoyl) pyrrolidine- 1-carboxylate (7.5 g, 57% yield).
[0331] Step b. To a solution of {S)-tert-hvXy\ 2-(4-oxocyclohexylcarbamoyl)pyrrolidine- 1-carboxylate (4.3 g, 13.87 mmol) in dichloromethane (350 mL) at -78 0C was slowly added LHMDS (29.1 mL, IM in THF, 29.1 mmol). After stirring for 2 h, 1,1,1-trifluoro-N-phenyl- N-(trifluoromethylsulfonyl)methanesulfonamide (10.4 g, 29.1 mmol) was added as solid at - 78 0C. The reaction was slowly warmed up to rt over 4 h and quenched by adding sat. NaHCθ3, extracted with ethyl acetate. The combined organic phases were washed with brine and H2O, dried with Na2SO4. After removal of the solvent, the crude product was purified by silica gel column chromatography (n-hexane/ethyl acetate, 1 :1) to afford (2S)-tert-bvAy\ 2-(4- (trifluoromethylsulfonyloxy)-cyclohex-3-enyl carbamoyl)pyrrolidine-l-carboxylate (2) (3.6 g, 59% yield).
[0332] Step c. To a solution of (2S)-tert-bvΛy\ 2-(4-(trifluoromethylsulfonyloxy) cyclohex-3-enyl carbamoyl)pyrrolidine-l-carboxylate (2) (1.65 g, 3.73 mmol) and (5)-tert- butyl 2-(5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)-lH-imidazol-2- yl)pyrrolidine-l-carboxylate (3) (1.95 g, 4.44 mmol) in THF (19 mL), Pd(PPh3)2Cl2 (130 mg, 0.185 mmol) and aqueous Na2CO3 (2M, 7.5 mL, 15 mmol) were added under N2 protection at rt. The reaction mixture was heated at 80 0C overnight, and cooled to rt. The mixture was then filtered through a CELITE™ pad and washed with ethyl acetate. The combined organic phases were concentrated to provide the crude product, which was purified by silica gel column chromatography (n-hexane/ethyl acetate, 1 :2) to afford (2S)-tert-bvXy\ 2-(4-(4-(2- ((S)- 1 -(tert-butoxycarbonyl)pyrrolidin-2-yl)- lH-imidazol-5-yl)phenyl)cyclohex-3- enylcarbamoyl)pyrrolidine-l-carboxylate (4) (2.1 g, 93% yield).
[0333] Step d. To a solution of (2S)-tert-buiyl 2-(4-(4-(2-((S)- 1 -(tert-butoxycarbonyl) pyrrolidin- 2-yl)- lH-imidazol-S-y^pheny^cyclohex-S-enylcarbamoy^pyrrolidine- 1 - carboxylate (50 mg, 0.082 mmol) in DCM (15 mL), was added TFA (1 mL) at rt. After 1.5 h stirring, the reaction was concentrated to give a TFA salt (5) (75 mg), which was dissolved in anhydrous TΗF (5 mL). N-Boc-D-Phg-OΗ (51 mg, 0.21 mmol), DMTMM (57 mg, 0.21 mmol) and Et3N (57 μL, 0.41 mmol) were added at rt. After three days of stirring, the reaction was quenched with brine and extracted with ethyl acetate. The combined organic phases were washed with brine and H2O and dried over Na2SO4. After removal of the solvent, the crude product was purified by prep-TLC (DCM /MeOH = 10 /1 (v/v)) to afford compound 6 (40 mg, 56% yield).
[0334] Step e. To a solution of the compound 6 (210 mg, 0.24 mmol) in DCM (10 mL) was added TFA (1 mL) at rt. After 1.5 h stirring, the reaction was concentrated to give the crude product, which was dissolved in anhydrous THF (20 mL). 4-Morpholinecarbonyl chloride (62 μL, 0.54 mmol) and Et3N (206 μL, 1.48 mmol) were added at rt. After overnight stirring, the reaction was quenched by water, extracted by ethyl acetate. After removal of the solvent, the crude product was purified by silica gel column chromatography (DCM / MeOH = 20 / 1 (v/v)) to afford compound 7 (110 mg, 51% yield) LC-MS (ESI): m/z 898 (M+H)+.
[0335] Step f. A mixture of compound 7 (20 mg, 0.022mmol) and 10% Pd/C (5 mg) in MeOH (2 mL) was hydrogenated (60 psi) for 2 days. The reaction was filtered through a CELITE™ pad and washed with MeOH. The combined organic phases was concentrated to give a crude product, which was purified by prep-TLC (DCM / MeOH= 20 / 1 (v/v)) to afford a less polar product (7a) (9 mg, 45% yield), LC-MS (ESI): m/z 900 (M+H)+.and a polar product (7b) (9 mg, 45% yield), LC-MS (ESI): m/z 900 (M+H)+.
Biological Activity
[0336] Biological activity of the compounds of the invention was determined using an HCV replicon assay. The lb_Huh-Luc/Neo-ET cell line persistently expressing a bicistronic genotype Ib replicon in Huh 7 cells was obtained from ReBLikon GMBH. This cell line was used to test compound inhibition using luciferase enzyme activity readout as a measurement of compound inhibition of replicon levels.
[0337] On Day 1 (the day after plating), each compound is added in triplicate to the cells. Plates incubated for 72 h prior to running the luciferase assay. Enzyme activity was measured using a Bright-Glo Kit (cat. number E2620) manufactured by Promega Corporation. The following equation was used to generate a percent control value for each compound.
% Control = (Average Compound Value/ Average Control)* 100
[0338] The EC50 value was determined using GraphPad Prism and the following equation:
Y = Bottom + (Top-Bottom)/ (1+10Λ ((LogIC50-X)*HillSlope)) [0339] EC50 values of compounds are repeated several times in the replicon assay.
[0340] Example compounds of the disclosed invention are illustrated in Tables 1-9 attached as appendices. The tables show inhibitory activity of many of the example compounds with respect to HCV Ib. The biological activity is indicated as being *, ** , ***, or ****, which corresponds to EC50 ranges of > 1000 nM, 999 nM to 10 nM, 9.9 nM to 1 nM, or <1 nM respectively. The tables further provide mass spectrometry results for the synthesized example compounds.
[0341] Pharmaceutical Compositions [0342] The sixteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention In a first embodiment, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients or vehicles, and optionally other therapeutic and/or prophylactic ingredients. Such excipients are known to those of skill in the art. The compounds of the present invention include, without limitation, basic compounds such as free bases. A thorough discussion of pharmaceutically acceptable excipients and salts is available in Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990)..
[0343] Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, creams, ointments, lotions or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, may include other pharmaceutical agents, adjuvants, diluents, buffers, etc.
[0344] The invention includes a pharmaceutical composition comprising a compound of the present invention including isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof together with one or more pharmaceutically acceptable carriers and optionally other therapeutic and/or prophylactic ingredients.
[0345] For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and the like.
[0346] For oral administration, the composition will generally take the form of a tablet, capsule, a softgel capsule nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used carriers such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. When liquid suspensions are used, the active agent may be combined with emulsifying and suspending agents. If desired, flavoring, coloring and/or sweetening agents may be added as well. Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents and the like. [0347] The seventeenth aspect of the invention provides the use of the compounds of the invention in the manufacture of a medicament.
[0348] In a first embodiment of the seventeenth aspect, the medicament is for the treatment of hepatitis C.
[0349] The eighteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, optionally in a pharmaceutical composition. A pharmaceutically or therapeutically effective amount of the composition will be delivered to the subject. The precise effective amount will vary from subject to subject and will depend upon the species, age, the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. Thus, the effective amount for a given situation can be determined by routine experimentation. The subject may be administered as many doses as is required to reduce and/or alleviate the signs, symptoms or causes of the disorder in question, or bring about any other desired alteration of a biological system. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of this invention for a given disease.
CombinationTherapy
[0350] The compounds of the present invention and their isomeric forms and pharmaceutically acceptable salts thereof are useful in treating and preventing HCV infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the HCV lifecycle. Classes of compounds useful in the invention may include, without limitation, all classes of HCV antivirals. For combination therapies, mechanistic classes of agents that may be useful when combined with the compounds of the present invention include, for example, nucleoside and non-nucleoside inhibitors of the HCV polymerase, protease inhibitors, helicase inhibitors, NS4B inhibitors and medicinal agents that functionally inhibit the internal ribosomal entry site (IRES) and other medicaments that inhibit HCV cell attachment or virus entry, HCV RNA translation, HCV RNA transcription, replication or HCV maturation, assembly or virus release. Specific compounds in these classes and useful in the invention include, but are not limited to, macrocyclic, heterocyclic and linear HCV protease inhibitors such as telaprevir (VX-950), boceprevir (SCH-503034), narlaprevir (SCH-900518), ITMN-191 (R-7227), TMC-435350 (a.k.a. TMC-435), MK- 7009, BI-201335, BI-2061 (ciluprevir), BMS-650032, ACH-1625, ACH-1095 (HCV NS4A protease co-factor inhibitor), VX-500, VX-813, PHX-1766, PHX2054, IDX-136, IDX-316, ABT-450 EP-013420 (and congeners) and VBY-376; the Nucleosidic HCV polymerase (replicase) inhibitors useful in the invention include, but are not limited to, R7128, PSI-7851, IDX-184, IDX-102, R1479, UNX-08189, PSI-6130, PSI-938 and PSI-879 and various other nucleoside and nucleotide analogs and HCV inhibitors including (but not limited to) those derived as 2'-C-methyl modified nucleos(t)ides, 4'-aza modified nucleos(t)ides, and 7'-deaza modified nucleos(t)ides. Non-nuclosidic HCV polymerase (replicase) inhibitors useful in the invention, include, but are not limited to , HCV-796, HCV-371, VCH-759, VCH-916, VCH- 222, ANA-598, MK-3281, ABT-333, ABT-072, PF-00868554, BI-207127, GS-9190, A- 837093, JKT-109, GL-59728 and GL-60667.
[0351] In addition, NS5A inhibitors of the present invention may be used in combination with cyclophyllin and immunophyllin antagonists (eg, without limitation, DEBIO compounds, NM-811 as well as cyclosporine and its derivatives), kinase inhibitors, , inhibitors of heat shock proteins (e.g., HSP90 and HSP70), other immunomodulatory agents that may include, without limitation, interferons (-alpha, -beta, -omega, -gamma, -lambda or synthetic) such as Intron A™, Roferon-A™, Canferon-A300™, Advaferon™, Infergen™, Humoferon™, Sumiferon MP™, Alfaferone™, IFN-β™, Feron™ and the like; polyethylene glycol derivatized (pegylated) interferon compounds, such as PEG interferon-α-2a (Pegasys™), PEG interferon-α-2b (PEGIntron™), pegylated IFN-α-conl and the like; long acting formulations and derivatizations of interferon compounds such as the albumin- fused interferon, Albuferon , Locteron and the like; interferons with various types of controlled delivery systems (e.g. ITCA-638, omega-interferon delivered by the DUROS ™ subcutaneous delivery system); compounds that stimulate the synthesis of interferon in cells, such as resiquimod and the like; interleukins; compounds that enhance the development of type 1 helper T cell response, such as SCV-07 and the like; TOLL-like receptor agonists such as CpG-IOlOl (actilon), isotorabine, ANA773 and the like; thymosin α -1; ANA-245 and ANA-246; histamine dihydrochloride; propagermanium; tetrachlorodecaoxide; ampligen; IMP-321; KRN-7000; antibodies, such as civacir, XTL-6865 and the like and prophylactic and therapeutic vaccines such as InnoVac C, HCV E1E2/MF59 and the like. In addition, any of the above-described methods involving administering an NS5A inhibitor, a Type I interferon receptor agonist (e.g., an IFN-α) and a Type II interferon receptor agonist (e.g., an IFN-γ) can be augmented by administration of an effective amount of a TNF-α antagonist. Exemplary, non-limiting TNF-α antagonists that are suitable for use in such combination therapies include ENBREL ™, REMIC ADE™ and HUMIRA ™.
[0352] In addition, NS5A inhibitors of the present invention may be used in combination with antiprotozoans and other antivirals thought to be effective in the treatment of HCV infection, such as, without limitation, the prodrug nitazoxanide. Nitazoxanide can be used as an agent in combination the compounds disclosed in this invention as well as in combination with other agents useful in treating HCV infection such as peginterferon alfa-2a and ribavarin (see, for example,_Rossignol, JF and Keeffe, EB, Future Microbiol. 3:539-545, 2008).
[0353] NS5A inhibitors of the present invention may also be used with alternative forms of interferons and pegylated interferons, ribavirin or its analogs (e.g., tarabavarin, levoviron), microRNA, small interfering RNA compounds (e.g., SIRPLEX-140-N and the like), nucleotide or nucleoside analogs, immunoglobulins, hepatoprotectants, anti-inflammatory agents and other inhibitors of NS5A. Inhibitors of other targets in the HCV lifecycle include NS3 helicase inhibitors; NS4A co-factor inhibitors; antisense oligonucleotide inhibitors, such as ISIS- 14803, AVI-4065 and the like; vector-encoded short hairpin RNA (shRNA); HCV specific ribozymes such as heptazyme, RPI, 13919 and the like; entry inhibitors such as HepeX-C, HuMax-HepC and the like; alpha glucosidase inhibitors such as celgosivir, UT- 23 IB and the like; KPE-02003002 and BIVN 401 and IMPDH inhibitors. Other illustrative HCV inhibitor compounds include those disclosed in the following publications: U.S. Pat. No. 5,807,876; U.S. Pat. No. 6,498,178; U.S. Pat. No. 6,344,465; U.S. Pat. No. 6,054,472; WO97/40028; WO98/40381; WO00/56331, WO 02/04425; WO 03/007945; WO 03/010141; WO 03/000254; WO 01/32153; WO 00/06529; WO 00/18231; WO 00/10573; WO 00/13708; WO 01/85172; WO 03/037893; WO 03/037894; WO 03/037895; WO 02/100851; WO 02/100846; EP 1256628; WO 99/01582; WO 00/09543; WO02/18369; WO98/17679, WO00/056331; WO 98/22496; WO 99/07734; WO 05/073216, WO 05/073195 and WO 08/021927.
[0354] Additionally, combinations of, for example, ribavirin and interferon, may be administered as multiple combination therapy with at least one of the compounds of the present invention. The present invention is not limited to the aforementioned classes or compounds and contemplates known and new compounds and combinations of biologically active agents (see, Strader, D.B., Wright, T., Thomas, DX. and Seeff, L. B., AASLD Practice Guidelines. 1-22, 2009 and Manns, M.P., Foster, G. R., Rockstroh, J.K., Zeuzem, S., Zoulim, F. and Houghton, M., Nature Reviews Drug Discovery. 6:991-1000, 2007, Pawlotsky, J-M., Chevaliez, S. and McHutchinson, J.G., Gastroenterology. 132:179-1998, 2007 , Lindenbach, B.D. and Rice, CM., Nature 436:933-938, 2005, Klebl, B.M., Kurtenbach, A., Salassidis, K., Daub, H. and Herget, T., Antiviral Chemistry & Chemotherapy. 16:69-90, 2005. Beaulieu, P.L., Current Opinion in Investigational Drugs . 8:614-634, 2007, Kim, S-J., Kim, J-H., Kim, Y-G., Lim, H-S. and Oh, W-J., The Journal of Biological Chemistry. 48:50031-50041, 2004. Okamoto, T., Nishimura, Y., Ichimura, T., Suzuki, K., Miyamura, T., Suzuki, T., Moriishi, K. and Matsuura, Y., The EMBO Journal. 1-11, 2006, Soriano, V., Peters, M. G. and Zeuzem, S. Clinical Infectious Diseases. 48:313-320, 2009, Huang, Z., Murray, M. G. and Secrist, J.A., Antiviral Research. 71 :351-362, 2006 and Neyts, J., Antiviral Research. 71 :363-371, 2006, each of which is incorporated by reference in their entirety herein). It is intended that combination therapies of the present invention include any chemically compatible combination of a compound of this inventive group with other compounds of the inventive group or other compounds outside of the inventive group, as long as the combination does not eliminate the anti-viral activity of the compound of this inventive group or the anti-viral activity of the pharmaceutical composition itself.
[0355] Combination therapy can be sequential, that is treatment with one agent first and then a second agent (for example, where each treatment comprises a different compound of the invention or where one treatment comprises a compound of the invention and the other comprises one or more biologically active agents) or it can be treatment with both agents at the same time (concurrently). Sequential therapy can include a reasonable time after the completion of the first therapy before beginning the second therapy. Treatment with both agents at the same time can be in the same daily dose or in separate doses. Combination therapy need not be limited to two agents and may include three or more agents. The dosages for both concurrent and sequential combination therapy will depend on absorption, distribution, metabolism and excretion rates of the components of the combination therapy as well as other factors known to one of skill in the art. Dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules may be adjusted over time according to the individual's need and the professional judgment of the person administering or supervising the administration of the combination therapy. [0356] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
[0357] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the invention as defined in the appended claims.
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
ı42
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Table 6
Compound Inhibition of HCV
Structure MS (M+H+)
# genotype 1 b
850 687.4
HN X
Table 7
Figure imgf000204_0001
Figure imgf000205_0001
Table 9
Figure imgf000206_0001

Claims

1. A compound having formula I:
Figure imgf000207_0001
wherein,
A and A' are independently selected from the group consisting of a single bond, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-S(O)k-N(RN)-(CR2)p- -(CR2)n-C(O)-N(RN)-(CR2)p- -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- -(CR2)n-C(O)-O-(CR2)p- -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a heteroaryl group selected from the group
consisting of
Figure imgf000207_0002
Figure imgf000207_0003
wherein:
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000208_0001
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3.
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that M, in the example of A or A' being HN- , the A-B-A' can be any of:
Figure imgf000209_0001
B is Q or Q Q , wherein each Q is independently selected from the group consisting of a cycloalkyl group, cycloalkenyl group, heterocycle, aryl group or heteroaryl group, with the proviso that only one Q is a six member aromatic ring when B is Q Q and with the proviso that if B is Q Q , any Q is that is poly cyclic is connected to the remainder of the molecule through only one cycle of the poly cycle;
Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of Rc, Rd, Re and Rf may optionally be substituted by Ci to C8 alkyl, Ci to C8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-,
each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R81 2, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R81 is independently chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently 0, 1, 2, 3, or 4, and
u is 0, 1, or 2.
2. The compound of claim 1 wherein each Q is independently optionally substituted with one or more substituents each independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and if Q is not aromatic, it is optionally substituted with oxo.
3. The compound of claim 2 wherein each Q is independently optionally substituted with -CN, -OCF3, -OCHF2, -CF3, or -F.
4. The compound of claim 1 wherein B is selected from the group consisting of
Figure imgf000210_0001
Figure imgf000210_0002
Figure imgf000211_0001
-©- is a
Figure imgf000211_0002
aryl or heteroaryl group which may be polycyclic with varying connective patterns;
V is -CH2-, -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or -(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0;
each r and s is independently 0, 1, 2, 3, or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
each Rb is independently Ci-Ci2 alkyl, hydroxyl, halogen, or oxo.
5. The compound of claim 4 wherein -©- is selected from the group consisting of
Figure imgf000211_0003
wherein * indicates attachment points to the remainder of the compound, and each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
6. The compound claim 4 or claim 5 wherein each Ra is independently -CN, -OCF3, -OCHF2, -CF3, or -F.
7. The compound of any one of claims 1 to 6 wherein A and A' are independently selected from the group consisting of a single bond, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p- -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- and
-(CR2)n-N(R >N- )-C(O)-O-(CR2)p- and a heteroaryl group selected from the group
consisting of
Figure imgf000212_0001
Figure imgf000212_0002
8. The compound of claim 7 wherein A and A' are independently selected from the group
consisting of a single bond,
Figure imgf000212_0003
Figure imgf000212_0004
9. The compound of any of the preceding claims wherein Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cs alkyl and Ci to Cs heteroalkyl, wherein,
each hetero atom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
10. The compound of claim 9 wherein one or both of Rc and Rd or Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
11. The compound of claim 9 wherein Rc and Rd are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000213_0001
Z wherein R is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
12. The compound of claim 9 or 11 wherein Re and Rf are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000213_0002
Figure imgf000214_0001
wherein R is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
13. The compound of claim 1 having formula III:
Figure imgf000214_0002
wherein
Figure imgf000214_0003
A' is selected from the group consisting of single bond,
Figure imgf000214_0004
Figure imgf000214_0005
Figure imgf000215_0001
-(CR2)n-C(O)N(RN)-(CR2)p- and -(CR2)n-N(RN)C(O)-(CR2)p- wherein RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
\=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
r is selected from the group consisting of 0, 1, 2, 3, or 4.
N,"\
\ Il
■ N N-
14. The compound of claim 13 wherein A' is H H -(CR2)n-C(O)N(RN)-(CR2)p- or -(CR2)n-N(RN)C(O)-(CR2)p-
N- 15. The compound of claim 14 wherein A' is H
16. The compound of claim 15 having formula Ilia:
Figure imgf000216_0001
wherein X and
X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl. 17. The compound of claim 13 wherein A' is selected from the group consisting of
Figure imgf000216_0002
18. The compound of claim 17 having formula IHb:
Figure imgf000216_0003
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl. 19. The compound of claim 1 having formula IV:
Figure imgf000217_0001
wherein
Il >
-N
A and A' are independently selected from the group consisting of single bond, H
Figure imgf000217_0002
wherein: RN is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide; \=/ optionally includes 1, 2, 3, or 4 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
r is O, 1, 2, 3 or 4;
each Rb is independently C1-C5 alkyl, hydroxyl, halogen, or oxo;
s is O, 1, 2, 3, 4, 5, or 6; and
each of X1 and X2 are independently C or N.
20. The compound of claim 19 having formula IVa:
Figure imgf000218_0001
21. The compound of claim 20 having formula IVb:
Figure imgf000218_0002
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2-, -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cs heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
22. The compound of claim 1 having formula V:
Figure imgf000219_0001
wherein
A and A' are independently selected from the group consisting of single bond,
Figure imgf000219_0002
Figure imgf000219_0003
wherein R is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide;
X3 is chosen from the group consisting Of-CH2-, -CH2-CH2-, -CH=CH -, -O-, -S-, -S(O)i_2-, -CH2-O-, -NR1- and -CH2-NR1- wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, and Ci to Cg heteroalkyl;
\=/ optionally includes 1 or 2 nitrogens as heteroatoms;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino; and
r is O, 1, 2, 3 or 4.
23. The : compound of claim 22 having formula Va:
Figure imgf000220_0001
24. The compound of claim 23 having formula Vb:
Figure imgf000220_0002
wherein X and X' are each independently selected from the group consisting of a bond, -CH2-, -CH2-CH2-, -CH=CH-, -O-, -S-, -S(O)1-2- -CH2O-, -CH2S-, -CH2S(O)1-2- and -CH2N(R1)-, wherein R1 is chosen from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkanoyl, alkoxycarbonyl, carbamoyl and substituted sulfonyl.
5. A compound having formula VI:
, wherein
Figure imgf000221_0001
each is independently a divalent aryl or heteroaryl group which may be polycyclic with varying connective patterns;
each r is independently 0, 1, 2, 3, or 4;
each Ra is independently selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
A and A' are independently selected from the group consisting of a single bond, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p- -(CR2)n-S(O)k-N(RN)-(CR2)p- -(CR2)n-C(O)-N(RN)-(CR2)p- -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- -(CR2)n-C(O)-O-(CR2)p- -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a heteroaryl group selected from the group
Figure imgf000221_0002
wherein:
X1 is CH2, NH, O or S,
Y1, Y2 and Z1 are each independently CH or N,
X2 is NH, O or S,
V is -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- or
-(CH2)a-O-(CH2)b-, wherein a and b are independently 0, 1, 2, or 3 with the proviso that a and b are not both 0,
Figure imgf000222_0001
optionally includes 1 or 2 nitrogens as heteroatoms on the phenyl residue,
the carbons of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
the nitrogens, if present, of the heteroaryl group are each independently optionally substituted with a substituent selected from the group consisting of -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide,
a and b are independently 1, 2, or 3.
c and d are independently 1 or 2,
n and p are independently 0, 1, 2 or 3,
k is 0, 1, or 2,
each R is independently selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino,
each RN is independently selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide, and
wherein for each A and A', B may be attached to either side of A and A' so that
in the example of A or A' being HN , the A-B-A' can be any of:
Figure imgf000223_0001
Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to C8 alkyl, Ci to Cs heteroalkyl, aralkyl and a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein, each hetero atom, if present, is independently N, O or S, each of Rc, Rd, Re and Rf may optionally be substituted by Ci to C8 alkyl, Ci to C8 heteroalkyl, aralkyl, or a 4- to 8- membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring, and Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle or heteroaryl ring;
Y and Y' are each independently carbon or nitrogen; and
Z and Z' are independently selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2)t]u-U-(CR4 2)t-O-(CR4 2)t-R8, wherein,
U is selected from the group consisting of -C(O)-, -C(S)- and -S(O)2-, each R4, R5 and R7 is independently selected from the group consisting of hydrogen, Ci to Cg alkyl, Ci to Cg heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
R8 is selected from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, -C(O)-R 81 , -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 and -S(O)2-N-R81 2, wherein each R , 81 is independently chosen from the group consisting of hydrogen, Ci to C8 alkyl, Ci to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
optionally, R7 and R8 together form a 4-7 membered ring,
each t is independently 0, 1, 2, 3, or 4, and
u is 0, 1, or 2.
26. The compound of claim 25 wherein each -O- IS l independently selected from
Figure imgf000224_0001
remainder of the compound and each phenyl residue optionally includes 1 or 2 nitrogens as heteroatoms.
27. The compound of one of claims 25 or 26 wherein A and A' are independently selected from the group consisting of a single bond, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p- -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p- and -(CR2)n-N(RN)-C(O)-O-(CR2)p- and a heteroaryl group selected from the group
consisting
Figure imgf000224_0002
Figure imgf000225_0001
28. The compound of claim 27 wherein A and A' are independently selected from the group
Figure imgf000225_0002
29. The compound according to any one of claims 13, 14 15, 17, 19, 20, 22, 23, 25, 26, 27 or 28 wherein Rc, Rd, Re and Rf are each independently selected from the group consisting of: hydrogen, Ci to Cs alkyl and Ci to Cs heteroalkyl, wherein,
each hetero atom, if present, is independently N, O or S,
Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle, and
Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
30. The compound according to claim 30 wherein one of Rc and Rd or Re and Rf are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
31. The compound according to claim 30 wherein both of Rc and Rd and Re and Rf are joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 6- membered heterocycle.
32. The compound of claim 31 wherein Rc and Rd are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000226_0001
wherein RN is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
33. The compound of any one of claims 29-32 wherein Re and Rf are joined and form a heterocyclic fused ring system selected from the group consisting of:
Figure imgf000226_0002
and wherein R is selected from the group consisting of hydrogen, -OH, Ci to Ci2 alkyl, Ci to Ci2 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
34. The compound according to any one of claims 13-33 wherein each Ra is independently -CN, -OCF3, -OCHF2, -CF3, or -F.
35. The compound of any one of claims 13, 14 15, 17, 19, 20, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, or 33 wherein one of Y and Y' is N.
36. The compound according to claim 35 wherein both Y and Y' are N.
37. The compound according to claim 19 or 22 wherein A and A' are each independently χy H ~ or -(CR2)n-C(O)N(RN)-(CR2)p-.
38. The compound according to any one of claims 1-37 wherein Z and Z' are each 1-3 amino acids.
39. The compound according to claim 38 wherein the amino acids are in the D configuration.
40. The compound of any one of claims 1-37 wherein Z and Z' are each independently selected from the group consisting of -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8, -U-(CR4 2),-R8 and -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8.
41. The compound of claim 40 wherein one or both of Z and Z' are -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8.
42. The compound of claim 41 wherein one or both of Z and Z' are -U-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-NR7-(CR4 2),-R8.
43. The compound of claim 41 wherein one or both of Z and Z' are -U-(CR4 2),-NR7-(CR4 2),-R8.
44. The compound of claim 41 wherein either one or both of Z and Z' are -[C(O)-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-NR7-(CR4 2),-R8.
45. The compound of claim 44 wherein one or both of Z and Z' are -C(O)-(CR4 2),-NR5-(CR4 2)t-U-(CR4 2)t-NR7-(CR4 2)t-R8.
46. The compound of claim 44 wherein one or both of Z and Z' are -[C(O)-(CR4 2),-NR5-(CR4 2),]U-C(O)-(CR4 2),-NR7-(CR4 2),-R8.
47. The compound of claim 46 wherein one or both of Z and Z' are -C(O)-(CR4 2),-NR5-(CR4 2),-C(O)-(CR4 2),-NR7-(CR4 2),-R8.
48. The compound of claim 44 wherein one or both of Z and Z' are -C(O)-(CR4 2),-NR7-(CR4 2),-R8.
49. The compound of claim 48 wherein one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-(CR4 2)n-C(O)-R81.
50. The compound of claim 49 wherein one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-C(O)-R81.
51. The compound of claim 48 wherein one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-(CR4 2)n-C(O)-O-R81.
52. The compound of claim 51 wherein one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-C(O)-O-R81.
53. The compound of claim 40 wherein one or both of Z and Z' are -U-(CR4 2)t-R8.
54. The compound of claim 53 wherein one or both of Z and Z' are -C(O)-(CR4 2)t-R8.
55. The compound of claim 40 wherein one or both of Z and Z' are -[U-(CR4 2),-NR5-(CR4 2),]U-U-(CR4 2),-O-(CR4 2),-R8.
56. The compound of claim 55 wherein one or both of Z and Z' are -U-(CR4 2),-NR5-(CR4 2),-U-(CR4 2),-O-(CR4 2),-R8.
57. The compound of claim 64 wherein one or both of Z and Z' are -C(O)-(CR4 2)t-NR5-(CR4 2)t-C(O)-(CR4 2)t-O-(CR4 2)t-R8.
58. The compound of claim 55 wherein one or both of Z and Z' are -U-(CR4 2)t-O-(CR4 2)t-R8.
59. The compound of claim 58 wherein one or both of Z and Z' are -C(O)-(CR4 2)t-O-(CR4 2)t-R8.
60. The compound of claim 40 wherein one or both of Z and Z' are -C(O)-(CR4 2)n-NR7-R8 wherein R7 and R8 together form a 4-7 membered ring.
61. A pharmaceutical composition comprising any one of the compounds of claims 1-60.
62. The use of the compound of any one of claims 1-60 in the manufacture of a medicament.
63. The use of a compound of claim 62 wherein the medicament is for the treatment of hepatitis C.
64. A method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of any one of the compounds of claims 1-61.
PCT/US2009/066467 2008-12-03 2009-12-02 Inhibitors of hcv ns5a WO2010065681A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2009322400A AU2009322400A1 (en) 2008-12-03 2009-12-02 Inhibitors of HCV NS5A
EP09831084A EP2373168A4 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a
CN200980155944.3A CN102300462B (en) 2008-12-03 2009-12-02 Inhibitors of HCV NS5A
NZ593808A NZ593808A (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a
JP2011539670A JP2012510525A (en) 2008-12-03 2009-12-02 Inhibitor of HCVNS5A
US13/132,606 US9120779B2 (en) 2008-12-03 2009-12-02 Inhibitors of HCV NS5A
CA2750577A CA2750577A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a
SG2011039781A SG171890A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a
ARP090104678A AR074474A1 (en) 2008-12-03 2009-12-03 HC5 NS5A INHIBITORS
IL213279A IL213279A0 (en) 2008-12-03 2011-05-31 Inhibitors of hcv ns5a

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11972308P 2008-12-03 2008-12-03
US61/119,723 2008-12-03
US17359009P 2009-04-28 2009-04-28
US61/173,590 2009-04-28
US18295209P 2009-06-01 2009-06-01
US61/182,952 2009-06-01

Publications (1)

Publication Number Publication Date
WO2010065681A1 true WO2010065681A1 (en) 2010-06-10

Family

ID=42233598

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/066451 WO2010065668A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a
PCT/US2009/066467 WO2010065681A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2009/066451 WO2010065668A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a

Country Status (20)

Country Link
US (3) US9120779B2 (en)
EP (3) EP2774927A1 (en)
JP (2) JP2012510525A (en)
KR (1) KR20110098779A (en)
CN (2) CN102300462B (en)
AR (2) AR080264A1 (en)
AU (2) AU2009322387A1 (en)
BR (1) BRPI0922364A2 (en)
CA (2) CA2745119A1 (en)
CL (1) CL2011001332A1 (en)
CO (1) CO6390076A2 (en)
EA (1) EA201190007A1 (en)
IL (2) IL213278A0 (en)
MX (1) MX2011005896A (en)
NZ (2) NZ593808A (en)
PE (1) PE20120207A1 (en)
SG (2) SG171891A1 (en)
TW (2) TWI472526B (en)
WO (2) WO2010065668A1 (en)
ZA (1) ZA201104911B (en)

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117704A1 (en) * 2009-03-30 2010-10-14 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011026920A1 (en) 2009-09-03 2011-03-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives
WO2011054834A1 (en) 2009-11-04 2011-05-12 Tibotec Pharmaceuticals Benzimidazole-imidazole derivatives
WO2011075607A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011112429A1 (en) 2010-03-09 2011-09-15 Schering Corporation Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
WO2012013643A1 (en) 2010-07-26 2012-02-02 Tibotec Pharmaceuticals Hetero-bicyclic derivatives as hcv inhibitors
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
WO2012040389A2 (en) * 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
WO2012041014A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2012051361A1 (en) 2010-10-13 2012-04-19 Abbott Laboratories Anti-viral compounds
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012058125A1 (en) 2010-10-26 2012-05-03 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2012074437A2 (en) 2010-11-30 2012-06-07 Алла Хем, Ллс Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
WO2012083170A1 (en) * 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2012083048A3 (en) * 2010-12-15 2012-08-02 Abbott Laboratories Anti-viral compounds
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
JP2012519185A (en) * 2009-02-27 2012-08-23 エナンタ ファーマシューティカルズ インコーポレイテッド Hepatitis C virus inhibitor
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
WO2012068234A3 (en) * 2010-11-17 2013-01-17 12Gilead Sciences, Inc. Antiviral compounds
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013016491A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
WO2013098313A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
WO2013098320A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Quinazolinone derivatives as hcv inhibitors
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8575135B2 (en) 2011-11-16 2013-11-05 Gilead Sciences, Inc. Antiviral compounds
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN103459399A (en) * 2010-09-29 2013-12-18 默沙东公司 Tetracyclic indole derivatives for treating hepatitis c virus infection
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN103880823A (en) * 2012-12-21 2014-06-25 广东东阳光药业有限公司 Spiro compound serving as hepatitis c inhibitor and application thereof in medicine
US8765731B2 (en) 2009-07-16 2014-07-01 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
US8779156B2 (en) 2010-03-24 2014-07-15 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8785487B2 (en) 2010-01-25 2014-07-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103987723A (en) * 2011-12-16 2014-08-13 弗·哈夫曼-拉罗切有限公司 Inhibitors of HCV NS5A
WO2014123456A2 (en) 2013-02-07 2014-08-14 ИВАЩЕНКО, Андрей Александрович Alkyl [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidine-2-yl]-3h-imidazole-4-yl}-buta-1,3-dienyl)-phenyl]-1h-imidazole-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamate naphthalene-1,5-disulfonate, pharmaceutical composition, medicinal agent and method for treatment of viral diseases
US8809548B2 (en) 2009-02-17 2014-08-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US8927739B2 (en) 2011-05-18 2015-01-06 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2015044866A (en) * 2009-11-11 2015-03-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis c virus inhibitors
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
JP2015510512A (en) * 2012-02-10 2015-04-09 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ Antiviral compounds having a heterotricyclic moiety
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9060971B2 (en) 2010-03-04 2015-06-23 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
WO2015094998A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
JP2016106075A (en) * 2010-10-13 2016-06-16 アッヴィ・バハマズ・リミテッド Anti-virus compound
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10086011B2 (en) 2013-08-27 2018-10-02 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10118920B2 (en) 2015-04-20 2018-11-06 Cellcentric Ltd Isoxazolyl substituted benzimidazoles
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10428065B2 (en) 2015-04-20 2019-10-01 Cellcentric Ltd Isoxazolyl substituted imidazopyridines
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
US10800789B2 (en) 2012-05-16 2020-10-13 Gilead Pharmasset Llc Antiviral compounds
US11203599B2 (en) 2014-06-11 2021-12-21 Gilead Pharmasset Llc Solid forms of an antiviral compound
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US11760764B2 (en) 2020-05-22 2023-09-19 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors
US12071428B2 (en) 2020-12-30 2024-08-27 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2373172E (en) * 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
AU2013204195B2 (en) * 2009-02-27 2016-09-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102471327A (en) 2009-07-21 2012-05-23 吉里德科学公司 Inhibitors of flaviviridae viruses
CA2768637A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20130072523A1 (en) * 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP3219713A1 (en) 2010-01-15 2017-09-20 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2523951B1 (en) 2010-01-15 2015-04-22 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
TW201141857A (en) * 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
CA2800530A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011156543A2 (en) * 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
CA2807305A1 (en) * 2010-08-04 2012-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2963034A1 (en) * 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
EP2619195A1 (en) * 2010-09-24 2013-07-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN103189371B (en) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 Novel inhibitors of hepatitis C virus
US20140364616A1 (en) * 2010-12-15 2014-12-11 Abbvie Inc. Anti-viral compounds
US20150031884A1 (en) * 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
WO2012083058A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2012091115A1 (en) * 2010-12-29 2012-07-05 キッセイ薬品工業株式会社 Acetylene derivative and pharmaceutical application therefor
CA2840445A1 (en) 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
CA2870264C (en) 2012-04-17 2016-11-08 Fujifilm Corporation Nitrogen-containing heterocyclic compound or salt thereof
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
CN103848821B (en) 2012-11-29 2016-10-12 广东东阳光药业有限公司 Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor
CN103664581B (en) * 2013-12-20 2016-07-06 中节能万润股份有限公司 A kind of anti-, trans-4, the preparation method of 4 '-dicyclohexyl dioctyl phthalate
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN105175408B (en) * 2014-06-04 2018-07-17 中国人民解放军第二军医大学 Benzothiazole compound and its purposes as drug
CN106279117A (en) * 2016-08-16 2017-01-04 上海同昌生物医药科技有限公司 A kind of synthetic method of Lei Dipawei intermediate and products thereof
CN108727345B (en) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 Preparation method of imidazole ring intermediate
KR20240035395A (en) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 Urea derivatives that can be used in cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1244507B (en) * 1991-04-11 1994-07-15 Sigma Tau Ind Farmaceuti PYROGLUTAMIC ACID DERIVATIVES AS ACTIVATORS OF LEARNING PROCESSES AND MEMORY AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH COMPOUNDS
DE4234295A1 (en) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds and process for their preparation
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JPH09227417A (en) * 1996-02-26 1997-09-02 Dainippon Ink & Chem Inc Alkenyltolan derivative and its production
NZ332405A (en) 1996-04-23 2000-06-23 Vertex Pharma oxazolyl, thiazolyl or phenyl urea derivatives as inhibitors of inosine monophosphate dehydrogenase enzyme
JP3865084B2 (en) * 1996-07-04 2007-01-10 大日本インキ化学工業株式会社 Dialkenyltolane derivatives
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ES2201452T3 (en) 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF THE IMPDH ENZYME.
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
ES2234144T3 (en) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. ANALOGS OF INHIBITING PEPTIDES OF HEPATITIS C.
DE69925918T2 (en) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. DIKETIC ACID DERIVATIVES AS POLYMERASES INHIBITORS
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
BR9913157A (en) 1998-08-21 2001-05-15 Viropharma Inc Processes for treating or preventing infection caused by at least one virus of the flaviviridae and diseases associated with said infection and infection caused by at least one virus of the genus hepacivirus of flavivirity and diseases associated with said infection, pharmaceutical composition to treat or prevent viral infections , it's composed
AU751201B2 (en) 1998-09-04 2002-08-08 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
JP2002525295A (en) 1998-09-25 2002-08-13 バイロファーマ・インコーポレイテッド How to treat or prevent viral infections and related diseases
TR200103428T2 (en) 1999-03-19 2002-04-22 Vertex Pharmaceuticals Incorporated IMPDH enzyme inhibitors.
WO2000066578A1 (en) * 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
JP2001294541A (en) * 2000-04-14 2001-10-23 Dainippon Ink & Chem Inc Method for producing tolane derivative
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
JP4544857B2 (en) 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Compounds and methods for the treatment or prevention of FLAVIRIRUS infection
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (en) 2001-06-26 2004-06-16 Japan Tobacco Inc THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005511572A (en) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Acyl dihydropyrrole derivatives as HCV inhibitors
JP2005511573A (en) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド 4- (5-membered) -heteroarylacylpyrrolidine derivatives as HCV inhibitors
JP2006505570A (en) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド Benzimidazole derivatives and their use as vanilloid receptor ligands
JP4206382B2 (en) 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド Substituted arylthioureas and related compounds; inhibitors of viral replication
AU2003294443A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
JP4584909B2 (en) 2003-05-09 2010-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hepatitis C virus NS5B polymerase inhibitor binding pocket
JP2007534624A (en) * 2003-07-16 2007-11-29 ニューロジェン・コーポレーション Biaryl piperazinyl-pyridine analogues
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
KR20070083484A (en) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Methods for treating hepatitis c
UA90477C2 (en) 2004-07-14 2010-05-11 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Methods for treating hepatitis c (variants)
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090086081A (en) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008073461A2 (en) * 2006-12-11 2008-06-19 Wyeth Ion channel modulators
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
CN101280196B (en) * 2008-06-03 2011-01-26 西安近代化学研究所 Four-ring liquid crystal compounds
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2373172E (en) * 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc Linked dibenzimidazole derivatives
WO2010099527A1 (en) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
NZ706236A (en) * 2009-05-13 2016-07-29 Gilead Pharmasset Llc Antiviral compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARBATO ET AL.: "Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.", THE EMBO JOURNAL, vol. 19, no. 6, 2000, pages 1195 - 1206 *
See also references of EP2373168A4 *

Cited By (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8809548B2 (en) 2009-02-17 2014-08-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
JP2012519185A (en) * 2009-02-27 2012-08-23 エナンタ ファーマシューティカルズ インコーポレイテッド Hepatitis C virus inhibitor
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010117704A1 (en) * 2009-03-30 2010-10-14 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8822444B2 (en) * 2009-03-30 2014-09-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120277266A1 (en) * 2009-03-30 2012-11-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2012522056A (en) * 2009-03-30 2012-09-20 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C virus inhibitor
EA021260B1 (en) * 2009-03-30 2015-05-29 Бристол-Маерс Сквибб Компани Hepatitis c virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
US8273341B2 (en) 2009-05-13 2012-09-25 Gilead Sciences, Inc. Antiviral compounds
US8822430B2 (en) 2009-05-13 2014-09-02 Gilead Pharmasset Llc Antiviral compounds
US8841278B2 (en) 2009-05-13 2014-09-23 Gilead Pharmasset Llc Antiviral compounds
JP2014169331A (en) * 2009-05-13 2014-09-18 Gilead Sciences Inc Antiviral compound
EA026536B1 (en) * 2009-05-13 2017-04-28 Джилид Фармассет Ллс Antiviral compounds
US8088368B2 (en) 2009-05-13 2012-01-03 Gilead Sciences, Inc. Antiviral compounds
US9511056B2 (en) 2009-05-13 2016-12-06 Gilead Pharmasset Llc Antiviral compounds
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
EA021974B1 (en) * 2009-05-13 2015-10-30 Джилид Фармассет Ллс Antiviral compound
US9981955B2 (en) 2009-05-13 2018-05-29 Gilead Pharmasset Llc Antiviral compounds
EA027493B1 (en) * 2009-05-13 2017-07-31 Джилид Фармассет Ллс Intermediates for preparing an antiviral compound
US8669234B2 (en) 2009-05-13 2014-03-11 Gilead Sciences, Inc. Antiviral compounds
EP2857394A1 (en) * 2009-05-13 2015-04-08 Gilead Pharmasset LLC Antiviral compounds
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10039754B2 (en) 2009-06-11 2018-08-07 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8921514B2 (en) 2009-06-11 2014-12-30 Abbvie Inc. Anti-viral compounds
US9586978B2 (en) 2009-06-11 2017-03-07 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US10028937B2 (en) 2009-06-11 2018-07-24 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8765731B2 (en) 2009-07-16 2014-07-01 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
CN102471324A (en) * 2009-08-07 2012-05-23 泰博特克药品公司 Bis-benzimidazole derivatives as hepatitis c virus inhibitors
AU2010280712B2 (en) * 2009-08-07 2015-10-22 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives as hepatitis C virus inhibitors
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
US8623899B2 (en) 2009-08-07 2014-01-07 Janssen Research & Development Ireland Bis-benzimidazole derivatives as hepatitis C virus inhibitors
WO2011026920A1 (en) 2009-09-03 2011-03-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives
US9150587B2 (en) 2009-09-04 2015-10-06 Janssen Pharmaceuticals, Inc. Chemical compounds
US9814699B2 (en) 2009-09-04 2017-11-14 Janssen Pharmaceuticals, Inc. Chemical compounds
US8492554B2 (en) 2009-09-04 2013-07-23 Glaxosmithkline Llc Chemical compounds
US8853416B2 (en) 2009-09-04 2014-10-07 Janssen Pharmaceuticals, Inc. Chemical compounds
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9427428B2 (en) 2009-11-04 2016-08-30 Janssen Sciences Ireland Uc Benzimidazole-imidazole derivatives
JP2013510119A (en) * 2009-11-04 2013-03-21 ヤンセン・アールアンドデイ・アイルランド Benzimidazole-imidazole derivatives
WO2011054834A1 (en) 2009-11-04 2011-05-12 Tibotec Pharmaceuticals Benzimidazole-imidazole derivatives
US9433609B2 (en) 2009-11-04 2016-09-06 Janssen Sciences Ireland Uc Benzimidazole-imidazole derivatives
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2015044866A (en) * 2009-11-11 2015-03-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis c virus inhibitors
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
WO2011075607A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US9796705B2 (en) 2009-12-22 2017-10-24 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US8735398B2 (en) 2009-12-30 2014-05-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8785487B2 (en) 2010-01-25 2014-07-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US9060971B2 (en) 2010-03-04 2015-06-23 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
WO2011112429A1 (en) 2010-03-09 2011-09-15 Schering Corporation Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US8609635B2 (en) 2010-03-09 2013-12-17 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US8779156B2 (en) 2010-03-24 2014-07-15 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012013643A1 (en) 2010-07-26 2012-02-02 Tibotec Pharmaceuticals Hetero-bicyclic derivatives as hcv inhibitors
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US8815849B2 (en) 2010-07-26 2014-08-26 Janssen R&D Ireland Hetero-bicyclic derivatives as HCV inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012040389A3 (en) * 2010-09-22 2012-05-10 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
WO2012040389A2 (en) * 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
WO2012041014A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
CN103459399A (en) * 2010-09-29 2013-12-18 默沙东公司 Tetracyclic indole derivatives for treating hepatitis c virus infection
JP2020059696A (en) * 2010-10-13 2020-04-16 アッヴィ・アイルランド・アンリミテッド・カンパニー Anti-viral compounds
JP2018065828A (en) * 2010-10-13 2018-04-26 アッヴィ・アイルランド・アンリミテッド・カンパニー Anti-virus compound
WO2012051361A1 (en) 2010-10-13 2012-04-19 Abbott Laboratories Anti-viral compounds
EP2692726A1 (en) 2010-10-13 2014-02-05 Abbvie Inc. Anti-viral compounds
JP2021035964A (en) * 2010-10-13 2021-03-04 アッヴィ・アイルランド・アンリミテッド・カンパニー Anti-viral compounds
EP3438106A1 (en) 2010-10-13 2019-02-06 AbbVie Ireland Unlimited Company Anti-viral compounds
EP2692346A1 (en) 2010-10-13 2014-02-05 Abbvie Inc. An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
JP2016106075A (en) * 2010-10-13 2016-06-16 アッヴィ・バハマズ・リミテッド Anti-virus compound
WO2012058125A1 (en) 2010-10-26 2012-05-03 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
KR101835474B1 (en) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 Antiviral compounds
WO2012068234A3 (en) * 2010-11-17 2013-01-17 12Gilead Sciences, Inc. Antiviral compounds
US10344019B2 (en) 2010-11-17 2019-07-09 Gilead Pharmasset Llc Antiviral compounds
US9156823B2 (en) 2010-11-17 2015-10-13 Gilead Pharmasset Llc Antiviral compounds
AU2011328980B2 (en) * 2010-11-17 2015-07-30 Gilead Sciences, Inc. Antiviral compounds
KR101771093B1 (en) * 2010-11-30 2017-08-24 이바센코 앤드리 알렌산드로비치 Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
JP2013544281A (en) * 2010-11-30 2013-12-12 アラ・ケム・エルエルシー Substituted azoles, antiviral active ingredients, pharmaceutical compositions, methods for their preparation and use.
EP2808325A1 (en) 2010-11-30 2014-12-03 Alla Chem, LLC. Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
WO2012074437A2 (en) 2010-11-30 2012-06-07 Алла Хем, Ллс Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
EP2651920A4 (en) * 2010-12-15 2014-12-17 Abbvie Inc Anti-viral compounds
EP2651920A2 (en) * 2010-12-15 2013-10-23 Abbvie Inc. Anti-viral compounds
WO2012083048A3 (en) * 2010-12-15 2012-08-02 Abbott Laboratories Anti-viral compounds
WO2012083170A1 (en) * 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
CN103354808B (en) * 2010-12-16 2016-08-10 Abbvie公司 Antiviral compound
JP2014504296A (en) * 2010-12-16 2014-02-20 アッヴィ・インコーポレイテッド Antiviral compounds
CN103354808A (en) * 2010-12-16 2013-10-16 Abbvie公司 Anti-viral compounds
WO2012087976A3 (en) * 2010-12-21 2012-11-29 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US9340520B2 (en) 2011-02-07 2016-05-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8927739B2 (en) 2011-05-18 2015-01-06 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016490A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
WO2013016491A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US10456414B2 (en) 2011-09-16 2019-10-29 Gilead Pharmasset Llc Methods for treating HCV
US10807990B2 (en) 2011-11-16 2020-10-20 Gilead Pharmasset Llc Antiviral compounds
US9809600B2 (en) 2011-11-16 2017-11-07 Gilead Pharmasset Llc Antiviral compounds
US9051340B2 (en) 2011-11-16 2015-06-09 Gilead Pharmasset Llc Antiviral compounds
US8921341B2 (en) 2011-11-16 2014-12-30 Gilead Pharmasset Llc Antiviral compounds
US9221833B2 (en) 2011-11-16 2015-12-29 Gilead Pharmasset Llc Antiviral compounds
US8575135B2 (en) 2011-11-16 2013-11-05 Gilead Sciences, Inc. Antiviral compounds
US9868745B2 (en) 2011-11-16 2018-01-16 Gilead Pharmasset Llc Antiviral compounds
US8940718B2 (en) 2011-11-16 2015-01-27 Gilead Pharmasset Llc Antiviral compounds
CN103987723B (en) * 2011-12-16 2017-03-01 弗·哈夫曼-拉罗切有限公司 Inhibitors of HCV NS5A
CN103987723A (en) * 2011-12-16 2014-08-13 弗·哈夫曼-拉罗切有限公司 Inhibitors of HCV NS5A
WO2013098313A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9382261B2 (en) 2011-12-28 2016-07-05 Janssen Sciences Ireland Uc Substituted quinazolinones as HCV inhibitors
WO2013098320A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Quinazolinone derivatives as hcv inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2015510512A (en) * 2012-02-10 2015-04-09 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ Antiviral compounds having a heterotricyclic moiety
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US10800789B2 (en) 2012-05-16 2020-10-13 Gilead Pharmasset Llc Antiviral compounds
CN103880823B (en) * 2012-12-21 2017-12-05 广东东阳光药业有限公司 Application as the spiro-compound of hepatitis c inhibitor and its in medicine
CN103880823A (en) * 2012-12-21 2014-06-25 广东东阳光药业有限公司 Spiro compound serving as hepatitis c inhibitor and application thereof in medicine
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014123456A2 (en) 2013-02-07 2014-08-14 ИВАЩЕНКО, Андрей Александрович Alkyl [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidine-2-yl]-3h-imidazole-4-yl}-buta-1,3-dienyl)-phenyl]-1h-imidazole-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamate naphthalene-1,5-disulfonate, pharmaceutical composition, medicinal agent and method for treatment of viral diseases
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US11707479B2 (en) 2013-08-27 2023-07-25 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10086011B2 (en) 2013-08-27 2018-10-02 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US9828365B2 (en) 2013-12-20 2017-11-28 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015094998A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11203599B2 (en) 2014-06-11 2021-12-21 Gilead Pharmasset Llc Solid forms of an antiviral compound
US10428065B2 (en) 2015-04-20 2019-10-01 Cellcentric Ltd Isoxazolyl substituted imidazopyridines
US10118920B2 (en) 2015-04-20 2018-11-06 Cellcentric Ltd Isoxazolyl substituted benzimidazoles
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
US11760764B2 (en) 2020-05-22 2023-09-19 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
US12071428B2 (en) 2020-12-30 2024-08-27 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Also Published As

Publication number Publication date
IL213278A0 (en) 2011-07-31
US20150038501A1 (en) 2015-02-05
AU2009322387A1 (en) 2011-06-30
EP2373167A4 (en) 2012-07-25
JP2012510523A (en) 2012-05-10
US9120779B2 (en) 2015-09-01
IL213279A0 (en) 2011-07-31
US20110237579A1 (en) 2011-09-29
CA2750577A1 (en) 2010-06-10
TWI494309B (en) 2015-08-01
WO2010065668A1 (en) 2010-06-10
AR074474A1 (en) 2011-01-19
CL2011001332A1 (en) 2011-11-11
AU2009322400A1 (en) 2011-06-30
CN102300462A (en) 2011-12-28
CN102300462B (en) 2015-01-28
CN102300461B (en) 2015-04-22
EP2373168A4 (en) 2012-08-01
TW201033196A (en) 2010-09-16
ZA201104911B (en) 2012-03-28
CA2745119A1 (en) 2010-06-10
BRPI0922364A2 (en) 2017-08-29
PE20120207A1 (en) 2012-03-31
EP2774927A1 (en) 2014-09-10
NZ593808A (en) 2014-04-30
TW201031654A (en) 2010-09-01
KR20110098779A (en) 2011-09-01
CN102300461A (en) 2011-12-28
SG171890A1 (en) 2011-07-28
US8865756B2 (en) 2014-10-21
EA201190007A1 (en) 2012-06-29
EP2373167A1 (en) 2011-10-12
JP2012510525A (en) 2012-05-10
SG171891A1 (en) 2011-07-28
NZ593806A (en) 2014-04-30
AR080264A1 (en) 2012-03-28
EP2373168A1 (en) 2011-10-12
TWI472526B (en) 2015-02-11
MX2011005896A (en) 2011-09-29
CO6390076A2 (en) 2012-02-29
US20120115855A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
US9120779B2 (en) Inhibitors of HCV NS5A
EP2373172B1 (en) Inhibitors of hcv ns5a
US8877707B2 (en) Inhibitors of HCV NS5A
US20120040977A1 (en) Inhibitors of hcv ns5a
WO2011150243A1 (en) Inhibitors of hcv ns5a
WO2011156543A2 (en) Inhibitors of hcv ns5a protein
WO2010111673A1 (en) Substituted bicyclic hcv inhibitors
WO2012040389A2 (en) Substituted bicyclic hcv inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980155944.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09831084

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2750577

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 213279

Country of ref document: IL

Ref document number: 2009831084

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011539670

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13132606

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 593808

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2009322400

Country of ref document: AU

Date of ref document: 20091202

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE